[go: up one dir, main page]

US20040214896A1 - Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient - Google Patents

Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient Download PDF

Info

Publication number
US20040214896A1
US20040214896A1 US10/851,210 US85121004A US2004214896A1 US 20040214896 A1 US20040214896 A1 US 20040214896A1 US 85121004 A US85121004 A US 85121004A US 2004214896 A1 US2004214896 A1 US 2004214896A1
Authority
US
United States
Prior art keywords
phenyl
hydroxyhexanamide
hydroxy
alkyl
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/851,210
Inventor
Mitoshi Konno
Katsuhito Sakaki
Masao Naka
Mikio Konishi
Tadamitsu Kishimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Priority to US10/851,210 priority Critical patent/US20040214896A1/en
Publication of US20040214896A1 publication Critical patent/US20040214896A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/26—Phenanthrenes; Hydrogenated phenanthrenes

Definitions

  • the present invention relates to hydroxamic acid derivatives, the methods for preparation thereof and inhibitors of interleukin-6 production comprising thereof, as an active ingredient.
  • inhibitors of IL-6 production comprising hydroxamic acid derivatives of the formula (I)
  • Cytokine is a multifunctional factor which plays an important role in the host defense system of living body and it relates to various life phenomena. However, there are many diseases which may be caused by overproduction thereof or overresponse thereto.
  • IL-6 is a cytokine produced from various cells, e.g. T cells, B cells, macrophages, kidney mesangial cells, fibroblasts, and its various physiological effects are known e.g. induction of B cells differentiation to antibody-producing cells, activation of T cells, increase of platelets, and production of acute phase protein from liver cells.
  • T cells e.g. T cells
  • B cells e.g. B cells
  • macrophages e.g. induction of B cells differentiation to antibody-producing cells
  • activation of T cells e.g. induction of B cells differentiation to antibody-producing cells
  • activation of T cells e.g. induction of B cells differentiation to antibody-producing cells
  • activation of T cells e.g. induction of B cells differentiation to antibody-producing cells
  • activation of T cells e.g. T cells
  • platelets e.g. IL-6
  • production of IL-6 e.g. induction of B cells differentiation to antibody-producing cells
  • the present invention is targeted for the cytokine and provides novel medicines through inhibiting the production thereof.
  • Clinical application of the compounds of the present invention involves those diseases which may be caused and be changed to worse by abnormal production of IL-6 or by overresponse to them.
  • Inhibitors of IL-6 production may be used for the prevention and/or treatment of various inflammatory diseases, sepsis, multiple myeloma, plasma cell leukemia, osteoporosis, cachexia, psoriasis, nephritis, renal cell carcinoma, Kaposi's sarcoma, rheumatoid arthritis, hypergammaglobulinemia, Castleman's disease, atrial myxoma, diabetes mellitus, autoimmne diseases, hepatitis, colitis, graft versus host disease, infectious diseases and endometriosis (J.
  • a x is R x X x m x (R x is phenyl, pyrrolyl, thienyl imidazolyl or thiazolyl, X x is halogen, lower alkyl, lower alkoxy or nitro, m x is 0 or an integer of 1-2 and each X x is the same or different optionally.), B x is —CHOH—, —CH—, —O—, or —CO—, or —CO—, nX is an integer of 2-10.
  • [0013] is useful as anti-parasite agent.
  • W Y is a bond, —O—, —S—, —NR 2Y —, —CH(OH)— or —NR 2Y —CO—, X Y is N or
  • R 1Y is hydrogen, lower alkyl, trifluoromethyl, nitro, hydroxy, lower alkoxy, mercapto, lower alkylthio or halogen,
  • R 2Y is hydrogen or lower alkyl
  • nY is 0 or 1
  • mY is 1-6.
  • Hydroxamic acid derivatives of the formula (I) of the present invention have not been known as inhibitors of IL-6 production at all. Further, almost hydroxamic acid derivatives of the formula (I), non-toxic salts thereof and prodrugs thereof are novel compounds which are not known at all.
  • the present invention relates to
  • R 2 is hydrogen, C1-8alkyl, C2-9 acyl or Cyc1,
  • R 3 and R 4 are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,
  • R 5 is hydroxy, C1-8 alkyl, C1-8 alkoxy, —NR 6 R 7 or Cyc1,
  • R 6 and R 7 are each independently hydrogen, C1-8 alkyl or Cyc1,
  • R 10 is C1-8 alkyl or Cyc1,
  • Cyc1 is C3-7 mono-carbocyclic ring or 5-7 membered mono-cyclic hetero ring containing 14 nitrogen atom(s), one oxygen atom and/or one sulfur atom,
  • R 11 is hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,
  • R 12 and R 13 are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc 1 ,
  • m is 0 or an integer of 1-5
  • ring A is C3-15 mono-, bi- or tri-carbocyclic ring or 5-18 membered mono-, bi- or tri-cyclic hetero ring containing 14 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s),
  • ring B is C5-15 mono-, bi- or tri-carbocyclic aryl or 5-18 membered mono-, bi- or tri-cyclic hetero aryl containing 14 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s),
  • E is a bond, —CH ⁇ CH— or —C ⁇ C—
  • R 1 and R 8 taken together, may be optionally C1-4 alkylene.
  • n is 0 or an integer of 1-5
  • R 9 is hydrogen, C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl.], nontoxic salts thereof or prodrugs thereof, as an active ingredient,
  • R 2 is hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,
  • R 3 and R 4 are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,
  • R 5 is hydroxyl, C1-8 alkyl, C1-8 alkoxy, —NR 6 R 7 or Cyc1,
  • R 6 and R 7 are each independently hydrogen, C1-8 alkyl or Cyc1,
  • R 10 is C1-8 alkyl or Cyc1,
  • Cyc1 is C3-7 mono-carbocyclic ring or 5-7 membered mono-cyclic hetero ring containing 14 nitrogen atom(s), one oxygen atom and/or one sulfur atom,
  • R 11 is hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,
  • R 12 and R 13 are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,
  • m is 0 or an integer of 1-5
  • ring A is C3-15 mono-, bi- or tri-carbocyclic ring or 5-18 membered mono-, bi- or tri-cyclic hetero ring containing 14 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s),
  • ring B is C5-15 mono-, bi- or tri-carbocyclic aryl or 5-18 membered mono-, bi- or tri-cyclic hetero aryl containing 14 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s),
  • E is a bond, —CH ⁇ CH— or —C ⁇ C—
  • n is 0 or an integer of 1-5
  • R 9 is hydrogen, C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl.
  • ring A is C3-7 mono-carbocyclic ring or 5-7 membered mono-cyclic hetero ring containing 1-4 nitrogen atom(s), one oxygen atom and/or one sulfur atom.], nontoxic salts thereof or prodrugs thereof,
  • alkyl, alkoxy and alkylene groups include straight or branched ones.
  • isomers on double bond, ring, fused ring (E-, Z-, cis-, trans-isomer), isomers generated from asymmetric carbon atom(s) (R-, S-, ⁇ , ⁇ -isomer, enantiomer, diastereomer), optically active isomer (D-, L-, d-, I-, (+)-, ( ⁇ )-isomer), polar compounds generated by chromatographic separation (more polar compound, less polar compound), equilibrium compounds, mixtures thereof at voluntary ratios and racemic mixtures are also included in the present invention.
  • C1-8 alkyl means methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl and the isomers thereof.
  • C2-8 alkenyl means vinyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, butadienyl, pentadienyl, hexadienyl, heptadienyl, octadienyl, hexatrienyl, heptatrienyl, octatrienyl and the isomer thereof.
  • C2-8 alkynyl means ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, butadiynyl, pentadiynyl, hexadiynyl, heptadiynyl, octadiynyl, hexatriynyl, heptatriynyl, octatriynyl and the isomer thereof.
  • Halogen means fluoride, chloride, bromide and iodide.
  • C1-4 alkylene means methylene, ethylene, trimethylene, tetramethylene and the isomers thereof.
  • C1-8 alkylene means methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, heptamethylene, octamethylene and isomers thereof.
  • C2-9 acyl means acetyl, propionyl, butyryl, valeryl, hexanoyl, heptanoyl, octanoyl, nonanoyl and the isomers thereof.
  • C1-8 alkoxy means methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy and the isomers thereof.
  • C3-7 mono-carbocyclic ring means C3-7 mono-aromatic carbocyclic ring, partially saturated carbocyclic ring thereof and fully saturated carbocyclic ring thereof. It includes, for example, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclopentene, cyclohexene, cycloheptene, cyclopentadiene, cyclohexadiene, cycloheptadiene and benzene etc.
  • 5-7 membered mono-cyclic hetero ring containing 14 nitrogen atom(s), one oxygen atom and/or one sulfur atom means 5-7membered mono-cyclic hetero aryl containing 1-4 nitrogen atom(s), one oxygen atom and/or one sulfur atom and partially or fully saturated one.
  • pyrrole imidazole, pyrazole, triazole, tetrazole, pyridine, pyrazine, pyrimidine, pyridazine, azepine, diazepine, furan, pyran, oxepine, oxazepine, thiophene, thiain (thiopyran), thiepine, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, oxazine, oxadiazine, oxazepine, oxadiazepine, thiadiazole, thiazine, thiadiazine, thiazepine, thiadiazepine, pyrroline, pyrrolidine, imidazoline, imidazolidine, pyrazoline, pyrazolidine, triazoline, triazolidine, tetrazoline, tetrazoline, te
  • C3-15 mono-, bi- or tri-carbocyclic ring means C3-15 mono-, bi- and tri-aromatic carbocyclic ring, partially saturated carbocyclic ring thereof and fully saturated carbocyclic ring thereof.
  • cyclopropane cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclopentene, cyclohexene, cycloheptene, cyclopentadiene, cyclohexadiene, cycloheptadiene, benzene, pentalene, indene, naphthalene, azulene, fluorene, phenanthrene, anthracene, acenaphthylene, biphenylene, perhydropentalene, perhydroindene, dihydronaphthalene, tetrahydronaphthalene, perhydronaphthalene, perhydroazulene, perhydrofluorene, perhydrophenanthrene, perhydroanthracene, perhydroacenaphthylene and perhydrobiphenylene, etc.
  • 5-18 membered mono-, bi- or tricyclic hetero ring containing 14 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s) means 5-18 membered mono-, bi- or tri-cyclic hetero aryl containing 14 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s) and partially or fully saturated one.
  • pyrrole imidazole, pyrazole, triazole, tetrazole, pyridine, pyrazine, pyrimidine, pyridazine, azepine, diazepine, furan, pyran, oxepine, oxazepine, thiophene, thiain (thiopyran), thiepine, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, oxazine, oxadiazine, oxazepine, oxadiazepine, thiadiazole, thiazine, thiadiazine, thiazepine, thiadiazepine, indole, isoindole, benzofuran, isobenzofuran, benzothiophene, isobenzothiophene, indazole, quinoline, isoquino
  • C5-15 mono-, bi- or tri-carbocyclic aryl means cyclopentadiene, cyclohexadiene, cycloheptadiene, cycloheptatriene, benzene, indene, naphthalene, fluorene and anthracene etc.
  • 5-18 membered mono-, bi- or tri-cyclic hetero aryl containing 14 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s) means pyrrole, imidazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, azepine, diazepine, furan, pyran, oxepine, thiophene, thiain (thiopyran), thiepine, oxazole, isoxazole, thiazole, isothiazole, furazan, oxadiazole, oxazine, oxadiazine, oxazepine, oxadiazepine, thiadiazole, thiazine, thiadiazine, thiazepine, thiadiazepine, indole, isoindo
  • [0142] represents bonding to back of the paper (that is, ⁇ -configuration).
  • [0143] represents bonding to front of the paper (that is, ⁇ -configuration),
  • [0144] represents ⁇ -, ⁇ - or mixture thereof
  • [0145] represents mixture of ⁇ -configuration and ⁇ -configuration.
  • Non-toxic salts of the present invention include all non-toxic salts, for example, general salts, acid addition salts, hydrate salts.
  • the compounds of the present invention may be converted into the corresponding salts by conventional means.
  • Water-soluble salts are preferred.
  • Suitable salts for example, include:
  • salts of alkali metals e.g. potassium, sodium
  • salts of alkaline earth metals e.g. calcium, magnesium
  • ammonium salts salts of pharmaceutically acceptable organic amines (e.g. tetramethylammonium, triethylamine, methylamine, dimethylamine, cyclopentylamine, benzylamine, phenethylamine, piperidine, monoethanolamine, diethanolamine, tris(hydroxymethyl)amine, lysine, arginine, N-methyl-D-glucamine).
  • the compounds of the present invention may be converted into the corresponding acid addition salts by conventional means.
  • Water-soluble salts are preferred. Suitable salts, for example, include:
  • salts of inorganic acids e.g. hydrochloride, hydrobromide, sulfate, phosphate, nitrate
  • salts of organic acids e.g. acetate, trifluoroacetate, lactate, tartrate, oxalate, fumarate, maleate, citrate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate, isethionate, glucuronate, gluconate.
  • prodrugs of the present invention means the compounds that —CONHOH group of the formula (I) is converted to
  • R 14 is C1-8 alkyl substituted by C1-8 alkyl or C1-8 alkoxy
  • preferred ring A is C3-10 mono-, bi-carbocyclic ring or 5-10 membered mono-, bi-cyclic hetero ring containing 1-4 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s).
  • C5-7 mono-carbocyclic ring or 5-10 membered mono-, bi-cyclic hetero ring containing 1-4 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s) is preferable.
  • Benzene, cyclohexane, benzoxazole, benzothiazole, benzimidazole, benzothiophene or benzofuran is more preferable.
  • R 1 is (1) C1-8 alkyl, (2) —OR 2 , (3) —SR 2 , (4) halogen, (5) Cyc1, (6) —NR 3 R 4 or (7) C1-8 alkyl substituted by —OR 2 , —SR 2 , halogen, Cyc1, —NR 3 R 4 .
  • Methyl, methoxy, methylthio, chloride, dimethylamino, dipropylamino, morpholine, piperidine, piperazine, methoxymethyl, methylthiomethyl, dimethylaminomethyl, dipropylaminomethyl, morpholine-1-ylmethyl, piperidine-1-ylmethyl or piperazine-1-ylmethyl is more preferable.
  • Preferred stereoisomer of hydroxy group is R configuration, S configuration or mixture thereof. Especially, R or S configuration is preferable. S configuration is more preferable.
  • Preferred E is, preferably, a bond, —CH ⁇ CH— or —C ⁇ C— and a bond or —C ⁇ C— is preferable.
  • Preferred B ring is C1-5 mono- or bi-carbocyclic aryl or 5-15 membered mono- or bi-cyclic hetero aryl.
  • benzene, naphthalene, pyridine, thiophene, benzofuran or benzoxazole is preferable.
  • R 8 is C1-4 alkyl. Especially, methyl is preferable.
  • R 9 is hydrogen, C1-4 alkyl, C2-4 alkenyl or C24 alkynyl. Especially, hydrogen, methyl or allyl is preferable.
  • Preferred m is 0 or an integer of 1-5. Especially, 0 or 1 is preferable.
  • n is 0 or an integer of 1-5. Especially, 0 or 1 is preferable.
  • preferred compounds are compounds prepared in example hereinafter, shown in the following table 1 to 7 and salts thereof etc. TABLE 1 (I-1) No. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
  • Hydroxamic acid derivatives of the formula (I) in the present invention, non-toxic salts thereof and prodrugs thereof may be prepared by the following methods or the methods described in examples.
  • the prodrugs of the formula (IA) may be prepared by the following methods of (a)-(c).
  • R 1-a has the same meaning as R 1 .
  • R 1-a doesn't represent a group containing of amino, thiol and carboxy and the other symbols have the same meaning as defined hereinbefore.
  • amidation is known. For example, it may be carried out
  • the method with acid halide may be carried out, for example; carboxylic acid is reacted with an acid halide (oxalyl chloride or thionyl chloride etc.) in an organic solvent (chloroform, methylene chloride, diethyl ether or tetrahydrofuran etc.) or without solvents at from ⁇ 20° C. to a refluxing temperature to give an acid halide.
  • an acid halide oxalyl chloride or thionyl chloride etc.
  • organic solvent chloroform, methylene chloride, diethyl ether or tetrahydrofuran etc.
  • the obtained acid halide and an amine are reacted in an organic solvent (chloroform, methylene chloride, diethyl ether or tetrahydrofuran etc.) in the presence of tertiary amine (pyridine, triethylamine, dimethylaniline or dimethylaminopyridine etc.), at 0-40° C.
  • tertiary amine pyridine, triethylamine, dimethylaniline or dimethylaminopyridine etc.
  • this reaction may be carried out by the reaction with amine and acid halide in an organic solvent, (dioxane or tetrahydrofuran etc.), with an aqueous alkali solution (solution of bicarbonate or solution of sodium hydroxide etc.) at 0-40° C.
  • the method with mixed acid anhydride may be carried out, for example; carboxylic acid is reacted with an acid halide (pivaloyl chloride etc.) or an acid derivative (ethyl chloroformate or isobutyl chloroformate etc.) in an organic solvent (chloroform, methylene chloride, diethyl ether or tetrahydrofuran etc.) or without solvents, in the presence of tertiary amine (pyridine, triethylamine, dimethylaniline or dimethylaminopylidine etc.), at 0-40° C.
  • the mixed acid anhydride is reacted with an amine in an organic solvent (chloroform, methylene chloride, diethyl ether or tetrahydrofuran etc.) at 0-40° C.
  • the method with condensing agent may be carried out, for example; a carboxylic acid and an amine are reacted in an organic solvent (chloroform, methylene chloride, dimethylformamide, diethyl ether or tetrahydrofuran etc.) or without solvents in the presence or absence of tertiary amine (pyridine, triethylamine, dimethylaniline or dimethylaminopyridine etc.) using with condensing agent (1,3-dicyclohexylcarbodiimido (DCC), 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimido (EDC), 1,1′-carbonyldiimidazole (CDI), 2-chloro-1-methylpyridinium iodide or 1-propanephosphonic acid cyclic anhydride (PPA) etc.) using or without 1-hydroxybenzotriazole (HOBt) at 0-40° C.
  • an organic solvent chlor
  • the above reactions (1), (2) and (3) are carried out under an atmosphere of an inert gas (argon, nitrogen etc.) on anhydrous condition.
  • an inert gas argon, nitrogen etc.
  • the reaction is known. For example, it may be carried out in an organic solvent (benzene, dimethylformamide, dioxane, tetrahydrofuran, methanol, acetonitrile, dimethoxyethane or acetone etc.) in the presence of a base (sodium ethylate, sodium hydroxide, potassium hydroxide, triethylamine, sodium carbonate, sodium hydrogen carbonate, potassium carbonate, cesium carbonate, thallium carbonate, tripotassium phosphate, cesium fluoride, barium hydroxide or tetrabutylammonium fluoride etc.
  • organic solvent benzene, dimethylformamide, dioxane, tetrahydrofuran, methanol, acetonitrile, dimethoxyethane or acetone etc.
  • a base sodium ethylate, sodium hydroxide, potassium hydroxide, triethylamine, sodium carbonate, sodium hydrogen carbonate, potassium
  • a catalyst tetrakis(triphenylphosphine)palladium (Pd(PPh 3 ) 4 ), dichlorobis(triphenylphosphine)palladium (PdCl 2 (PPh 3 ) 2 ), palladium acetate (Pd(OAc) 2 ), palladium black, 1,1-bis(diphenylphosphinoferrocene)dichloro palladium (PdCl 2 (dppf) 2 ), dichlorodiallylpalladium (PdCl 2 (allyl) 2 ) or iodephenylbis(triphenylphosphine)palladium (PhPdl(PPh 3 ) 2 ) etc.) at room temperature ⁇ 120° C.
  • R 1-c is a group containing at least one of amino, thiol or carboxy and the other symbols have the same meaning as defined hereinbefore.
  • R 1-c is a group containing at least one of amino, thiol or carboxy and the other symbols have the same meaning as defined hereinbefore.
  • R 1-a1 is a group containing at least one of protected amino, protected thiol or protected carboxy and the other symbols have the same meaning as defined hereinbefore.
  • a protecting group of amino includes, for example, benzyloxycarbonyl, allyloxycarbonyl, t-butoxycarbonyl, trifluoroacetyl or 9-fluorenylmethoxycarbonyl.
  • a protecting group of thiol includes, for example, benzyl, methoxybenzyl, acetoamidemethyl, triphenylmethyl or acetyl.
  • a protecting group of carboxy includes, for example, methyl, ethyl, t-butyl, benzyl or allyl.
  • the protecting group of amino, thiol or carboxy includes the above one, in addition, the other protecting group which is removable selectively and easily, for example, one described in T. W. Greene et. al., Protective Groups in Organic Synthesis, Third Edition, Wiley-Interscience, New York, 1999
  • the removal of protecting group in an alkaline condition may be carried out, for example, in an organic solvent (methanol, tetrahydrofuran or dioxane etc.) with hydroxide of alkaline metal (sodium hydroxide, potassium hydroxide or lithium hydroxide etc.), hydroxide of alkaline earth metal (barium hydroxide or calcium hydroxide etc.), carbonate (sodium carbonate or potassium carbonate etc.), or an aqueous solution thereof or a mixture thereof at 040° C.
  • an organic solvent methanol, tetrahydrofuran or dioxane etc.
  • the removal of protecting group in an acidic condition may be carried out, for example, in an organic solvent (dichloromethane, chloroform, dioxane, ethyl acetate or anisole etc.), organic acid (acetic acid, trifluoroacetic acid or methanesulfonic acid) or inorganic acid (hydrochloric acid or sulfuric acid etc.), or a mixture thereof (hydrogen bromide/acetic acid etc.) at 0-100° C.
  • organic solvent dichloromethane, chloroform, dioxane, ethyl acetate or anisole etc.
  • organic acid acetic acid, trifluoroacetic acid or methanesulfonic acid
  • inorganic acid hydroochloric acid or sulfuric acid etc.
  • a mixture thereof hydrogen bromide/acetic acid etc.
  • the removal of a protecting group by hydrogenelysis may be carried out, for example, in a solvent (ether (tetrahydrofuran, dioxane, dimethoxyethane or diethylether etc.), alcohol(methanol or ethanol etc.), benzene(benzene or toluene etc.), ketone (acetone or methylethylketoneetc.), nitrile (acetonitrileetc.), amido (dimethylformamide etc.), water, ethyl acetate, acetic acid or a mixture thereof etc.) in the presence of a catalyst (palladium-carbon, palladium black, palladium hydroxide, platinum oxide, raney nickel etc.), at atmospheric or reduced pressure under an atmosphere of hydrogen or ammonium formate at 0-200° C.
  • a solvent ether (tetrahydrofuran, dioxane, dimethoxyethane or diethylether etc.), alcohol(methanol or ethanol etc.
  • the removal of a protecting group using metal complex may be carried out, for example, in an organic solvent (dichloromethane, dimethylformamide or tetrahydrofuran etc.) in the presence of a trap reagent (tributyltin hydride or dimedone etc.) and/or an organic acid (acetic acid etc.) with metal complex (tetrakis(triphenylphosphine)palladium(O) complex etc.) at 0-40° C.
  • a trap reagent tributyltin hydride or dimedone etc.
  • organic acid acetic acid etc.
  • metal complex tetrakis(triphenylphosphine)palladium(O) complex etc.
  • the aimed compounds of present invention may be prepared easily by choice of these reaction.
  • hydroxamic acid derivatives of the formula (I) may be prepared by the method of (d) or (e).
  • amidation may be carried out by the same procedure as described hereinbefore.
  • Hydroxamic acid derivatives of the formula (I) may be prepared by the removal of a protecting group of the compounds of the above formula (IA).
  • the reaction of the removal of a protecting group of hydroxamic acid in the present invention means an ordinal one which is well known to the person in the art, for example, the removal of a protecting group in an alkaline condition, the removal of a protecting group in an acidic condition or the removal of a protecting group by hydrogenelysis.
  • the aimed compounds of the present invention may be prepared easily by choice of these reaction.
  • a protecting group of hydroxamic acid includes, for example, t-butyl, —C(CH 3 ) 2 —OCH 3 and benzyl.
  • such a group includes the other protecting group which is removable selectively and easily, for example, one described in T. W. Greene et. al., Protective Groups in Organic Synthesis, Third Edition, Wiley-Interscience, New York, 1999.
  • the prodrugs of the formula (IB) may be prepared by the removal of the methanol in the compounds of the formula (IA) wherein R 14 is 1-methoxy-1-methylethyl, i.e., the compounds of the formula (IA-3)
  • the reaction of the removal of methanol is known.
  • it may be carried out in an organic solvent (benzene, toluene, dioxane or pyridine etc.) at 60-150° C.
  • organic solvent benzene, toluene, dioxane or pyridine etc.
  • R 101 is C1-4 alkyl or —CH 2 CH 2 OCH 2 CH 2 OCH 3 ,
  • R 1-a , R 8 , R 9 , R 14 , ring A, ring B, E, m, n or X have the same meaning as defined hereinbefore.
  • each reaction may be carried out by each conventional technique.
  • the compounds of the formula (X), (XIV), (III), (V) and (VI) used as starting materials have been known per se or may be prepared by known methods easily.
  • obtained products may be purified by conventional techniques. For example, purification may be carried out by distillation at atmospheric or reduced pressure, by high performance liquid chromatography, by thin layer chromatography or by column chromatography using silica gel or magnesium silicate, by washing or by recrystallization. Purification may be carried out after each reaction, or after a series of reactions.
  • the compound of the present invention has an inhibitory activity on IL-6 production.
  • A549 cells human lung epithelial cell line
  • DMEM Dulbecco's Modified Eagle Medium
  • FBS fetal bovine serum
  • DMEM Dulbecco's Modified Eagle Medium
  • FBS fetal bovine serum
  • the supernatant 100 ⁇ L was collected to measure the amount of IL-6 being produced using enzyme linked immuno solvent assay (ELISA) (R&D Systems Co., cat. No. D6050). Then the inhibitory activity of the test compound was calculated and the 50% inhibitory concentration (IC 50 ) was determined. For example, the IC 50 value of the compound of example 3 was 0.052 ⁇ M.
  • the supernatant 100 ⁇ L was collected to measure the amount of IL-6 being produced using ELISA (R&D Systems Co., cat. No. D6050). Then the inhibitory activity of the test compound was calculated and the 50% inhibitory concentration (IC 50 ) was determined. For example, the IC 50 value of the compound of example 3 was 0.041 ⁇ M.
  • bovine type II collagen (0.3% collagen solution, KOKEN #K-41, lot.11214, abbreviated as CII)
  • incomplete Freund's adjuvant DIFCO #0639-60
  • saline with the ratio of 1:2:1
  • the intradermal injection of 0.1 mL of the emulsion (0.75mg of CII/mL) was performed on each four different portions of the back on day 0.
  • arthritis was elicited by the intradermal injection of 0.15 mL of the emulsion at the basal portion of the tail.
  • test compound was suspended in 0.5% carboxymethylcellulose solution, and was administered orally in the morning and evening twice a day from day 0 to day 28.
  • the hind paw volume of each animal was also measured with the plethysmometer (UNICOM, TK-101CMP).
  • a plethysmometer UNICOM, TK-101CMP.
  • 10 mg/kg/day (b.i.d.) of the compound of the example 3 completely inhibited the development of arthritis, and the example 3 even at the dose of 3 mg/kg/day showed significant inhibition by approximately 60% on the arthritis score and the hind paw edema.
  • the compounds of the present invention possess an inhibitory activity of IL-6 production in animal, especially human, so they are useful for the prevention and/or treatment of, for example, various inflammatory diseases, sepsis, multiple myeloma, plasma cell leukemia, osteoporosis, cachexia, psoriasis, nephritis, renal cell carcinoma, Kaposi's sarcoma, rheumatoid arthritis, hypergammaglobulinemia , Castleman's disease, atrial myxoma, diabetes mellitus, autoimmne diseases, hepatitis, colitis, graft versus host disease, infectious diseases and endometriosis.
  • various inflammatory diseases for example, various inflammatory diseases, sepsis, multiple myeloma, plasma cell leukemia, osteoporosis, cachexia, psoriasis, nephritis, renal cell carcinoma, Kaposi's sarcoma, rheumatoi
  • the compounds of formula (I), non-toxic salts thereof or prodrugs thereof may be normally administered systemically or locally, usually by oral or parenteral administration.
  • the doses to be administered are determined depending upon, for example, age, body weight, symptom, the desired therapeutic effect, the route of administration, and the duration of the treatment.
  • the doses per person are generally from 1 mg to 1000 mg, by oral administration, up to several times per day, and from 0.1 mg to 100 mg, by parenteral administration (preferably intravenous administration), up to several times per day, or continuous administration from 1 to 24 hours per day from vein.
  • the doses to be used depend upon various conditions. Therefore, there are cases in which doses lower than or greater than the ranges specified above may be used.
  • the compounds of the present invention may be administered in the form of, for example, solid forms for oral administration, liquid forms for oral administration, injections, liniments or suppositories for parenteral administration.
  • Solid forms for oral administration include compressed tablets, pills, capsules, dispersible powders, and granules.
  • Capsules include hard capsules and soft capsules.
  • one or more of the active compound(s) may be admixed with vehicles (such as lactose, mannitol, glucose, microcrystalline cellulose, starch), binders (such as hydroxypropyl cellulose, polyvinylpyrrolidone or magnesium metasilicate aluminate), disintegrants (such as cellulose calcium glycolate), lubricants (such as magnesium stearate), stabilizing agents, and solution adjuvants (such as glutamic acid or aspartic acid) and prepared according to methods well known in normal pharmaceutical practice.
  • vehicles such as lactose, mannitol, glucose, microcrystalline cellulose, starch
  • binders such as hydroxypropyl cellulose, polyvinylpyrrolidone or magnesium metasilicate aluminate
  • disintegrants such as cellulose calcium glycolate
  • lubricants such as magnesium stearate
  • stabilizing agents such as glutamic acid or aspartic acid
  • the solid forms may, if desired, be coated with coating agents (such as sugar, gelatin, hydroxypropyl cellulose or hydroxypropylmethyl cellulose phthalate), or be coated with two or more films. And further, coating may include containment within capsules of absorbable materials such as gelatin.
  • coating agents such as sugar, gelatin, hydroxypropyl cellulose or hydroxypropylmethyl cellulose phthalate
  • coating may include containment within capsules of absorbable materials such as gelatin.
  • Liquid forms for oral administration include pharmaceutically acceptable solutions, suspensions and emulsions, syrups and elixirs.
  • one or more of the active compound(s) may be dissolved, suspended or emulized into diluent(s) commonly used in the art (such as purified water, ethanol or a mixture thereof).
  • diluent(s) commonly used in the art (such as purified water, ethanol or a mixture thereof).
  • such liquid forms may also comprise some additives, such as wetting agents, suspending agents, emulsifying agents, sweetening agents, flavoring agents, aroma, preservative or buffering agent.
  • injections for parenteral administration include sterile aqueous, suspensions, emulsions and solid forms which are dissolved or suspended into solvent(s) for injection immediately before use.
  • one or more of the active compound(s) may be dissolved, suspended or emulized into solvent(s).
  • the solvents may include distilled water for injection, physiological salt solution, vegetable oil, propylene glycol, polyethylene glycol, alcohol, e.g. ethanol, or a mixture thereof.
  • Injections may comprise some additives, such as stabilizing agents, solution adjuvants (such as glutamic acid, aspartic acid or POLYSORBATE80 (registered trade mark)), suspending agents, emulsifying agents, soothing agent, buffering agents, preservative. They may be sterilized at a final step, or may be prepared and compensated according to sterile methods. They may also be manufactured in the form of sterile solid forms such as freeze-dried products, which may be dissolved in sterile water or some other sterile diluent(s) for injection immediately before use.
  • parenteral administration include liquids for external use, ointments and endermic liniments, inhalations, sprays, suppositories and pessaries for vaginal administration which comprise one or more of the active compound(s) and may be prepared by methods known per se.
  • Sprays may comprise additional substances other than diluents, such as stabilizing agents (such as sodium sulfate), isotonic buffers (such as sodium chloride, sodium citrate or citric acid).
  • stabilizing agents such as sodium sulfate
  • isotonic buffers such as sodium chloride, sodium citrate or citric acid.
  • the extract was washed with a saturated aqueous solution of sodium hydrogen carbonate and a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate, and concentrated.
  • NMR(CDCl 3 ): ⁇ 7.73 (brs, 1H), 7.60-7.35 (m, 8H), 4.74 (t, J 6 Hz, 1H), 3.31 (s, 3H), 2.50-1.15 (m, 8H), 1.41 (s, 6H).
  • NMR(d 6 -DMSO): ⁇ 10.29 (brs, 1H), 8.64 (brs, 1H), 7.66-7.58 (m, 4H), 7.47-7.30 (m, 5H), 5.18-5.09 (m, 1H), 4.57-4.55 (m, 1H), 1.91 (t, J 7.5 Hz, 2H), 1.64-1.44 (m, 4H), 1.40-1.20 (m, 2H).
  • the reaction mixture was concentrated, diluted with ethyl acetate, washed with water and a saturated aqueous solution of sodium chloride, dried over magnesium sulfate, and concentrated.
  • TLC Rf 0.39 (ethyl acetate).
  • the extract was washed with 2N hydrochloric acid, a saturated aqueous solution of sodium hydrogen carbonate and a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and concentrated.
  • Column: DAICEL CHIRAL CELAD-RH, 4.6 ⁇ 150 mm; Eluant: acetonitrile:water 65:35; UV: 256 nm; Flow rate: 1.0 mL/min.
  • Column: DAICEL CHIRAL CELAD-RH, 4.6 ⁇ 150 mm; Eluant: acetonitrile:water 65:35; UV: 256 nm; Flow rate: 1.0 mL/min.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Hydroxamic acid derivatives of the formula (I)
Figure US20040214896A1-20041028-C00001
(wherein all the symbols have the same meaning as defined in the specification.),
non-toxic salts thereof or prodrugs thereof.
The compounds of the formula (I) inhibit producing IL-6, so it may be used for the prevention and/or treatment of various inflammatory diseases, sepsis, multiple myeloma, plasma cell leukemia, osteoporosis, cachexia, psoriasis, nephritis, renal cell carcinoma, Kaposi's sarcoma, rheumatoid arthritis, hypergammaglobulinemia, Castleman's disease, atrial myxoma, diabetes mellitus, autoimmne diseases, hepatitis, colitis, graft versus host disease, infectious diseases and endometriosis.

Description

    TECHNICAL FIELD
  • The present invention relates to hydroxamic acid derivatives, the methods for preparation thereof and inhibitors of interleukin-6 production comprising thereof, as an active ingredient. [0001]
  • More particularly, it relates to (1) inhibitors of IL-6 production comprising hydroxamic acid derivatives of the formula (I) [0002]
    Figure US20040214896A1-20041028-C00002
  • (wherein all the symbols have the same meaning as defined hereinafter), [0003]
  • non-toxic salts thereof and prodrugs thereof, as an active ingredient, [0004]
  • (2) novel hydroxamic acid derivatives of the above formula (I), non-toxic salts thereof and prodrugs thereof and [0005]
  • (3) the methods for preparation of hydroxamic acid derivatives of the above formula (I), non-toxic salts thereof and prodrugs thereof. [0006]
    • BACKGROUND
  • Cytokine is a multifunctional factor which plays an important role in the host defense system of living body and it relates to various life phenomena. However, there are many diseases which may be caused by overproduction thereof or overresponse thereto. [0007]
  • IL-6 is a cytokine produced from various cells, e.g. T cells, B cells, macrophages, kidney mesangial cells, fibroblasts, and its various physiological effects are known e.g. induction of B cells differentiation to antibody-producing cells, activation of T cells, increase of platelets, and production of acute phase protein from liver cells. But an abnormal production of IL-6 has been observed in various inflammations, autoimmune diseases and neoplastic diseases and it is suggested that IL-6 plays a certain role in the causes of such pathophysiological situations. In the experiment using an animal model in which IL-6 was forcibly expressed, various types of diseases could be observed and such results strongly suggest the existence of relationship between the abnormal production of IL-6 and the cause of certain diseases (Biochem. J., 265, 621 (1990), Immunol. Today, 11, 443 (1990), J. Autoimmun., 5 Suppl A, 123 (1992), Clin. Immunol. Immunopathol., 62, S60 (1992)). [0008]
  • Therefore inhibition of IL-6 production is expected to improve various kinds of diseases such as inflammatory diseases as a representative. The present invention is targeted for the cytokine and provides novel medicines through inhibiting the production thereof. [0009]
  • Clinical application of the compounds of the present invention involves those diseases which may be caused and be changed to worse by abnormal production of IL-6 or by overresponse to them. Inhibitors of IL-6 production may be used for the prevention and/or treatment of various inflammatory diseases, sepsis, multiple myeloma, plasma cell leukemia, osteoporosis, cachexia, psoriasis, nephritis, renal cell carcinoma, Kaposi's sarcoma, rheumatoid arthritis, hypergammaglobulinemia, Castleman's disease, atrial myxoma, diabetes mellitus, autoimmne diseases, hepatitis, colitis, graft versus host disease, infectious diseases and endometriosis (J. Immunol., 145, 4185 (1990), J. Exp. Med., 172, 1505 (1990), J. Clin. Invest., 87, 739 (1991), J. Clin. Invest., 89, 1681 (1992), EMBO J., 13, 1189 (1994), Hematol. Oncol. Clin. North Am., 11, 159 (1997), Cytokines Cell Mol. Ther., 4(3),161 (1998), Folia Med. (Plovdiv), 41(1), 78 (1999), JPEN J. Parenter Enteral Nutr., 23(5), S20 (1999), J. Infect. Dis., 180(1), 10 (1999), Am. J. Obstet. Gynecol., 176(3), 593 (1997)). [0010]
  • For example, in the specification of Japanese Patent Application Kokai S59-46244, it is described that hydroxamic acid derivatives of the formula (X)[0011]
  • Ax—Bx—(CH2)nX—CONHOH  (X)
  • [wherein A[0012] x is RxXxmx (Rx is phenyl, pyrrolyl, thienyl imidazolyl or thiazolyl, Xx is halogen, lower alkyl, lower alkoxy or nitro, mx is 0 or an integer of 1-2 and each Xx is the same or different optionally.), Bx is —CHOH—, —CH—, —O—, or —CO—, or —CO—, nX is an integer of 2-10.]
  • is useful as anti-parasite agent. [0013]
  • And in the U.S. Pat. No. 4,769,461, it is described that hydroxamic acid derivatives of the formula (Y) [0014]
    Figure US20040214896A1-20041028-C00003
  • [wherein W[0015] Y is a bond, —O—, —S—, —NR2Y—, —CH(OH)— or —NR2Y—CO—, XY is N or
  • CR[0016] 2Y,
  • when nY=0, Y[0017] Y, is O, S, NR2Y or C(R2Y)2
  • when nY=1, Y[0018] Y is N or CR2Y,
  • Z[0019] Y is —CH2O—, —CH2—, —CH2NR2Y—, —O—, —S—, —NR2Y—, —CO—, —CONR2Y—, —CHR2YCHR2Y—, —C(R2Y)=C(R2Y)— or —C≡C—,
  • R[0020] 1Y is hydrogen, lower alkyl, trifluoromethyl, nitro, hydroxy, lower alkoxy, mercapto, lower alkylthio or halogen,
  • R[0021] 2Y is hydrogen or lower alkyl,
  • nY is 0 or 1, [0022]
  • mY is 1-6. [0023]
  • With the proviso that when W[0024] Y is a bond, then mY is 0-5.] is useful as anti-inflammatory or anti-allergy agent by inhibition of cyclooxygenase and lipoxygenase.
    • DISCLOSURE OF THE INVENTION
  • Energetic investigations have been carried out to discover a compound possessing an inhibitory activity of IL-6 production. As a results, the present inventors have found that the purpose has been achieved by hydroxamic acid derivatives of the formula (I) or non-toxic salts thereof. [0025]
  • Hydroxamic acid derivatives of the formula (I) of the present invention have not been known as inhibitors of IL-6 production at all. Further, almost hydroxamic acid derivatives of the formula (I), non-toxic salts thereof and prodrugs thereof are novel compounds which are not known at all. [0026]
  • The present invention relates to [0027]
  • 1) an inhibitor of IL-6 production comprising hydroxamic acid derivatives of the formula (I), [0028]
    Figure US20040214896A1-20041028-C00004
  • [wherein, R[0029] 1 is
  • (a) C1-8 alkyl, [0030]
  • (b) C2-8 alkenyl, [0031]
  • (c) C2-8 alkynyl, [0032]
  • (d) halogen, [0033]
  • (e) nitro, [0034]
  • (f) nitrile, [0035]
  • (g) trifluoromethyl, [0036]
  • (h) trifluoromethoxy, [0037]
  • (i) —R[0038] 2,
  • (j) —SR[0039] 2,
  • (k) —NR[0040] 3R4,
  • (l) —COR[0041] 5,
  • (m) keto, [0042]
  • (n) Cyc1, [0043]
  • (o) C1-8 alkyl substituted by —OR[0044] 2, —SR2, —NR3R4, —CR5 or Cyc1,
  • (p) —SO[0045] 2R10,
  • (q) O—(C1-8 alkylene)—OR[0046] 11,
  • (r) C1-8 alkyl substituted by nitrile, —SO[0047] 2R10 or —O—(C1-8 alkylene)—OR11,
  • (s) —O—(C1-8 alkylene)—NR[0048] 2R13,
  • (t) —S—(C1-8 alkylene)—NR[0049] 12R13,
  • (u) C1-8 alkyl substituted by —O—(C1-8 alkylene)—NR[0050] 12R13— or —S—C1-8 alkylene)—NR12R13,
  • (v) C2-8 alkenyl substituted by —OR[0051] 2, —SR2, —NR3R4, COR5, Cyc1 nitrile, —SO2R10, —O—(C1-8 alkylene)—OR11, —O—(C1-8 alkylene)—NR12R13 or —S—(C1-8 alkylene)—NR12R13 or
  • (w) C2-8 alkynyl substituted by —OR[0052] 2, —SR2, —NR3R4, —COR5, Cyc1, nitrile, —SO2R10, —O—(C1-8 alkylene)—OR11, —O—(C1-8 alkylene)—NR12R13, or —S—(C1-8 alkylene)—NR12R13,
  • R[0053] 2 is hydrogen, C1-8alkyl, C2-9 acyl or Cyc1,
  • R[0054] 3 and R4 are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,
  • R[0055] 5 is hydroxy, C1-8 alkyl, C1-8 alkoxy, —NR6R7 or Cyc1,
  • R[0056] 6 and R7 are each independently hydrogen, C1-8 alkyl or Cyc1,
  • R[0057] 10 is C1-8 alkyl or Cyc1,
  • Cyc1 is C3-7 mono-carbocyclic ring or 5-7 membered mono-cyclic hetero ring containing 14 nitrogen atom(s), one oxygen atom and/or one sulfur atom, [0058]
  • R[0059] 11 is hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,
  • R[0060] 12 and R13 are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,
  • m is 0 or an integer of 1-5, [0061]
  • ring A is C3-15 mono-, bi- or tri-carbocyclic ring or 5-18 membered mono-, bi- or tri-cyclic hetero ring containing 14 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s), [0062]
  • ring B is C5-15 mono-, bi- or tri-carbocyclic aryl or 5-18 membered mono-, bi- or tri-cyclic hetero aryl containing 14 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s), [0063]
  • E is a bond, —CH═CH— or —C≡C—, [0064]
  • R[0065] 8 is
  • (a) C1-8 alkyl, [0066]
  • (b) C1-8 alkoxy, [0067]
  • (c) halogen, [0068]
  • (d) nitro, [0069]
  • (e) nitrile, [0070]
  • (f) trifluoromethyl or [0071]
  • (g) trifluoromethoxy. [0072]
  • With the proviso that when E is a bond, then R[0073] 1 and R8, taken together, may be optionally C1-4 alkylene.
  • n is 0 or an integer of 1-5, [0074]
  • R[0075] 9 is hydrogen, C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl.], nontoxic salts thereof or prodrugs thereof, as an active ingredient,
  • 2) Hydroxamic acid derivatives of the formula (I) [0076]
    Figure US20040214896A1-20041028-C00005
  • [wherein, R[0077] 1 is
  • (a) C1-8 alkyl, [0078]
  • (b) C2-8 alkenyl, [0079]
  • (c) C2-8 alkynyl, [0080]
  • (d) halogen, [0081]
  • (e) nitro, [0082]
  • (f) nitrile, [0083]
  • (g) trifluoromethyl, [0084]
  • (h) trifluoromethoxy, [0085]
  • (i) —OR[0086] 2,
  • (j) —SR[0087] 2,
  • (k) —NR[0088] 3R4,
  • (l) —COR[0089] 5,
  • (m) keto, [0090]
  • (n) Cyc1, [0091]
  • (o) C1-8 alkyl substituted by —OR[0092] 2, —SR2, —NR3R4, —OR5 or Cyc1,
  • (p) —SO[0093] 2R10,
  • (q) —O—(C1-8 alkylene)—OR[0094] 11,
  • (r) —O—(C1-8 alkyl substituted by nitrile, —SO[0095] 2R10 or —O—(C1-8 alkylene)—OR11,
  • (s) —S—(C1-8 alkylene)—NR[0096] 12R13,
  • (t) (C1-8 alkylene)—NR[0097] 12R13,
  • (u) C1-8 alkyl substituted by —O—(C1-8 alkylene)—NR[0098] 12R13— or —S—(C1-8 alkylene)—NR12R13,
  • (v) C2-8 alkenyl substituted by —OR[0099] 2, —SR2, —NR3R4, —COR5, Cyc1, nitrile, —SO2R10, —O—(C1-8 alkylene)—OR11, —(C1-8 alkylene)—NR12R13 or (C1-8 alkylene)—NR12R13 or
  • (w) C2-8 alkynyl substituted by —OR[0100] 2, —SR2, —NR3R4, —COR5, Cyc1, nitrile, —SO2R10, —O—(C1-8 alkylene)—OR11, —O—(C1-8 alkylene)—NR12R13 or —S—(C1-8 alkylene)—NR12R13,
  • R[0101] 2 is hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,
  • R[0102] 3 and R4 are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,
  • R[0103] 5 is hydroxyl, C1-8 alkyl, C1-8 alkoxy, —NR6R7 or Cyc1,
  • R[0104] 6 and R7 are each independently hydrogen, C1-8 alkyl or Cyc1,
  • R[0105] 10 is C1-8 alkyl or Cyc1,
  • Cyc1 is C3-7 mono-carbocyclic ring or 5-7 membered mono-cyclic hetero ring containing 14 nitrogen atom(s), one oxygen atom and/or one sulfur atom, [0106]
  • R[0107] 11 is hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,
  • R[0108] 12 and R13 are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,
  • m is 0 or an integer of 1-5, [0109]
  • ring A is C3-15 mono-, bi- or tri-carbocyclic ring or 5-18 membered mono-, bi- or tri-cyclic hetero ring containing 14 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s), [0110]
  • ring B is C5-15 mono-, bi- or tri-carbocyclic aryl or 5-18 membered mono-, bi- or tri-cyclic hetero aryl containing 14 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s), [0111]
  • E is a bond, —CH═CH— or —C≡C—, [0112]
  • R[0113] 8 is
  • (a) C1-8 alkyl, [0114]
  • (b) C1-8 alkoxy, [0115]
  • (c) halogen, [0116]
  • (d) nitro, [0117]
  • (e) nitrile, [0118]
  • (f) trifluoromethyl or [0119]
  • (g) trifluoromethoxy. [0120]
  • With the proviso that when E is a bond then R[0121] 1 and R8, taken together, is C1-4 alkylene optionally.
  • n is 0 or an integer of 1-5, [0122]
  • R[0123] 9 is hydrogen, C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl.
  • With the proviso that when E is —CH═CH— or —C≡C—, ring A is C3-7 mono-carbocyclic ring or 5-7 membered mono-cyclic hetero ring containing [0124] 1-4 nitrogen atom(s), one oxygen atom and/or one sulfur atom.], nontoxic salts thereof or prodrugs thereof,
  • 3) the methods for preparation of hydroxamic acid derivatives of the above formula (I), non-toxic salts thereof and prodrugs thereof. [0125]
    • DETAILED EXPLANATION OF THE INVENTION
  • Unless otherwise specified, all isomers are included in the present invention. For example, alkyl, alkoxy and alkylene groups include straight or branched ones. In addition, isomers on double bond, ring, fused ring (E-, Z-, cis-, trans-isomer), isomers generated from asymmetric carbon atom(s) (R-, S-, α, β-isomer, enantiomer, diastereomer), optically active isomer (D-, L-, d-, I-, (+)-, (−)-isomer), polar compounds generated by chromatographic separation (more polar compound, less polar compound), equilibrium compounds, mixtures thereof at voluntary ratios and racemic mixtures are also included in the present invention. [0126]
  • In the present invention, C1-8 alkyl means methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl and the isomers thereof. [0127]
  • C2-8 alkenyl means vinyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, butadienyl, pentadienyl, hexadienyl, heptadienyl, octadienyl, hexatrienyl, heptatrienyl, octatrienyl and the isomer thereof. [0128]
  • C2-8 alkynyl means ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, butadiynyl, pentadiynyl, hexadiynyl, heptadiynyl, octadiynyl, hexatriynyl, heptatriynyl, octatriynyl and the isomer thereof. [0129]
  • Halogen means fluoride, chloride, bromide and iodide. [0130]
  • C1-4 alkylene means methylene, ethylene, trimethylene, tetramethylene and the isomers thereof. [0131]
  • C1-8 alkylene means methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, heptamethylene, octamethylene and isomers thereof. [0132]
  • C2-9 acyl means acetyl, propionyl, butyryl, valeryl, hexanoyl, heptanoyl, octanoyl, nonanoyl and the isomers thereof. [0133]
  • C1-8 alkoxy means methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy and the isomers thereof. [0134]
  • C3-7 mono-carbocyclic ring means C3-7 mono-aromatic carbocyclic ring, partially saturated carbocyclic ring thereof and fully saturated carbocyclic ring thereof. It includes, for example, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclopentene, cyclohexene, cycloheptene, cyclopentadiene, cyclohexadiene, cycloheptadiene and benzene etc. [0135]
  • 5-7 membered mono-cyclic hetero ring containing 14 nitrogen atom(s), one oxygen atom and/or one sulfur atom means 5-7membered mono-cyclic hetero aryl containing 1-4 nitrogen atom(s), one oxygen atom and/or one sulfur atom and partially or fully saturated one. It includes, for example, pyrrole, imidazole, pyrazole, triazole, tetrazole, pyridine, pyrazine, pyrimidine, pyridazine, azepine, diazepine, furan, pyran, oxepine, oxazepine, thiophene, thiain (thiopyran), thiepine, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, oxazine, oxadiazine, oxazepine, oxadiazepine, thiadiazole, thiazine, thiadiazine, thiazepine, thiadiazepine, pyrroline, pyrrolidine, imidazoline, imidazolidine, pyrazoline, pyrazolidine, triazoline, triazolidine, tetrazoline, tetrazolidine, dihydropyridine, dihydropyrimidine, dihydropyridazine, piperidine, piperazine, tetrahydropyrimidine, tetrahydropyridazine, dihydroazepine, dihydrodiazepine, tetrahydroazepine, tetrahydrodiazepine, dihydrofuran, tetrahydrofuran, dihydropyran, tetrahydropyran, dihydrothiophene, tetrahydrothiophene, dihydrothiain (dihydrothiopyran), tetrahydrothiain (tetrahydrothiopyran), dihydrooxazole, tetrahydrooxazole, dihydroisoxazole, tetrahydroisoxazole, dihydrothiazole, tetrahydrothiazole, dihydroisothiazole, tetrahydroisothiazole, tetrahydroxadiazole, tetrahydroxazine, tetrahydroxadiazine, tetrahydroxazepine, tetrahydroxadiazepine, tetrahydrothiadiazole, tetrahydrothiazine, tetrahydrothiadiazine, tetrahydrothiazepine, tetrahydrothiadiazepine, morpholine and thiomorpholine etc. [0136]
  • C3-15 mono-, bi- or tri-carbocyclic ring means C3-15 mono-, bi- and tri-aromatic carbocyclic ring, partially saturated carbocyclic ring thereof and fully saturated carbocyclic ring thereof. It includes, for example, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclopentene, cyclohexene, cycloheptene, cyclopentadiene, cyclohexadiene, cycloheptadiene, benzene, pentalene, indene, naphthalene, azulene, fluorene, phenanthrene, anthracene, acenaphthylene, biphenylene, perhydropentalene, perhydroindene, dihydronaphthalene, tetrahydronaphthalene, perhydronaphthalene, perhydroazulene, perhydrofluorene, perhydrophenanthrene, perhydroanthracene, perhydroacenaphthylene and perhydrobiphenylene, etc. [0137]
  • 5-18 membered mono-, bi- or tricyclic hetero ring containing 14 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s) means 5-18 membered mono-, bi- or tri-cyclic hetero aryl containing 14 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s) and partially or fully saturated one. It includes, for example, pyrrole, imidazole, pyrazole, triazole, tetrazole, pyridine, pyrazine, pyrimidine, pyridazine, azepine, diazepine, furan, pyran, oxepine, oxazepine, thiophene, thiain (thiopyran), thiepine, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, oxazine, oxadiazine, oxazepine, oxadiazepine, thiadiazole, thiazine, thiadiazine, thiazepine, thiadiazepine, indole, isoindole, benzofuran, isobenzofuran, benzothiophene, isobenzothiophene, indazole, quinoline, isoquinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, benzoxazole, benzothiazole, benzimidazole, carbazole, acridine, dibenzofuran, dibenzothiophene, pyrroline, pyrrolidine, imidazoline, imidazolidine, pyrazoline, pyrazolidine, triazoline, triazolidine, tetrazoline, tetrazolidine, dihydropyridine, dihydropyrimidine, dihydropyridazine, piperidine, piperazine, tetrahydropyrimidine, tetrahydropyridazine, dihydroazepine, dihydrodiazepine, tetrahydroazepine, tetrahydrodiazepine, dihydrofuran, tetrahydrofuran, dihydropyran, tetrahydropyran, dihydrothiophene, tetrahydrothiophene, dihydrothiain (dihydrothiopyran), tetrahydrothiain (tetrahydrothiopyran), dihydrooxazole, tetrahydrooxazole, dihydroisoxazole, tetrahydroisoxazole, dihydrothiazole, tetrahydrothiazole, dihydroisothiazole, tetrahydroisothiazole, tetrahydrooxadiazole, tetrahydrooxazine, tetrahydrooxadiazine, tetrahydrooxazepine, tetrahydrooxadiazepine, tetrahydrothiadiazole, tetrahydrothiazine, tetrahydrothiadiazine, tetrahydrothiazepine, tetrahydrothiadiazepine, morpholine, thiomorpholine, indoline, isoindoline, dihydrobenzofuran, perhydrobenzofuran, dihydroisobenzofuran, perhydroisobenzofuran, dihydrobenzothiophene, perhydrobenzothiophene, dihydroisobenzothiophene, perhydroisobenzothiophene, dihydroindazole, dihydroquinoline, tetrahydroquinoline, perhydroquinoline, dihydroisoquinoline, tetrahydroisoquinoline, perhydroisoquinoline, dihydrophthalazine, tetrahydrophthalazine, perhydrophthalazine, dihydronaphthyridine, tetrahydronaphthyridine, perhydronaphthyridine, dihydroquinoxaline, tetrahydroquinoxaline, perhydroquinoxaline, dihydroquinazoline, tetrahydroquinazoline, perhydroquinazoline, dihydrocinnoline, tetrahydrocinnoline, perhydrocinnoline, dihydrobenzoxazole, perhydrobenzoxazole, dihydrobenzothiazole, perhydrobenzothiazole, dihydrobenzimidazole, perhydrobenzimidazole, benzoxazepine, benzoxadiazepine, benzothiazepine, benzothiadiazepine, benzazepine, benzodiazepine, indroxoazepine, indrotetrahydroxazepine, indroxadiazepine, indrotetrahydroxadiazepine, indrothiazepine, indrotetrahydrothiazepine, indrothiadiazepine, indrotetrahydrothiadiazepine, indroazepine, indrotetrahydroazepine, indrodiazepine, indrotetrahydrodiazepine, benzofurazan, benzothiadiazole, benzotriazole, imidazothiazole, dihydrocarbazole, tetrahydrocarbazole, perhydrocarbazole, dihydroacridine, tetrahydroacridine, perhydroacridine, dihydrodibenzofuran, dihydrodibenzothiophene, tetrahydrodibenzofuran, tetrahydrodibenzothiophene, perhydrodibenzofuran, perhydrodibenzothiophene, 1,3-dioxaindan and 1,4-dioxotetrahydronaphthalene. [0138]
  • C5-15 mono-, bi- or tri-carbocyclic aryl means cyclopentadiene, cyclohexadiene, cycloheptadiene, cycloheptatriene, benzene, indene, naphthalene, fluorene and anthracene etc. [0139]
  • 5-18 membered mono-, bi- or tri-cyclic hetero aryl containing 14 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s) means pyrrole, imidazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, azepine, diazepine, furan, pyran, oxepine, thiophene, thiain (thiopyran), thiepine, oxazole, isoxazole, thiazole, isothiazole, furazan, oxadiazole, oxazine, oxadiazine, oxazepine, oxadiazepine, thiadiazole, thiazine, thiadiazine, thiazepine, thiadiazepine, indole, isoindole, benzofuran, isobenzofuran, benzothiophene, isobenzothiophene, indazole, quinoline, isoquinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, benzoxazole, benzothiazole, benzimidazole, benzoxepine, benzoxazepine, benzoxadiazepine, benzothiepine, benzothiazepine, benzothiadiazepine, benzazepine, benzodiazepine, benzofurazan, benzothiadiazole, benzotriazole, carbazole, acridine, dibenzofuran and dibenzothiophene. [0140]
  • In the present invention, unless otherwise specified, as will be apparent to those skilled in the art, a symbol [0141]
    Figure US20040214896A1-20041028-P00001
  • represents bonding to back of the paper (that is, α-configuration), [0142]
    Figure US20040214896A1-20041028-P00002
  • represents bonding to front of the paper (that is, β-configuration), [0143]
    Figure US20040214896A1-20041028-P00003
  • represents α-, β- or mixture thereof and [0144]
    Figure US20040214896A1-20041028-P00004
  • represents mixture of α-configuration and β-configuration. [0145]
  • [Salts][0146]
  • Non-toxic salts of the present invention include all non-toxic salts, for example, general salts, acid addition salts, hydrate salts. [0147]
  • The compounds of the present invention may be converted into the corresponding salts by conventional means. Water-soluble salts are preferred. Suitable salts, for example, include: [0148]
  • salts of alkali metals (e.g. potassium, sodium), salts of alkaline earth metals (e.g. calcium, magnesium), ammonium salts, salts of pharmaceutically acceptable organic amines (e.g. tetramethylammonium, triethylamine, methylamine, dimethylamine, cyclopentylamine, benzylamine, phenethylamine, piperidine, monoethanolamine, diethanolamine, tris(hydroxymethyl)amine, lysine, arginine, N-methyl-D-glucamine). [0149]
  • The compounds of the present invention may be converted into the corresponding acid addition salts by conventional means. Water-soluble salts are preferred. Suitable salts, for example, include: [0150]
  • salts of inorganic acids e.g. hydrochloride, hydrobromide, sulfate, phosphate, nitrate; salts of organic acids e.g. acetate, trifluoroacetate, lactate, tartrate, oxalate, fumarate, maleate, citrate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate, isethionate, glucuronate, gluconate. [0151]
  • The compounds of the present invention and salts thereof may be converted into the corresponding hydrates by conventional means. [0152]
  • Furthermore, the prodrugs of the present invention means the compounds that —CONHOH group of the formula (I) is converted to [0153]
    Figure US20040214896A1-20041028-C00006
  • (wherein, R[0154] 14 is C1-8 alkyl substituted by C1-8 alkyl or C1-8 alkoxy) or
    Figure US20040214896A1-20041028-C00007
  • Among the compounds of the present invention, preferred ring A is C3-10 mono-, bi-carbocyclic ring or 5-10 membered mono-, bi-cyclic hetero ring containing 1-4 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s). Especially, C5-7 mono-carbocyclic ring or 5-10 membered mono-, bi-cyclic hetero ring containing 1-4 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s) is preferable. Benzene, cyclohexane, benzoxazole, benzothiazole, benzimidazole, benzothiophene or benzofuran is more preferable. [0155]
  • Preferred R[0156] 1 is (1) C1-8 alkyl, (2) —OR2, (3) —SR2, (4) halogen, (5) Cyc1, (6) —NR3R4 or (7) C1-8 alkyl substituted by —OR2, —SR2, halogen, Cyc1, —NR3R4. Especially, (1) C1-8 alkyl, (2) C1-8 alkoxy, (3) C1-8 alkylthio, (4) halogen, (5) 5-7 membered mono-cyclic hetero ring containing 14 nitrogen atom(s), one oxygen atom and/or one sulfur atom, (6) di(C1-8 alkyl)amino or (7) C1-8 alkyl substituted by C1-8 alkoxy, C1-8 alkylthio, halogen, 5-7 membered mono-cyclic hetero ring, di(C1-8 alkyl)amino is preferable. Methyl, methoxy, methylthio, chloride, dimethylamino, dipropylamino, morpholine, piperidine, piperazine, methoxymethyl, methylthiomethyl, dimethylaminomethyl, dipropylaminomethyl, morpholine-1-ylmethyl, piperidine-1-ylmethyl or piperazine-1-ylmethyl is more preferable.
  • Preferred stereoisomer of hydroxy group is R configuration, S configuration or mixture thereof. Especially, R or S configuration is preferable. S configuration is more preferable. [0157]
  • Preferred E is, preferably, a bond, —CH═CH— or —C≡C— and a bond or —C≡C— is preferable. [0158]
  • Preferred B ring is C1-5 mono- or bi-carbocyclic aryl or 5-15 membered mono- or bi-cyclic hetero aryl. Especially, benzene, naphthalene, pyridine, thiophene, benzofuran or benzoxazole is preferable. [0159]
  • Preferred R[0160] 8 is C1-4 alkyl. Especially, methyl is preferable.
  • Preferred R[0161] 9 is hydrogen, C1-4 alkyl, C2-4 alkenyl or C24 alkynyl. Especially, hydrogen, methyl or allyl is preferable.
  • Preferred m is 0 or an integer of 1-5. Especially, 0 or 1 is preferable. [0162]
  • Preferred n is 0 or an integer of 1-5. Especially, 0 or 1 is preferable. [0163]
  • In the present invention, preferred compounds are compounds prepared in example hereinafter, shown in the following table 1 to 7 and salts thereof etc. [0164]
    TABLE 1
    (I-1)
    Figure US20040214896A1-20041028-C00008
    No.
    Figure US20040214896A1-20041028-C00009
    1
    Figure US20040214896A1-20041028-C00010
    2
    Figure US20040214896A1-20041028-C00011
    3
    Figure US20040214896A1-20041028-C00012
    4
    Figure US20040214896A1-20041028-C00013
    5
    Figure US20040214896A1-20041028-C00014
    6
    Figure US20040214896A1-20041028-C00015
    7
    Figure US20040214896A1-20041028-C00016
    8
    Figure US20040214896A1-20041028-C00017
    9
    Figure US20040214896A1-20041028-C00018
    10
    Figure US20040214896A1-20041028-C00019
    11
    Figure US20040214896A1-20041028-C00020
    12
    Figure US20040214896A1-20041028-C00021
    13
    Figure US20040214896A1-20041028-C00022
    14
    Figure US20040214896A1-20041028-C00023
    15
    Figure US20040214896A1-20041028-C00024
    16
    Figure US20040214896A1-20041028-C00025
    17
    Figure US20040214896A1-20041028-C00026
    18
    Figure US20040214896A1-20041028-C00027
  • [0165]
    TABLE 2
    (I-1)
    Figure US20040214896A1-20041028-C00028
    No.
    Figure US20040214896A1-20041028-C00029
    1
    Figure US20040214896A1-20041028-C00030
    2
    Figure US20040214896A1-20041028-C00031
    3
    Figure US20040214896A1-20041028-C00032
    4
    Figure US20040214896A1-20041028-C00033
    5
    Figure US20040214896A1-20041028-C00034
    6
    Figure US20040214896A1-20041028-C00035
    7
    Figure US20040214896A1-20041028-C00036
    8
    Figure US20040214896A1-20041028-C00037
    9
    Figure US20040214896A1-20041028-C00038
    10
    Figure US20040214896A1-20041028-C00039
    11
    Figure US20040214896A1-20041028-C00040
    12
    Figure US20040214896A1-20041028-C00041
    13
    Figure US20040214896A1-20041028-C00042
    14
    Figure US20040214896A1-20041028-C00043
    15
    Figure US20040214896A1-20041028-C00044
    16
    Figure US20040214896A1-20041028-C00045
    17
    Figure US20040214896A1-20041028-C00046
    18
    Figure US20040214896A1-20041028-C00047
    19
    Figure US20040214896A1-20041028-C00048
    20
    Figure US20040214896A1-20041028-C00049
  • [0166]
    TABLE 3
    (I-1)
    Figure US20040214896A1-20041028-C00050
    No.
    Figure US20040214896A1-20041028-C00051
    1
    Figure US20040214896A1-20041028-C00052
    2
    Figure US20040214896A1-20041028-C00053
    3
    Figure US20040214896A1-20041028-C00054
    4
    Figure US20040214896A1-20041028-C00055
    5
    Figure US20040214896A1-20041028-C00056
    6
    Figure US20040214896A1-20041028-C00057
    7
    Figure US20040214896A1-20041028-C00058
    8
    Figure US20040214896A1-20041028-C00059
    9
    Figure US20040214896A1-20041028-C00060
    10
    Figure US20040214896A1-20041028-C00061
    11
    Figure US20040214896A1-20041028-C00062
    12
    Figure US20040214896A1-20041028-C00063
  • [0167]
    TABLE 4
    (I-2)
    Figure US20040214896A1-20041028-C00064
    No.
    Figure US20040214896A1-20041028-C00065
    Figure US20040214896A1-20041028-C00066
    1
    Figure US20040214896A1-20041028-C00067
    Figure US20040214896A1-20041028-C00068
    2
    Figure US20040214896A1-20041028-C00069
    Figure US20040214896A1-20041028-C00070
    3
    Figure US20040214896A1-20041028-C00071
    Figure US20040214896A1-20041028-C00072
    4
    Figure US20040214896A1-20041028-C00073
    Figure US20040214896A1-20041028-C00074
    5
    Figure US20040214896A1-20041028-C00075
    Figure US20040214896A1-20041028-C00076
    6
    Figure US20040214896A1-20041028-C00077
    Figure US20040214896A1-20041028-C00078
    7
    Figure US20040214896A1-20041028-C00079
    Figure US20040214896A1-20041028-C00080
    8
    Figure US20040214896A1-20041028-C00081
    Figure US20040214896A1-20041028-C00082
  • [0168]
    TABLE 5
    (I-3)
    Figure US20040214896A1-20041028-C00083
    No. R1
    1
    Figure US20040214896A1-20041028-C00084
    2
    Figure US20040214896A1-20041028-C00085
    3
    Figure US20040214896A1-20041028-C00086
    4
    Figure US20040214896A1-20041028-C00087
    5
    Figure US20040214896A1-20041028-C00088
    6
    Figure US20040214896A1-20041028-C00089
    7
    Figure US20040214896A1-20041028-C00090
    8 3-CH2—N(CH3)2
    9 2-CH2—N(CH3)2
    10 4-(CH2)2—N(CH2CH2CH3)2
    11 3-(CH2)2—N(CH2CH2CH3)2
    12 2-(CH2)2—N(CH2CH2CH3)2
    13 3-CH2—N(CH2CH2CH3)2
    14 2-CH2—N(CH2CH2CH3)2
    15 4-O—(CH2)2—N(CH2CH2CH3)2
    16 4-S—(CH2)2—N(CH2CH2CH3)2
    17 4-O—(CH2)2—N(CH3)2
    18 4-S—(CH2)2—N(CH3)2
  • [0169]
    TABLE 6
    (I-4)
    Figure US20040214896A1-20041028-C00091
    No. R1
    1
    Figure US20040214896A1-20041028-C00092
    2
    Figure US20040214896A1-20041028-C00093
    3
    Figure US20040214896A1-20041028-C00094
    4
    Figure US20040214896A1-20041028-C00095
    5
    Figure US20040214896A1-20041028-C00096
    6
    Figure US20040214896A1-20041028-C00097
    7
    Figure US20040214896A1-20041028-C00098
    8
    Figure US20040214896A1-20041028-C00099
    9
    Figure US20040214896A1-20041028-C00100
    10 4-CH2—N(CH3)2
    11 3-CH2—N(CH3)2
    12 2-CH2—N(CH3)2
    13 4-(CH2)2—N(CH2CH2CH3)2
    14 3-(CH2)2—N(CH2CH2CH3)2
    15 2-(CH2)2—N(CH2CH2CH3)2
    16 4-CH2—N(CH2CH2CH3)2
    17 3-CH2—N(CH2CH2CH3)2
    18 2-CH2—N(CH2CH2CH3)2
    19 4-O—(CH2)2—N(CH2CH2CH3)2
    20 4-S—(CH2)2—N(CH2CH2CH3)2
    21 4-O—(CH2)2—N(CH3)2
    22 4-S—(CH2)2—N(CH3)2
  • [0170]
    TABLE 7
    (I-5)
    Figure US20040214896A1-20041028-C00101
    No. R1
    1
    Figure US20040214896A1-20041028-C00102
    2
    Figure US20040214896A1-20041028-C00103
    3
    Figure US20040214896A1-20041028-C00104
    4
    Figure US20040214896A1-20041028-C00105
    5
    Figure US20040214896A1-20041028-C00106
    6
    Figure US20040214896A1-20041028-C00107
    7
    Figure US20040214896A1-20041028-C00108
    8
    Figure US20040214896A1-20041028-C00109
    9
    Figure US20040214896A1-20041028-C00110
    10 4-CH2—N(CH3)2
    11 3-CH2—N(CH3)2
    12 2-CH2—N(CH3)2
    13 4-(CH2)2—N(CH2CH2CH3)2
    14 3-(CH2)2—N(CH2CH2CH3)2
    15 2-(CH2)2—N(CH2CH2CH3)2
    16 4-CH2—N(CH2CH2CH3)2
    17 3-CH2—N(CH2CH2CH3)2
    18 2-CH2—N(CH2CH2CH3)2
    19 4-O—(CH2)2—N(CH2CH2CH3)2
    20 4-S—(CH2)2—N(CH2CH2CH3)2
    21 4-O—(CH2)2—N(CH3)2
    22 4-S—(CH2)2—N(CH3)2
  • [Methods for Preparation of the Compounds of the Present Invention][0171]
  • Hydroxamic acid derivatives of the formula (I) in the present invention, non-toxic salts thereof and prodrugs thereof may be prepared by the following methods or the methods described in examples. [0172]
  • [1] Among the compounds of the present invention, the prodrugs of the formula (IA) may be prepared by the following methods of (a)-(c). [0173]
  • (a) Among the prodrugs of the formula (IA), the compounds in which R[0174] 1 doesn't represent a group containing amino, thiol and carboxy, that is, the compounds of the formula (IA-a)
    Figure US20040214896A1-20041028-C00111
  • (wherein, R[0175] 1-a has the same meaning as R1. With the proviso that R1-a doesn't represent a group containing of amino, thiol and carboxy and the other symbols have the same meaning as defined hereinbefore.) may be prepared by amidation of the compounds of the formula (II)
    Figure US20040214896A1-20041028-C00112
  • (wherein, all the symbols have the same meaning as defined hereinbefore.) and the compounds of the formula (III)[0176]
  • H2N—OR14  (III)
  • (wherein, R[0177] 14 has the same meaning as defined hereinbefore.).
  • The amidation is known. For example, it may be carried out [0178]
  • (1) by the method with using acid halide, [0179]
  • (2) by the method with using mixed acid anhydride, [0180]
  • (3) by the method with using conducing agent etc. [0181]
  • Concrete description of these methods are as follows: [0182]
  • (1) The method with acid halide may be carried out, for example; carboxylic acid is reacted with an acid halide (oxalyl chloride or thionyl chloride etc.) in an organic solvent (chloroform, methylene chloride, diethyl ether or tetrahydrofuran etc.) or without solvents at from −20° C. to a refluxing temperature to give an acid halide. The obtained acid halide and an amine are reacted in an organic solvent (chloroform, methylene chloride, diethyl ether or tetrahydrofuran etc.) in the presence of tertiary amine (pyridine, triethylamine, dimethylaniline or dimethylaminopyridine etc.), at 0-40° C. Also this reaction may be carried out by the reaction with amine and acid halide in an organic solvent, (dioxane or tetrahydrofuran etc.), with an aqueous alkali solution (solution of bicarbonate or solution of sodium hydroxide etc.) at 0-40° C. [0183]
  • (2) The method with mixed acid anhydride may be carried out, for example; carboxylic acid is reacted with an acid halide (pivaloyl chloride etc.) or an acid derivative (ethyl chloroformate or isobutyl chloroformate etc.) in an organic solvent (chloroform, methylene chloride, diethyl ether or tetrahydrofuran etc.) or without solvents, in the presence of tertiary amine (pyridine, triethylamine, dimethylaniline or dimethylaminopylidine etc.), at 0-40° C. The mixed acid anhydride is reacted with an amine in an organic solvent (chloroform, methylene chloride, diethyl ether or tetrahydrofuran etc.) at 0-40° C. [0184]
  • (3) The method with condensing agent may be carried out, for example; a carboxylic acid and an amine are reacted in an organic solvent (chloroform, methylene chloride, dimethylformamide, diethyl ether or tetrahydrofuran etc.) or without solvents in the presence or absence of tertiary amine (pyridine, triethylamine, dimethylaniline or dimethylaminopyridine etc.) using with condensing agent (1,3-dicyclohexylcarbodiimido (DCC), 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimido (EDC), 1,1′-carbonyldiimidazole (CDI), 2-chloro-1-methylpyridinium iodide or 1-propanephosphonic acid cyclic anhydride (PPA) etc.) using or without 1-hydroxybenzotriazole (HOBt) at 0-40° C. [0185]
  • Preferably, the above reactions (1), (2) and (3) are carried out under an atmosphere of an inert gas (argon, nitrogen etc.) on anhydrous condition. [0186]
  • (b) Among the prodrugs of the formula (IA), the above compounds of the formula (IA-a) may be prepared by coupling reaction with the compounds of the formula (IV) [0187]
    Figure US20040214896A1-20041028-C00113
  • (wherein, X is halogen and the other symbols have the same meaning as defined hereinbefore.) and the compounds of the formula (V) [0188]
    Figure US20040214896A1-20041028-C00114
  • (wherein all the symbols have the same meaning as defined hereinbefore.) or the compounds of the formula (VI) [0189]
    Figure US20040214896A1-20041028-C00115
  • (wherein all the symbols have the same meaning as defined hereinbefore.). [0190]
  • The reaction is known. For example, it may be carried out in an organic solvent (benzene, dimethylformamide, dioxane, tetrahydrofuran, methanol, acetonitrile, dimethoxyethane or acetone etc.) in the presence of a base (sodium ethylate, sodium hydroxide, potassium hydroxide, triethylamine, sodium carbonate, sodium hydrogen carbonate, potassium carbonate, cesium carbonate, thallium carbonate, tripotassium phosphate, cesium fluoride, barium hydroxide or tetrabutylammonium fluoride etc. ) and a catalyst (tetrakis(triphenylphosphine)palladium (Pd(PPh[0191] 3)4), dichlorobis(triphenylphosphine)palladium (PdCl2(PPh3)2), palladium acetate (Pd(OAc)2), palladium black, 1,1-bis(diphenylphosphinoferrocene)dichloro palladium (PdCl2(dppf)2), dichlorodiallylpalladium (PdCl2(allyl)2) or iodephenylbis(triphenylphosphine)palladium (PhPdl(PPh3)2) etc.) at room temperature −120° C.
  • (c) Among the prodrugs of the formula (IA), the compounds in which R[0192] 1 is a group containing at least one of amino, thiol or carboxy, i.e., the compounds of the formula (IA-c)
    Figure US20040214896A1-20041028-C00116
  • (wherein, R[0193] 1-c is a group containing at least one of amino, thiol or carboxy and the other symbols have the same meaning as defined hereinbefore.) may be prepared by the removal of a protecting group in the compounds of the formula (IA-a) in which amino, thiol or carboxy is protected by a protecting group, i.e., the compounds (IA-a1)
    Figure US20040214896A1-20041028-C00117
  • (wherein, R[0194] 1-a1 is a group containing at least one of protected amino, protected thiol or protected carboxy and the other symbols have the same meaning as defined hereinbefore.).
  • A protecting group of amino includes, for example, benzyloxycarbonyl, allyloxycarbonyl, t-butoxycarbonyl, trifluoroacetyl or 9-fluorenylmethoxycarbonyl. [0195]
  • A protecting group of thiol includes, for example, benzyl, methoxybenzyl, acetoamidemethyl, triphenylmethyl or acetyl. [0196]
  • A protecting group of carboxy includes, for example, methyl, ethyl, t-butyl, benzyl or allyl. [0197]
  • The protecting group of amino, thiol or carboxy includes the above one, in addition, the other protecting group which is removable selectively and easily, for example, one described in T. W. Greene et. al., Protective Groups in Organic Synthesis, Third Edition, Wiley-Interscience, New York, 1999 [0198]
  • The removal of a protecting group of amino, thiol or carboxy is well known. For example, it is [0199]
  • (1) the removal of a protecting group in an alkaline condition, [0200]
  • (2) the removal of a protecting group in an acidic condition, [0201]
  • (3) the removal of a protecting group by hydrogenelysis, or [0202]
  • (4) the removal of a protecting group using metal complex etc. [0203]
  • Concrete description of these methods are as follows: [0204]
  • (1) The removal of protecting group in an alkaline condition may be carried out, for example, in an organic solvent (methanol, tetrahydrofuran or dioxane etc.) with hydroxide of alkaline metal (sodium hydroxide, potassium hydroxide or lithium hydroxide etc.), hydroxide of alkaline earth metal (barium hydroxide or calcium hydroxide etc.), carbonate (sodium carbonate or potassium carbonate etc.), or an aqueous solution thereof or a mixture thereof at 040° C. [0205]
  • (2) The removal of protecting group in an acidic condition may be carried out, for example, in an organic solvent (dichloromethane, chloroform, dioxane, ethyl acetate or anisole etc.), organic acid (acetic acid, trifluoroacetic acid or methanesulfonic acid) or inorganic acid (hydrochloric acid or sulfuric acid etc.), or a mixture thereof (hydrogen bromide/acetic acid etc.) at 0-100° C. [0206]
  • (3) The removal of a protecting group by hydrogenelysis may be carried out, for example, in a solvent (ether (tetrahydrofuran, dioxane, dimethoxyethane or diethylether etc.), alcohol(methanol or ethanol etc.), benzene(benzene or toluene etc.), ketone (acetone or methylethylketoneetc.), nitrile (acetonitrileetc.), amido (dimethylformamide etc.), water, ethyl acetate, acetic acid or a mixture thereof etc.) in the presence of a catalyst (palladium-carbon, palladium black, palladium hydroxide, platinum oxide, raney nickel etc.), at atmospheric or reduced pressure under an atmosphere of hydrogen or ammonium formate at 0-200° C. [0207]
  • (4) The removal of a protecting group using metal complex may be carried out, for example, in an organic solvent (dichloromethane, dimethylformamide or tetrahydrofuran etc.) in the presence of a trap reagent (tributyltin hydride or dimedone etc.) and/or an organic acid (acetic acid etc.) with metal complex (tetrakis(triphenylphosphine)palladium(O) complex etc.) at 0-40° C. [0208]
  • As well known to the person in the art, the aimed compounds of present invention may be prepared easily by choice of these reaction. [0209]
  • [2] Among the compounds of the present invention, hydroxamic acid derivatives of the formula (I) may be prepared by the method of (d) or (e). [0210]
  • (d) Among hydroxamic acid derivatives of the formula (I), the compound wherein R[0211] 1 doesn't represent a group containing amino, thiol or carboxy, i.e., the compound of the formula (I-d)
    Figure US20040214896A1-20041028-C00118
  • (wherein, all the symbols have the same meaning as defined hereinbefore.) may be prepared by the amidation with the compound of the above formula (II) and hydroxyamine (H[0212] 2N—OH).
  • The amidation may be carried out by the same procedure as described hereinbefore. [0213]
  • (e) Hydroxamic acid derivatives of the formula (I) may be prepared by the removal of a protecting group of the compounds of the above formula (IA). [0214]
  • The removal of a protecting group of the hydroxamic acid is known. For example, it is [0215]
  • (1) the removal of a protecting group in an alkaline condition, [0216]
  • (2) the removal of a protecting group in an acidic condition, or [0217]
  • (3) the removal of a protecting group by hydrogenelysis etc. [0218]
  • The removal of a protecting group may be carried out by the same procedure as described hereinbefore. [0219]
  • The reaction of the removal of a protecting group of hydroxamic acid in the present invention means an ordinal one which is well known to the person in the art, for example, the removal of a protecting group in an alkaline condition, the removal of a protecting group in an acidic condition or the removal of a protecting group by hydrogenelysis. The aimed compounds of the present invention may be prepared easily by choice of these reaction. [0220]
  • As well known to the person in the art, a protecting group of hydroxamic acid includes, for example, t-butyl, —C(CH[0221] 3)2—OCH3 and benzyl. In addition, such a group includes the other protecting group which is removable selectively and easily, for example, one described in T. W. Greene et. al., Protective Groups in Organic Synthesis, Third Edition, Wiley-Interscience, New York, 1999.
  • [3] Among the compounds of the present invention, the prodrugs of the formula (IB) may be prepared by the removal of the methanol in the compounds of the formula (IA) wherein R[0222] 14 is 1-methoxy-1-methylethyl, i.e., the compounds of the formula (IA-3)
    Figure US20040214896A1-20041028-C00119
  • (wherein, all the symbols have the same meaning as defined hereinbefore.). [0223]
  • The reaction of the removal of methanol is known. For example, it may be carried out in an organic solvent (benzene, toluene, dioxane or pyridine etc.) at 60-150° C. [0224]
  • The compounds of the formula (II) and (IV) are known per se or may be prepared according to the following Reaction Scheme 1 and Reaction Scheme 2 or by known methods easily. [0225]
    Figure US20040214896A1-20041028-C00120
    Figure US20040214896A1-20041028-C00121
  • In reaction scheme, [0226]
  • R[0227] 101 is C1-4 alkyl or —CH2CH2OCH2CH2OCH3,
  • R[0228] 1-a, R8, R9, R14, ring A, ring B, E, m, n or X have the same meaning as defined hereinbefore.
  • In above reaction schemes, each reaction may be carried out by each conventional technique. Further, in above reaction scheme, the compounds of the formula (X), (XIV), (III), (V) and (VI) used as starting materials have been known per se or may be prepared by known methods easily. [0229]
  • In each reaction in the present specification, obtained products may be purified by conventional techniques. For example, purification may be carried out by distillation at atmospheric or reduced pressure, by high performance liquid chromatography, by thin layer chromatography or by column chromatography using silica gel or magnesium silicate, by washing or by recrystallization. Purification may be carried out after each reaction, or after a series of reactions. [0230]
  • The other starting materials and each test compounds in the present invention have been known per se or may be prepared by known methods. [0231]
  • [Pharmacological Activities of the Compounds of the Present Invention][0232]
  • According to following experiments, it is confirmed that the compound of the present invention has an inhibitory activity on IL-6 production. [0233]
    • (1) The measurement of an Inhibitory Activity on IL-6 Production from A549 Cells
  • [Method][0234]
  • 1.5×10[0235] 4 of A549 cells (human lung epithelial cell line) were suspended in 100 μL of Dulbecco's Modified Eagle Medium (DMEM) containing 0.5% fetal bovine serum (abbreviated as FBS) and incubated for a day and night in 96 well-microplate. 20 μL of the test compound dissolved in dimethylsulfoxide (DMSO) at various concentrations and 80 μL of tumor necrosis factor-α (TNFα (Genzyme Co., cat. No. TNF-H)) dissolved in serum-free DMEM at the concentration of 12.5 ng/mL were added thereto. After the incubation for 24 hours, the supernatant (100 μL) was collected to measure the amount of IL-6 being produced using enzyme linked immuno solvent assay (ELISA) (R&D Systems Co., cat. No. D6050). Then the inhibitory activity of the test compound was calculated and the 50% inhibitory concentration (IC50) was determined. For example, the IC50 value of the compound of example 3 was 0.052 μM.
    • (2) The Measurement of an Inhibitory Activity on IL-6 Production from Human Synovial Cells
  • [Method][0236]
  • 3.0×10[0237] 3 of synovial cells from rheumatoid arthritis patients were suspended in 200 μL of DMEM containing 10% FBS and incubated for a day and night in 96 well-microplate, followed by the incubation for 5 hours in serum-free DMEM. 20 μL of the test compound dissolved in DMSO at various concentrations and 80 μL of interleukin-1β (IL-1β (Genzyme Co., cat. No. 80-3688-01)). dissolved in DMEM containing 2.5% fetal bovine serum at the concentration of 5 ng/mL were added thereto. After the incubation for 24 hours, the supernatant (100 μL) was collected to measure the amount of IL-6 being produced using ELISA (R&D Systems Co., cat. No. D6050). Then the inhibitory activity of the test compound was calculated and the 50% inhibitory concentration (IC50) was determined. For example, the IC50 value of the compound of example 3 was 0.041 μM.
    • (3) The Effect on Collagen-induced Arthritis Model in Rats
  • [Method][0238]
  • Eight weeks old female DA rats were used. During the experimental period, they were housed in animal room artificially kept the room temperature of 24±2° C., humidity of 55±5%, and 12 hours interval of light and dark cycle. They had free access to a standard solid pellet chow (CE-2, Japan CLEA) and drinking tap water, and were used for the experiment after a week acclimation. The collagen-induced arthritis was performed by the following method. After the mixing of bovine type II collagen (0.3% collagen solution, KOKEN #K-41, lot.11214, abbreviated as CII), incomplete Freund's adjuvant (DIFCO #0639-60) and saline with the ratio of 1:2:1, the mixture was then ultra-sonicated to form emulsion for 20 seconds×3 times at 1 minute interval. The intradermal injection of 0.1 mL of the emulsion (0.75mg of CII/mL) was performed on each four different portions of the back on day 0. A week after the first immunization, arthritis was elicited by the intradermal injection of 0.15 mL of the emulsion at the basal portion of the tail. The test compound was suspended in 0.5% carboxymethylcellulose solution, and was administered orally in the morning and evening twice a day from day 0 to day 28. According to the method of Osterman T et al. (Inflamm. Res., 44, 258-263, 1995), the severity of arthritis was judged and scored. The hind paw volume of each animal was also measured with the plethysmometer (UNICOM, TK-101CMP). For example, 10 mg/kg/day (b.i.d.) of the compound of the example 3 completely inhibited the development of arthritis, and the example 3 even at the dose of 3 mg/kg/day showed significant inhibition by approximately 60% on the arthritis score and the hind paw edema. [0239]
  • [Toxicity][0240]
  • The toxicity of the compounds of formula (I) of the present invention, non-toxic salts thereof or prodrugs thereof is very low and therefore the compounds may be considered safe for pharmaceutical use. [0241]
  • [Application for Pharmaceuticals][0242]
  • The compounds of the present invention possess an inhibitory activity of IL-6 production in animal, especially human, so they are useful for the prevention and/or treatment of, for example, various inflammatory diseases, sepsis, multiple myeloma, plasma cell leukemia, osteoporosis, cachexia, psoriasis, nephritis, renal cell carcinoma, Kaposi's sarcoma, rheumatoid arthritis, hypergammaglobulinemia , Castleman's disease, atrial myxoma, diabetes mellitus, autoimmne diseases, hepatitis, colitis, graft versus host disease, infectious diseases and endometriosis. [0243]
  • For the purpose above described, the compounds of formula (I), non-toxic salts thereof or prodrugs thereof may be normally administered systemically or locally, usually by oral or parenteral administration. [0244]
  • The doses to be administered are determined depending upon, for example, age, body weight, symptom, the desired therapeutic effect, the route of administration, and the duration of the treatment. In the human adult, the doses per person are generally from 1 mg to 1000 mg, by oral administration, up to several times per day, and from 0.1 mg to 100 mg, by parenteral administration (preferably intravenous administration), up to several times per day, or continuous administration from 1 to 24 hours per day from vein. [0245]
  • As mentioned above, the doses to be used depend upon various conditions. Therefore, there are cases in which doses lower than or greater than the ranges specified above may be used. [0246]
  • The compounds of the present invention may be administered in the form of, for example, solid forms for oral administration, liquid forms for oral administration, injections, liniments or suppositories for parenteral administration. [0247]
  • Solid forms for oral administration include compressed tablets, pills, capsules, dispersible powders, and granules. Capsules include hard capsules and soft capsules. [0248]
  • In such solid forms, one or more of the active compound(s) may be admixed with vehicles (such as lactose, mannitol, glucose, microcrystalline cellulose, starch), binders (such as hydroxypropyl cellulose, polyvinylpyrrolidone or magnesium metasilicate aluminate), disintegrants (such as cellulose calcium glycolate), lubricants (such as magnesium stearate), stabilizing agents, and solution adjuvants (such as glutamic acid or aspartic acid) and prepared according to methods well known in normal pharmaceutical practice. The solid forms may, if desired, be coated with coating agents (such as sugar, gelatin, hydroxypropyl cellulose or hydroxypropylmethyl cellulose phthalate), or be coated with two or more films. And further, coating may include containment within capsules of absorbable materials such as gelatin. [0249]
  • Liquid forms for oral administration include pharmaceutically acceptable solutions, suspensions and emulsions, syrups and elixirs. In such forms, one or more of the active compound(s) may be dissolved, suspended or emulized into diluent(s) commonly used in the art (such as purified water, ethanol or a mixture thereof). Furthermore, such liquid forms may also comprise some additives, such as wetting agents, suspending agents, emulsifying agents, sweetening agents, flavoring agents, aroma, preservative or buffering agent. [0250]
  • Injections for parenteral administration include sterile aqueous, suspensions, emulsions and solid forms which are dissolved or suspended into solvent(s) for injection immediately before use. In injections, one or more of the active compound(s) may be dissolved, suspended or emulized into solvent(s). The solvents may include distilled water for injection, physiological salt solution, vegetable oil, propylene glycol, polyethylene glycol, alcohol, e.g. ethanol, or a mixture thereof. Injections may comprise some additives, such as stabilizing agents, solution adjuvants (such as glutamic acid, aspartic acid or POLYSORBATE80 (registered trade mark)), suspending agents, emulsifying agents, soothing agent, buffering agents, preservative. They may be sterilized at a final step, or may be prepared and compensated according to sterile methods. They may also be manufactured in the form of sterile solid forms such as freeze-dried products, which may be dissolved in sterile water or some other sterile diluent(s) for injection immediately before use. [0251]
  • Other forms for parenteral administration include liquids for external use, ointments and endermic liniments, inhalations, sprays, suppositories and pessaries for vaginal administration which comprise one or more of the active compound(s) and may be prepared by methods known per se. [0252]
  • Sprays may comprise additional substances other than diluents, such as stabilizing agents (such as sodium sulfate), isotonic buffers (such as sodium chloride, sodium citrate or citric acid). For preparation of such sprays, for example, the method described in the U.S. Pat. Nos. 2,868,691 or 3,095,355 may be used. [0253]
    • The Best Mode for Carrying Out the Invention
  • The following reference examples and examples are intended to illustrate the present invention, but do not limit them. [0254]
  • In chromatographic separations and TLC, the solvents in parenthesis show the eluting and developing solvents and the ratios of the solvents used are by volume. [0255]
  • The solvents in parenthesis in NMR show the solvents used for measurement. [0256]
    • REFERENCE EXAMPLE 1 Ethyl 6-(4-(4-chlorophenyl)phenyl)-6-oxohexanoate
  • [0257]
    Figure US20040214896A1-20041028-C00122
  • To adipic acid mono ethyl ester (34.8 g) was added thionyl chloride (72 mL). The reaction mixture was stirred at 100° C. for 1.5 hours. The reaction mixture was concentrated to give adipinyl chloride mono ethyl ester. To a suspension of aluminium chloride (53.3 g) in dichloromethane (500 mL) was added 4-chlorobiphenyl (37.7 g) at 5° C. The reaction mixture was stirred for 15 minutes and a solution of adipinyl chloride mono ethyl ester in dichloromethane (200 mL) was added thereto at 5° C. The reaction mixture was stirred at room temperature for 2 hours. To the reaction mixture was added ice water and the mixture was extracted with dichloromethane. The extract was washed with water, a saturated aqueous solution of sodium hydrogen carbonate and a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, and concentrated. The obtained residue was recrystallized from hexane/ethyl acetate and dried to give the title compound (53.8 g) having the following physical data. [0258]
  • TLC: Rf 0.60 (chloroform), [0259]
  • NMR (CDCl[0260] 3): δ 8.04 (d, J=8.8 Hz, 2H), 7.64 (d, J=8.8 Hz, 2H), 7.56 (d, J=8.4 Hz, 2H), 7.44 (d, J=8.4 Hz, 2H), 4.14 (q, J=7.2 Hz, 2H), 3.03 (t, J=6.6 Hz, 2H), 2.38 (t, J=7.0 Hz, 2H), 1.95-1.60 (m, 4H), 1.26 (t, J=7.2 Hz, 3H).
    • REFERENCE EXAMPLE 2 Ethyl 6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanoate
  • [0261]
    Figure US20040214896A1-20041028-C00123
  • To a mixture solution of the compound prepared in reference example 1 (10.02 g) in dichloromethane (300 mL) and methanol (100 mL) was added sodium borohydride (5.4 g) at 0° C. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into a saturated aqueous solution of ammonium chloride and extracted with dichloromethane. The extract was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate, and concentrated to give the title compound (10.03 g) having the following physical data. [0262]
  • TLC: Rf 0.25 (chloroform), [0263]
  • NMR (CDCl[0264] 3): δ 7.65-7.34 (m, 8H), 4.73 (t, J=6.2 Hz, 1H), 4.11 (q, J=7.0 Hz, 2H), 2.03 (t, J=7.0 Hz, 2H), 1.90-1.30 (m, 6H), 1.23 (t, J=7.0 Hz, 3H).
    • REFERENCE EXAMPLE 3 6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanoic acid
  • [0265]
    Figure US20040214896A1-20041028-C00124
  • To a solution of the compound prepared in reference example 2 (10.03 g) in ethanol (100 mL) was added 2N aqueous solution of sodium hydroxide (50 mL). The reaction mixture was stirred at 60° C. for 1 hour. To the reaction mixture was added 1N aqueous solution of hydrochloric acid and the mixture was extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was recrystallized from isopropylalcohol and dried to give the title compound (9.12 g) having the following physical data. [0266]
  • TLC: Rf 0.52 (chloroform:tetrahydrofuran:acetic acid=10:4:1), [0267]
  • NMR(d[0268] 6-DMSO): δ 11.80 (brs, 1H), 7.68 (d, J=8 Hz, 2H), 7.61 (d, J=8 Hz, 2H), 7.49 (d, J=8 Hz, 2H), 7.40 (d, J=8 Hz, 2H), 5.16 (brs, 1H), 4.65-4.40 (m, 1H), 2.18 (t, J=7 Hz, 2H), 1.80-1.05 (m, 6H).
    • EXAMPLE 1 N-(1-methoxy-1-methyl)ethoxy-6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanamide
  • [0269]
    Figure US20040214896A1-20041028-C00125
  • Under an atmosphere of argon, to a solution of the compound prepared in reference example 3 (7.74 g) in dimethylformamide (150 mL) was added 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide (6.99 g), 1-hydroxybenzotriazol (5.58 g), (1-methoxy-1-methylethyl)hydroxyamine (8.0 g) and triethylamine (15.5 mL). The reaction mixture was stirred at room temperature overnight. The reaction mixture was poured into ice water and extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium hydrogen carbonate and a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by column chromatography on silica gel (ethyl acetate:hexane:triethylamine=80:20:1) to give the compound of the present invention (8.1 g) having the following physical data. [0270]
  • TLC: Rf 0.50 (ethyl acetate:methanol=20:1), [0271]
  • NMR(CDCl[0272] 3): δ 7.73 (brs, 1H), 7.60-7.35 (m, 8H), 4.74 (t, J=6 Hz, 1H), 3.31 (s, 3H), 2.50-1.15 (m, 8H), 1.41 (s, 6H).
    • EXAMPLE 2 N-hydroxy-6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanamide
  • [0273]
    Figure US20040214896A1-20041028-C00126
  • To a solution of the compound prepared in example 1 (7.27 g) in methanol (100 mL) was added concentrated hydrochloric acid (2.0 mL). The reaction mixture was stirred at room temperature for 30 minutes. The reaction mixture was concentrated and distilled off an azetropic mixture with ethanol. To the obtained residue was added ethyl acetate and the precipitated crystal was filtered and dried to give the compound of the present invention (5.55 g) having the following physical data. [0274]
  • TLC: Rf 0.21 (chloroform:methanol:acetic acid=10:1:1), [0275]
  • NMR(d[0276] 6-DMSO): δ 10.31 (s, 1H), 8.64 (s, 1H), 7.68 (d, J=8.8 Hz, 2H), 7.65 (d, J=8.8 Hz, 2H), 7.50 (d, J=8.4 Hz, 2H), 7.40 (d, J=8.4 Hz, 2H), 5.15 (d, J=4.4 Hz, 1H), 4.54 (m, 1H), 1.93 (t, J=7.3 Hz, 2H), 1.70-1.40 (m, 4H), 1.40-1.10 (m, 2H).
    • EXAMPLE 2(1)-2(5)
  • By the same procedure as a series of reactions of reference example 1→reference example 2→reference example 3→example 1→example 2 using a corresponding benzene derivative instead of 4-chlorobiphenyl, the following compounds of the present invention were obtained. [0277]
    • EXAMPLE 2(1) N-hydroxy-6-(4-biphenyl)-6-hydroxyhexanamide
  • [0278]
    Figure US20040214896A1-20041028-C00127
  • TLC: Rf 0.42 (ethyl acetate:methanol=39:1), [0279]
  • NMR(d[0280] 6-DMSO): δ 10.29 (brs, 1H), 8.64 (brs, 1H), 7.66-7.58 (m, 4H), 7.47-7.30 (m, 5H), 5.18-5.09 (m, 1H), 4.57-4.55 (m, 1H), 1.91 (t, J=7.5 Hz, 2H), 1.64-1.44 (m, 4H), 1.40-1.20 (m, 2H).
    • EXAMPLE 2(2) N-hydroxy-6-(4-cyclohexylphenyl)-6-hydroxyhexanamide
  • [0281]
    Figure US20040214896A1-20041028-C00128
  • TLC: Rf 0.32 (ethyl acetate), [0282]
  • NMR(d[0283] 6-DMSO): δ 10.29 (s, 1H), 8.63 (s, 1H), 7.19 (d, J=7.8 Hz, 2H), 7.12 (d, J=7.8 Hz, 2H), 4.98 (d, J=4.5 Hz, 1H), 4.40-4.38 (m, 1H), 2.48-2.40 (m, 1H), 1.89 (t, J=7.5 Hz, 2H), 1.81-1.12 (m, 16H).
    • EXAMPLE 2(3) N-hydroxy-6-(4-(4-methylphenyl)phenyl)-6-hydroxyhexanamide
  • [0284]
    Figure US20040214896A1-20041028-C00129
  • TLC: Rf 0.43 (ethyl acetate), [0285]
  • NMR(d[0286] 6-DMSO): δ 10.29 (brs, 1H), 8.62 (d, J=1.5 Hz, 1H), 7.56 (d, J=8.4 Hz, 2H), 7.53 (d, J=8.4 Hz, 2H), 7.36 (d, J=8.4 Hz, 2H), 7.25 (d, J=8.4 Hz, 2H), 5.11 (d, J=4.5 Hz, 1H), 4.54-4.48 (m, 1H), 2.33 (s, 3H), 1.91 (t, J=7.5 Hz, 2H), 1.63-1.16 (m, 6H).
    • EXAMPLE 2(4) N-hydroxy-6-(4-(4-methoxyphenyl)phenyl)-6-hydroxyhexanamide
  • [0287]
    Figure US20040214896A1-20041028-C00130
  • TLC: Rf 0.27 (chloroform:methanol:acetic acid=90:10:1), [0288]
  • NMR(d[0289] 6-DMSO): δ 10.29 (brs, 1H), 8.63 (d, J=1.5 Hz, 1H), 7.57 (d, J=8.1 Hz, 2H), 7.53 (d, J=8.1 Hz, 2H), 7.34 (d, J=8.1 Hz, 2H), 7.00 (d, J=8.1 Hz, 2H), 5.10 (d, J=4.5 Hz, 1H), 4.53-4.47 (m, 1H), 3.78 (s, 3H), 1.91 (t, J=7.2 Hz, 2H), 1.66-1.55 (m, 6H).
    • EXAMPLE 2(5) N-hydroxy-6-(4-(trans-4-propylcycrohexyl)phenyl)-6-hydroxyhexanamide
  • [0290]
    Figure US20040214896A1-20041028-C00131
  • TLC: Rf 0.16 (ethyl acetate), [0291]
  • NMR(d[0292] 6-DMSO): δ 10.29 (s, 1H), 8.63 (s, 1H), 7.20 (d, J=8.5 Hz, 2H), 7.13 (d, J=8.5 Hz, 2H), 4.98 (d, J=4.4 Hz, 1H), 4.43 (m, 1H), 2.41 (m, 1H), 2.00-0.90 (m, 21H), 0.88 (t, J=7.0 Hz, 3H).
    • REFERENCE EXAMPLE 4 Ethyl (R)-6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanoate
  • [0293]
    Figure US20040214896A1-20041028-C00132
  • To a solution of the compound prepared in reference example 1 (17.2 g) in tetrahydrofuran (1500 mL) was added a solution of 1.0M (S)-2-methyl-oxazaborolidine in toluene (5 mL) at room temperature. The reaction mixture was cooled to −15° C. and a solution of 2.0M borane-dimethylsulfide complex in tetrahydrofuran (21.3 mL) was added thereto. The reaction mixture was stirred at room temperature for 3 hours. To the reaction mixture was added methanol and the mixture was stirred over night. The reaction mixture was concentrated, diluted with ethyl acetate, washed with water and a saturated aqueous solution of sodium chloride, dried over magnesium sulfate, and concentrated. The obtained residue was purified by column chromatography on silica gel (hexane: ethyl acetate=1:1) to give the title compound (17 g, 94.2% e.e., HPLC) having the following physical data. [0294]
  • TLC: Rf 0.25 (chloroform), [0295]
  • HPLC: 13.7 min (retention time), Column: DAICEL CHIRAL CEL AD-RH, 4.6×150 mm; Eluant: acetonitrile:water=75:25; UV: 260 nm; Flow rate: 1.0 mL/min. [0296]
    • REFERENCE EXAMPLE 5 Ethyl (S)-6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanoate
  • [0297]
    Figure US20040214896A1-20041028-C00133
  • By the same procedure as a series of reactions of reference example 4 using a solution of 1.0M (R)-2-methyl-oxazaborolidine in toluene instead of a solution of 1.0M (S)-2-methyl-oxazaborolidine in toluene , the title compound (91% e.e., HPLC) having the following physical data was obtained. [0298]
  • TLC: Rf 0.25 (chloroform), [0299]
  • HPLC: 9.8 min (retention time), Column: DAICEL CHIRAL CEL AD-RH, 4.6×150 mm; Eluant: acetonitrile:water=75:25; UV: 260 nm; Flow rate: 1.0 mL/min. [0300]
    • EXAMPLE 3 (R)-(+)-N-hydroxy-6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanamide
  • [0301]
    Figure US20040214896A1-20041028-C00134
  • By the same procedure as a series of reactions of reference example 3→example 1→example 2 using the compound prepared in reference example 4 instead of the compound prepared in reference example 2, the compound of the present invention (98.7% e.e., HPLC) having the following physical data was obtained. [0302]
  • TLC: Rf 0.21 (chloroform:methanol:acetic acid=10:1:1), [0303]
  • [α][0304] D: +9.27 (c 0.280, methanol),
  • HPLC: 16.8 min (retention time), Column: DAICEL CHIRAL CELAD-RH, 4.6×150 mm; Eluant: acetonitrile:water=35:65; UV: 260 nm; Flow rate: 1.0 mL/min. [0305]
    • EXAMPLE 3(1) (S)-(−)-N-hydroxy-6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanamide
  • [0306]
    Figure US20040214896A1-20041028-C00135
  • By the same procedure as a series of reactions of example 3 using the compound prepared in reference example 5 instead of the compound prepared in reference example 4, the compound of the present invention (>98% e.e., HPLC) having the following physical data was obtained. [0307]
  • TLC: Rf 0.21 (chloroform:methanol:acetic acid=10:1:1), [0308]
  • [α][0309] D: −9.60 (c 0.265, methanol),
  • HPLC: 11.6 min (retention time), Column: DAICEL CHIRAL CELAD-RH, 4.6×150 mm; Eluant: acetonitrile:water=35:65; UV: 260 nm; Flow rate: 1.0 mL/min. [0310]
    • REFERENCE EXAMPLE 6 N-(1-methoxy-1-methyl)ethoxy-6-(4-iodophenyl)-6-hydroxyhexanamide
  • [0311]
    Figure US20040214896A1-20041028-C00136
  • By the same procedure as a series of reactions of reference example 1→reference example 2→reference example 3→example 1 using iodobenzene instead of 4-chlorobiphenyl, the title compound having the following physical data was obtained. [0312]
  • TLC: Rf 0.40 (ethyl acetate), [0313]
  • NMR(CDCl[0314] 3): δ 7.69-7.63 (m, 3H), 7.08 (d, J=8.2 Hz, 2H), 4.64 (t, J=6.2 Hz, 1H), 3.31 (s, 3H), 2.42-1.21 (m, 8H), 1.41 (s, 6H).
    • EXAMPLE 4 N-(1-methoxy-1-methyl)ethoxy-6-(4-(benzofuran-2-yl)phenyl)-6-hydroxyhexanamide
  • [0315]
    Figure US20040214896A1-20041028-C00137
  • To a solution of the compound prepared in reference example 6 (440 mg) in dimethylformamide (10 mL) was added tri-potassium phosphate (333 mg), tetrakis(triphenylphosphine)palladium (120 mg) and benzofuran-2-boronic acid (400 mg). The reaction mixture was stirred at 60° C. for 2 hours. To the reaction mixture was added water and the mixture was extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium chloride, dried over sodium sulfate and concentrated. The obtained residue was purified by column chromatography on silica gel (ethyl acetate:hexane=1:1→7:3→1:0) to give the compound of the present invention (178 mg) having the following physical data. [0316]
  • TLC: Rf 0.39 (ethyl acetate). [0317]
    • EXAMPLE 5 N-hydroxy-6-(4-(benzofuran-2-yl)phenyl)-6-hydroxyhexanamide
  • [0318]
    Figure US20040214896A1-20041028-C00138
  • By the same procedure as a series of reactions of example 2 using the compound prepared in example 4 instead of the compound prepared in example 1, the compound of the present invention having the following physical data was obtained. [0319]
  • TLC: Rf 0.29 (ethyl acetate), [0320]
  • NMR(d[0321] 6-DMSO): δ 10.28 (s, 1H), 7.85 (d, J=8.1 Hz, 2H), 7.65-7.59 (m, 2H), 7.42 (d, J=8.1 Hz, 2H), 7.37 (s, 1H), 7.32-7.21 (m, 2H), 4.58-4.51 (m, 1H), 1.90 (t, J=7.2 Hz, 2H), 1.62-1.14 (m, 6H).
    • EXAMPLE 5(1)-5(18)
  • By the same procedure as a series of reactions of example 4→example 5 using a corresponding boronic acid instead of benzofuran-2-boronic acid, the following compounds of the present invention were obtained. [0322]
    • EXAMPLE 5(1) N-hydroxy-6-(4-(pyridin-4-yl)phenyl)-6-hydroxyhexanamide
  • [0323]
    Figure US20040214896A1-20041028-C00139
  • TLC: Rf 0.33 (chloroform:methanol:acetic acid=90:10:1), [0324]
  • NMR(d[0325] 6-DMSO): δ 10.30 (s, 1H), 8.63 (s, 1H), 8.61 (dd, J=4.8 Hz, 1.5 Hz, 2H), 7.74 (d, J=8.1 Hz, 2H), 7.68 (dd, J=4.8 Hz, 1.5 Hz, 2H), 7.44 (d, J=8.1 Hz, 2H), 5.21 (d, J=4.5 Hz, 1H), 4.58-4.52 (m, 1H), 1.91 (t, J=7.2 Hz, 2H), 1.64-1.14 (m, 6H).
    • EXAMPLE 5(2) N-hydroxy-6-(4-(pyridin-3-yl)phenyl)-6-hydroxyhexanamide
  • [0326]
    Figure US20040214896A1-20041028-C00140
  • TLC: Rf 0.34 (chloroform:methanol:acetic acid=90:10:1), [0327]
  • NMR(d[0328] 6-DMSO): δ 10.29 (s, 1H), 8.86 (d, J=1.8 Hz, 1H), 8.62 (s, 1H), 8.54 (dd, J=4.8 Hz, 1.8 Hz, 1H), 8.06-8.02 (m, 1H), 7.65 (d, J=8.1 Hz, 2H), 7.48-7.43 (m, 1H), 7.42 (d, J=8.1 Hz, 2H), 5.17 (d, J=4.5 Hz, 1H), 4.56-4.50 (m, 1H), 1.90 (t, J=7.5 Hz, 2H), 1.63-1.18 (m, 6H).
    • EXAMPLE 5(3) N-hydroxy-6-(4-(2-chlorophenyl)phenyl)-6-hydroxyhexanamide
  • [0329]
    Figure US20040214896A1-20041028-C00141
  • TLC: Rf 0.25 (ethyl acetate), [0330]
  • NMR(d[0331] 6-DMSO): δ 10.29 (s, 1H), 8.63 (s, 1H), 7.55-7.52 (m, 1H), 7.40-7.33 (m, 7H), 5.16 (d, J=4.5 Hz, 1H), 4.54-4.51 (m, 1H), 1.91 (t, J=6.9 Hz, 2H), 1.65-1.20 (m, 6H).
    • EXAMPLE 5(4) N-hydroxy-6-(4-(3-chlorophenyl)phenyl)-6-hydroxyhexanamide
  • [0332]
    Figure US20040214896A1-20041028-C00142
  • TLC: Rf 0.23 (ethyl acetate), [0333]
  • NMR(d[0334] 6-DMSO): δ 10.29 (s, 1H), 8.63 (s, 1H), 7.68 (t, J=1.8 Hz, 1H), 7.63-7.60 (m, 3H), 7.46 (t, J=8.1 Hz, 1H), 7.40-7.37 (m, 3H), 5.16 (d, J=4.2 Hz, 1H), 4.54-4.50 (m, 1H), 1.90 (t, J=7.2 Hz, 2H), 1.63-1.20 (m, 6H).
    • EXAMPLE 5(5) N-hydroxy-6-(4-(4-bromophenyl)phenyl)-6-hydroxyhexanamide
  • [0335]
    Figure US20040214896A1-20041028-C00143
  • TLC: Rf 0.35 (ethyl acetate:methanol=9:1), [0336]
  • NMR(d[0337] 6-DMSO): δ 10.31 (s, 1H), 8.64 (s, 1H), 7.70-7.50 (m, 6H), 7.40 (d, J=8.4 Hz, 2H), 5.15 (d, J=4.5 Hz, 1H), 4.54 (m, 1H), 1.93 (t, J=7.2 Hz, 2H), 1.70-120 (m, 6H).
    • EXAMPLE 5(6) N-hydroxy-6-(4-(thiophen-2-yl)phenyl)-6-hydroxyhexanamide
  • [0338]
    Figure US20040214896A1-20041028-C00144
  • TLC: Rf 0.26 (ethyl acetate), [0339]
  • NMR(d[0340] 6-DMSO): δ 10.28 (s, 1H), 8.62 (brs, 1H), 7.57 (d, J=8.7 Hz, 2H), 7.49 (dd, J=5.1 Hz, 1.2 Hz, 1H), 7.45 (dd, J=3.6 Hz, 1.2 Hz, 1H), 7.32 (d, J=8.7 Hz, 2H), 7.10 (dd, J=5.1 Hz, 3.6 Hz, 1H), 5.13 (d, J=4.5 Hz, 1H), 4.51-4.45 (m, 1H), 1.89 (t, J=6.9 Hz, 2H), 1.60-1.15 (m, 6H).
    • EXAMPLE 5(7) N-hydroxy-6-(4-(furan-2-yl)phenyl)-6-hydroxyhexanamide
  • [0341]
    Figure US20040214896A1-20041028-C00145
  • TLC: Rf 0.27 (ethyl acetate), [0342]
  • NMR(d[0343] 6-DMSO): δ 10.28 (brs, 1H), 8.65 (brs, 1H), 7.70 (d, J=2.1 Hz, 1H), 7.62 (d, J=8.4 Hz, 2H), 7.33 (d, J=8.4 Hz, 2H), 6.87 (d, J=3.6 Hz, 1H), 6.56 (dd, J=3.6 Hz, 2.1 Hz, 1H), 5.13 (d, J=4.5 Hz, 1H), 4.50-4.45 (m, 1H), 1.89 (t, J=7.2 Hz, 2H), 1.60-1.12 (m, 6H).
    • EXAMPLE 5(8) N-hydroxy-6-(4-(1,3-dioxy-2,3-dihydroinden-5-yl)phenyl)-6-hydroxyhexanamide
  • [0344]
    Figure US20040214896A1-20041028-C00146
  • TLC: Rf 0.22 (ethyl acetate), [0345]
  • NMR(d[0346] 6-DMSO): δ 10.28 (s, 1H), 8.62 (brs, 1H), 7.51 (d, J=8.1 Hz, 2H), 7.32 (d, J=8.1 Hz, 2H), 7.21 (d, J=1.8 Hz, 1H), 7.10 (dd, J=8.1 Hz, 1.8 Hz, 1H), 6.96 (d, J=8.1 Hz, 1H), 6.03 (s, 2H), 5.10 (d, J=4.5 Hz, 1H), 4.52-4.47 (m, 1H), 1.90 (t, J=7.2 Hz, 2H), 1.60-1.12 (m, 6H).
    • EXAMPLE 5(9) N-hydroxy-6-(4-(4-methylthiophenyl)phenyl)-6-hydroxyhexanamide
  • [0347]
    Figure US20040214896A1-20041028-C00147
  • TLC: Rf 0.27 (ethyl acetate), [0348]
  • NMR(d[0349] 6-DMSO): δ 10.28 (s, 1H), 8.62 (brs, 1H), 7.59 (d, J=8.4 Hz, 2H), 7.57 (d, J=8.4 Hz, 2H), 7.36 (d, J=8.4 Hz, 2H), 7.32 (d, J=8.4 Hz, 2H), 5.12 (d, J=4.2 Hz, 1H), 4.53-4.48 (m, 1H), 3.30 (s, 3H), 1.90 (t, J=7.2 Hz, 2H), 1.62-1.16 (m, 6H),
    • EXAMPLE 5(10) N-hydroxy-6-(4-(naphthalen-1-yl)phenyl)-6-hydroxyhexanamide
  • [0350]
    Figure US20040214896A1-20041028-C00148
  • TLC: Rf 0.30 (ethyl acetate), [0351]
  • NMR(d[0352] 6-DMSO): δ 10.31 (s, 1H), 8.64 (s, 1H), 7.99-7.91 (m, 2H), 7.80 (d, J=8.1 Hz, 1H), 7.58-7.39 (m, 8H), 5.19 (d, J=4.5 Hz, 1H), 4.61-4.55 (m, 1H), 1.94 (t, J=7.5 Hz, 2H), 1.68-1.23 (m, 6H).
    • EXAMPLE 5(11) N-hydroxy-6-(4-(naphthalen-2-yl)phenyl)-6-hydroxyhexanamide
  • [0353]
    Figure US20040214896A1-20041028-C00149
  • TLC: Rf 0.27 (ethyl acetate), [0354]
  • NMR(d[0355] 6-DMSO): δ 10.29 (s, 1H), 8.27 (s, 1H), 8.19 (s, 1H), 7.99-7.90 (m, 3H), 7.83 (dd, J=8.1 Hz, 1.5 Hz, 1H), 7.75 (d, J=8.1 Hz, 2H), 7.55-7.47 (m, 2H), 7.43 (d, J=8.1 Hz, 2H), 5.16 (d, J=4.2 Hz, 1H), 4.60-4.51 (m, 1H), 1.91 (t, J=7.2 Hz, 2H), 1.66-1.20 (m, 6H).
    • EXAMPLE 5(12) N-hydroxy-6-(4-(4-acetylphenyl)phenyl)-6-hydroxyhexanamide
  • [0356]
    Figure US20040214896A1-20041028-C00150
  • TLC: Rf 0.19 (chloroform:methanol:triethylamine=8:1:1), [0357]
  • NMR(d[0358] 6-DMSO): δ 10.31 (s, 1H), 8.64 (s, 1H), 8.03 (d, J=8.4 Hz, 2H), 7.82 (d, J=8.4 Hz, 2H), 7.70 (d, J=8.4 Hz, 2H), 7.44 (d, J=8.4 HZ, 2H), 5.18 (d, J=4.5 Hz, 1H), 4.56 (m, 1H), 2.61 (s, 3H), 1.92 (t, J=7.8 Hz, 2H), 1.70-1.42 (m, 4H), 1.42-1.18 (m, 2H).
    • EXAMPLE 5(13) N-hydroxy-6-(4-(4-hydroxyphenyl)phenyl)-6-hydroxyhexanamide
  • [0359]
    Figure US20040214896A1-20041028-C00151
  • TLC: Rf 0.23 (ethyl acetate), [0360]
  • NMR(d[0361] 6-DMSO): δ 10.28 (s, 1H), 9.47 (s, 1H), 8.62 (s, 1H), 7.48 (d, J=8.4 Hz, 2H), 7.44 (d, J=8.7 Hz, 2H), 7.31 (d, J=8.4 Hz, 2H), 6.81 (d, J=8.7 Hz, 2H), 5.07 (d, J=4.2 Hz, 1H), 4.51-4.45 (m, 1H), 1.90 (t, J=7.2 Hz, 2H), 1.62-1.17 (m, 6H).
    • EXAMPLE 5(14) N-hydroxy-6-(4-(dibenzofuran4-yl)phenyl)-6-hydroxyhexanamide
  • [0362]
    Figure US20040214896A1-20041028-C00152
  • TLC: Rf 0.29 (ethyl acetate), [0363]
  • NMR(d[0364] 6-DMSO): δ 10.30 (s, 1H), 8.63 (s, 1H), 8.18 (d, J=7.2 Hz, 1H), 8.13 (dd, J=7.5 Hz, 1.2 Hz, 1H), 7.84 (d, J=8.1 Hz, 2H), 7.73 (d, J=7.2 Hz, 1H), 7.67 (dd, J=7.5 Hz, 1.2 Hz, 1H), 7.56-7.39 (m, 5H), 5.19 (d, J=4.2 Hz, 1H), 4.60-4.55 (m, 1H), 1.93 (t, J=7.2 Hz, 2H), 1.66-1.21 (m, 6H).
    • EXAMPLE 5(15) N-hydroxy-6-(4-(2-methoxyphenyl)phenyl)-6-hydroxyhexanamide
  • [0365]
    Figure US20040214896A1-20041028-C00153
  • TLC: Rf 0.20 (chloroform:methanol:triethylamine=8:1:1), [0366]
  • NMR(d[0367] 6-DMSO): δ 10.31 (s, 1H), 8.65 (s, 1H), 7.40 (d, J=8.4 Hz, 2H), 7.36-7.23 (m, 2H), 7.33 (d, J=8.4 Hz, 2H), 7.10 (d, J=8.4 Hz, 1H), 7.02 (t, J=7.5 Hz, 1H), 5.11 (d, J=4.5 Hz, 1H), 4.51 (m, 1H), 3.76 (s, 3H), 1.93 (t, J=7.2 Hz, 2H), 1.68-1.15 (m, 6H).
    • EXAMPLE 5(16) N-hydroxy-6-(4-(3-methoxyphenyl)phenyl)-6-hydroxyhexanamide
  • [0368]
    Figure US20040214896A1-20041028-C00154
  • TLC: Rf 0.20 (chloroform:methanol:triethylamine=8:1:1), [0369]
  • NMR(d[0370] 6-DMSO): δ 10.30 (s, 1H), 8.64 (s, 1H), 7.60 (d, J=8.1 Hz, 2H), 7.38 (d, J=8.1 Hz, 2H), 7.36 (t, J=8.1 Hz, 1H), 7.23-7.13 (m, 2H), 6.95-6.87 (m, 1H), 5.14 (d, J=4.2 Hz, 1H), 4.53 (m, 1H), 3.80 (s, 3H), 1.92 (t, J=7.2 Hz, 2H), 1.70-1.15 (m, 6H).
    • EXAMPLE 5(17) N-hydroxy-6-(4-(4-trifluoromethylphenyl)phenyl)-6-hydroxyhexanamide
  • [0371]
    Figure US20040214896A1-20041028-C00155
  • TLC: Rf 0.20 (chloroform:methanol:triethylamine=8:1:1), [0372]
  • NMR(d[0373] 6-DMSO): δ 10.31 (s, 1H), 8.65 (s, 1H), 7.89 (d, J=8.7 Hz, 2H), 7.80 (d, J=8.7 Hz, 2H), 7.69 (d, J=8.7 Hz, 2H), 7.44 (d, J=8.7 Hz, 2H), 5.20 (d, J=4.2 Hz, 1H), 4.56 (m, 1H), 1.93 (t, J=7.5 Hz, 2H), 1.70-1.15 (m, 6H).
    • EXAMPLE 5(18) N-hydroxy-6-(4-(4-t-butylphenyl)phenyl)-6-hydroxyhexanamide
  • [0374]
    Figure US20040214896A1-20041028-C00156
  • TLC: Rf 0.20 (chloroform:methanol:triethylamine=8:1:1), [0375]
  • NMR(d[0376] 6-DMSO): δ 10.31 (s, 1H), 8.64 (s, 1H), 7.57 (d, J=8.4 Hz, 4H), 7.46 (d, J=8.4 Hz, 2H), 7.38 (d, J=8.4 Hz, 2H), 5.13 (d, J=4.2 Hz, 1H), 4.52 (m, 1H), 1.92 (t, J=7.2 Hz, 2H), 1.65-1.20 (m, 6H), 1.31 (s, 9H).
    • REFERENCE EXAMPLE 7 2-(2-methoxyethoxy)ethyl 6-(4-bromophenyl)-6-oxohexanoate
  • [0377]
    Figure US20040214896A1-20041028-C00157
  • To a solution of 6-(4-bromophenyl)-6-oxohexanoic acid (52 g) in dichloromethane (200 mL) was added oxalyl chloride (32 mL). The reaction mixture was stirred at 40° C. for 3 hours. The reaction mixture was concentrated. A solution of the obtained residue in toluene (500 mL) was dropped to di(ethylene glycol)methyl ether (65 mL) at 0° C. The reaction mixture was stirred at room temperature overnight and triethylamine (25 mL) was dropped thereto at room temperature. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water and extracted with ethyl acetate. The extract was washed with water and a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and concentrated. To the obtained residue was added methanol and the precipitate was filtrated. The filtrate was concentrated to give the title compound (88 g) having the following physical data. [0378]
  • TLC: Rf 0.43 (hexane:ethyl acetate=2:3), [0379]
  • NMR(CDCl[0380] 3): δ 7.81 (d, J=8.7 Hz, 2H), 7.60 (d, J=8.7 Hz, 2H), 4.24 (t, J=4.8 Hz, 2H), 3.69 (t, J=4.8 Hz, 2H), 3.66-3.62 (m, 2H), 3.56-3.53 (m, 2H), 3.38 (s, 3H), 2.95 (t, J=7.2 Hz, 2H), 2.40 (t, J=7.2 Hz, 2H), 1.83-1.67 (m, 4H).
    • REFERENCE EXAMPLE 8 2-(2-methoxyethoxy)ethyl 6-[4-(N-(2-hydroxy-5-methylphenyl)carbamoyl)phenyl]-6-oxohexanoate
  • [0381]
    Figure US20040214896A1-20041028-C00158
  • Under an atmosphere of argon, to a solution of compound prepared in reference example 7 (75 g) in dimethylacetamide (300 mL) was added 4-methyl-2-aminophenol (17.9 g), dichlorobis(triphenylphosphine)palladium(II) (2.78 g), triphenylphosphine (2.07 g), 1,8-diazabicyclo[5.4.0]undec-7-ene (23.7 mL). The atmosphere of argon was replaced with carbon monoxide. The reaction mixture was stirred at 150° C. for 2.5 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The extract was washed with 1N hydrochloric acid water and a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and concentrated. The obtained residue was washed with diethyl ether to give the title compound (51.3 g) having the following physical data. [0382]
  • TLC: Rf 0.27 (hexane:ethyl acetate=1:2), [0383]
  • NMR(CDCl[0384] 3): δ 8.29 (brs, 1H), 8.04 (d, J=8.7 Hz, 2H), 8.00-7.98 (m, 1H), 7.97 (d, J=8.7 Hz, 2H), 7.19 (s, 1H), 6.98-6.93 (m, 2H), 4.24 (t, J=5.0 Hz, 2H), 3.70 (t, J=5.0 Hz, 2H), 3.66-3.63 (m, 2H), 3.56-3.53 (m, 2H), 3.37 (s, 3H), 3.02 (t, J=6.9 Hz, 2H), 2.40 (t, J=6.9 Hz, 2H), 2.29 (s, 3H), 1.86-1.68 (m, 4H).
    • REFERENCE EXAMPLE 9 2-(2-methoxyethoxy)ethyl 6-[4-(5-methylbenzoxazol-2-yl)phenyl]-6-oxohexanoate
  • [0385]
    Figure US20040214896A1-20041028-C00159
  • To a suspension of the compound prepared in reference example 8 (49 g) in toluene (500 mL) was added camphor sulfonic acid (24.9 g). The reaction mixture was stirred at. 150° C. for 3.5 hours with dehydrating with Dean-Stark. The reaction mixture was poured into ice water and extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium hydrogen carbonate, water and a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and concentrated. The obtained residue was purified by column chromatography on silica gel (dichloromethane:ethyl acetate=10:1˜1:1) to give the title compound (33.1 g) having the following physical data. [0386]
  • TLC: Rf 0.42 (hexane:ethyl acetate=1:2), [0387]
  • NMR(CDCl[0388] 3): δ 8.33 (d, J=8.7 Hz, 2H), 8.08 (d, J=8.7 Hz, 2H), 7.58 (d, J=1.5 Hz, 1H), 7.48 (d, J=8.1 Hz, 1H), 7.20 (dd, J=8.1, 1.5 Hz, 1H), 4.25 (t, J=4.8 Hz, 2H), 3.70 (t, J=4.8 Hz, 2H), 3.66-3.62 (m, 2H), 3.57-3.53 (m, 2H), 3.38 (s, 3H), 3.05 (t, J=7.0 Hz, 2H), 2.50 (s, 3H), 2.42 (t, J=7.0 Hz, 2H), 1.87-1.70 (m, 4H).
    • REFERENCE EXAMPLE 9(1) 2-(2-methoxyethoxy)ethyl 6-[4-(benzoxazol-2-yl)phenyl]-6-oxohexanoate
  • [0389]
    Figure US20040214896A1-20041028-C00160
  • By the same procedure as a series of reactions of reference example 8→reference example 9 using 2-aminophenol instead of 4-methyl-2-aminophenol, the title compound having the following physical data were obtained. [0390]
  • TLC: Rf 0.45 (hexane:ethyl acetate=2:3), [0391]
  • NMR(CDCl[0392] 3): δ 8.35 (d, J=8.8 Hz, 2H), 8.09 (d, J=8.8 Hz, 2H), 7.85-7.77 (m, 1H), 7.67-7.58 (m, 1H), 7.45-7.37 (m, 2H), 4.24 (t, J=4.8 Hz, 2H), 3.72 (t, J=4.8 Hz, 2H), 3.67-3.62 (m, 2H), 3.58-3.53 (m, 2H), 3.38 (s, 3H), 3.05 (t, J=7.0 Hz, 2H), 2.42 (t, J=7.0 Hz, 2H), 1.90-1.70 (m, 4H).
    • REFERENCE EXAMPLE 10 2-(2-methoxyethoxy)ethyl 6-[4-(2-(4-methylthiophenyl)ethynyl)phenyl]-6-oxohexanoate
  • [0393]
    Figure US20040214896A1-20041028-C00161
  • Under an atmosphere of argon, to a mixture solution of the compound prepared in reference example 7 (80 g) in dimethylformamide (310 mL) and triethylamine (155 mL) was added 1-ethynyl-4-methylthiobenzene (27.5 g) and dichlorobis(triphenylphosphine)palladium(II) (10.9 g). The reaction mixture was stirred at 50° C. for 3 hours. The reaction mixture was poured into an aqueous solution of 2N hydrochloric acid cooled with ice and extracted with ethyl acetate. The extract was washed with 2N hydrochloric acid, a saturated aqueous solution of sodium hydrogen carbonate and a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and concentrated. The obtained residue was purified by column chromatography on silica gel (hexane:ethyl acetate=2:1→2:3 chloroform:methanol=20:1) to give the title compound (41.1 g) having the following physical data. [0394]
  • TLC: Rf 0.21 (hexane:ethyl acetate 2:1), [0395]
  • NMR(CDCl[0396] 3): δ 7.93 (d, J=8.6 Hz, 2H), 7.59 (d, J=8.6 Hz, 2H), 7.46 (d, J=8.6 Hz, 2H), 7.22 (d, J=8.6 Hz, 2H), 4.28-4.20 (m, 2H), 3.75-3.60 (m, 4H), 3.60-3.50 (m, 2H), 3.38 (s, 3H), 2.99 (t, J=7.0 Hz, 2H), 2.51 (s, 3H), 2.41 (t, J=7.0 Hz, 2H), 1.85-1.65 (m, 4H).
    • REFERENCE EXAMPLE 11 2-(2-methoxyethoxy)ethyl 6-[4-(4-methylthiophenyl)phenyl]-6-oxohexanoate
  • [0397]
    Figure US20040214896A1-20041028-C00162
  • By the same procedure as a series of reactions of example 4 using the compound prepared in reference example 7 and 4-methylthiophenylboronic acid, the title compound having the following physical data was obtained. [0398]
  • TLC: Rf 0.24 (hexane:ethyl acetate=1:1), [0399]
  • NMR(CDCl[0400] 3): δ 8.01 (d, J=8.7 Hz, 2H), 7.65 (d, J=8.7 Hz, 2H), 7.56 (d, J=8.4 Hz, 2H), 7.34 (d, J=8.4 Hz, 2H), 4.25 (t, J=4.8 Hz, 2H), 3.70 (t, J=4.8 Hz, 2H), 3.66-3.63 (m, 2H), 3.56-3.53 (m, 2H), 3.38 (s, 3H), 3.01 (t, J=6.9 Hz, 2H), 2.53 (s, 3H), 2.41 (t, J=6.9 Hz, 2H), 1.86-1.70 (m, 4H).
    • REFERENCE EXAMPLE 12 Methyl 6-[4-(4-methylthiophenyl)phenyl]-6-oxohexanoate
  • [0401]
    Figure US20040214896A1-20041028-C00163
  • By the same procedure as a series of reactions of reference example 1 using monomethyl adipate and 4-(N,N-dimethylamino)methylbiphenyl, the title compound having the following physical data was obtained. [0402]
  • TLC: Rf 0.51 (dichloromethane:methanol=4:1), [0403]
  • NMR(CDCl[0404] 3): δ 8.01 (d, J=8.7 Hz, 2H), 7.68 (d, J=8.7 Hz, 2H), 7.59 (d, J=8.3 Hz, 2H), 7.42 (d, J=8.3 Hz, 2H), 3.67 (s, 3H), 3.50 (s, 2H), 3.02 (t, J=7.0 Hz, 2H), 2.39 (t, J=7.0 Hz, 2H), 2.29 (s, 6H), 1.86-1.70 (m, 4H).
    • EXAMPLE 6 (R)-(+)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(5-methylbenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide
  • [0405]
    Figure US20040214896A1-20041028-C00164
  • By the same procedure as a series of reactions of reference example 4→reference example 3→example 1 using the compound prepared in reference example 9, the compound of the present invention having the following physical data was obtained. [0406]
  • [α][0407] D: +22.46 (c 0.615, dimethylformamide),
  • TLC: Rf 0.34 (ethyl acetate), [0408]
  • NMR(CDCl[0409] 3): δ 8.19 (d, J=8.1 Hz, 2H), 7.84 (brs, 1H), 7.54-7.53 (m, 1H), 7.47 (d, J=8.1 Hz, 2H), 7.44 (d, J=8.1 Hz, 1H), 7.16-7.13 (m, 1H), 4.80-4.75 (m, 1H), 3.30 (s, 3H), 2.48 (s, 3H), 2.42-2.08 (m, 2H), 1.94-1.32 (m, 6H), 1.41 (s, 6H).
    • EXAMPLE 6(1)-6(4)
  • By the same procedure as a series of reactions of example 6 using the compound prepared in reference example 9(1), 10, 11 or 12 instead of the compound prepared in reference example 9, the compounds of the present invention having the following physical data were obtained. [0410]
    • EXAMPLE 6(1) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(benzoxazol-2-yl)phenyl]-6-hydroxyhexanamide
  • [0411]
    Figure US20040214896A1-20041028-C00165
  • TLC: Rf 0.50 (chloroform:methanol:acetic acid=90:10:1), [0412]
  • NMR(CDCl[0413] 3): δ 8.22 (d, J=8.2 Hz, 2H), 7.83 (br, 1H), 7.75 (m, 1H), 7.59 (m, 1H), 7.49 (d, J=8.2 Hz, 2H), 7.35 (m, 2H), 4.76 (t, J=6.5 Hz, 1H), 3.30 (s, 3H), 2.45-2.12 (m, 2H), 1.85-1.62 (m, 4H), 1.53-1.38 (m, 2H), 1.41 (s, 6H).
    • EXAMPLE 6(2) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(2-(4-methylthiophenyl)ethynyl)phenyl]-6-hydroxyhexanamide
  • [0414]
    Figure US20040214896A1-20041028-C00166
  • TLC: Rf 0.41 (chloroform:methanol:acetic acid=90:10:1), [0415]
  • NMR(CDCl[0416] 3): δ 7.86 (br, 1H), 7.48 (d, J=8.4 Hz, 2H), 7.42 (d, J=8.4 Hz, 2H), 7.30 (d, J=8.4 Hz, 2H), 7.20 (d, J=8.4 Hz, 2H), 4.68 (t-like, J=6.0 Hz, 1H), 3.31 (s, 3H), 2.49 (s, 3H), 2.40-2.10 (m, 2H), 1.82-1.65 (m, 4H), 1.50-1.35 (m, 2H), 1.41 (s, 6H).
    • EXAMPLE 6(3) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-methylthiophenyl)phenyl]-6-hydroxyhexanamide
  • [0417]
    Figure US20040214896A1-20041028-C00167
  • TLC: Rf 0.44 (ethyl acetate), [0418]
  • NMR(CDCl[0419] 3): δ 7.79 (br, 1H), 7.53 (d, J=8.5 Hz, 2H), 7.51 (d, J=8.5 Hz, 2H), 7.38 (d, J=8.5 Hz, 2H), 7.31 (d, J=8.5 Hz, 2H), 4.71 (t, J=6.0 Hz, 1H), 3.30 (s, 3H), 2.52 (s, 3H), 2.43-2.08 (m, 2H), 1.90-1.65 (m, 5H), 1.57-1.36 (m, 1H), 1.41 (s, 6H).
    • EXAMPLE 6(4) (R)-(+)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-(dimethylaminomethyl)phenyl)phenyl]-6-hydroxyhexanamide
  • [0420]
    Figure US20040214896A1-20041028-C00168
  • [α][0421] D: +22.6 (c 1.04, dimethylformamide),
  • TLC: Rf 0.17 (chloroform:methanol=9:1), [0422]
  • NMR(d[0423] 6-DMSO): δ 7.58 (d, J=8.1 Hz, 2H), 7.57 (d, J=8.1 Hz, 2H), 7.36 (d, J=8.1 Hz, 2H), 7.34 (d, J=8.1 Hz, 2H), 5.12 (d, J=4.5 Hz, 1H), 4.52 (m, 1H), 3.39 (s, 2H), 3.18 (s, 3H), 2.14 (s, 6H), 1.98 (t, J=7.2 Hz, 2H), 1.65-1.54 (m, 2H), 1.49 (m, 2H), 1.40-1.18 (m, 2H), 1.24 (s, 6H).
    • EXAMPLE 7 (R)-(+)-N-hydroxy-6-[4-(5-methylbenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide
  • [0424]
    Figure US20040214896A1-20041028-C00169
  • By the same procedure as a series of reactions of example 2 using the compound prepared in example 6, the compound of the present invention having the following physical data was obtained. [0425]
  • TLC: Rf 0.28 (chloroform:methanol=9:1), [0426]
  • m.p.: 178-179° C., [0427]
  • [α][0428] D: +31.0 (c 1.05, dimethylformamide),
  • NMR(d[0429] 6-DMSO): δ 10.30 (s, 1H), 8.63 (s, 1H), 8.12 (d, J=8.4 Hz, 2H), 7.63 (d, J=8.4 Hz, 1H), 7.57 (m, 1H), 7.53 (d, J=8.4 Hz, 2H), 7.22 (m, 1H), 5.31 (d, J=4.2 Hz, 1H), 4.59 (m, 1H), 2.43 (s, 3H), 1.91 (t, J=7.2 Hz, 2H), 1.65-1.56 (m, 2H), 1.54-1.45 (m, 2H), 1.41-1.18 (m, 2H).
    • EXAMPLE 7(1)˜7(4)
  • By the same procedure as a series of reactions of example 7 using the compound prepared in example 6(1)-(4) instead of the compound prepared in example 6, if desired, the conversion into the acid addition salts by conventional means, the following compounds of the present invention were obtained. [0430]
    • EXAMPLE 7(1) (R)-(+)-N-hydroxy-6-[4-(benzoxazol-2-yl)phenyl]-6-hydroxyhexanamide
  • [0431]
    Figure US20040214896A1-20041028-C00170
  • TLC: Rf 0.20 (chloroform:methanol:acetic acid=90:10:1), [0432]
  • m.p.: 160-161° C., [0433]
  • [α][0434] D: +10.10 (c 0.81, methanol),
  • NMR(d[0435] 6-DMSO): δ 10.31 (s, 1H), 8.64 (s, 1H), 8.14 (d, J=8.2 Hz, 2H), 7.82-7.72 (m, 2H), 7.54 (d, J=8.2 Hz, 2H), 7.47-7.34 (m, 2H), 5.32 (d, J=4.4 Hz, 1H), 4.64-4.57 (m, 1H), 1.92 (t, J=7.0 Hz, 2H), 1.70-1.10 (m, 6H).
    • EXAMPLE 7(2) (R)-(+)-N-hydroxy-6-[4-(2-(4-methylthiophenyl)ethynyl)phenyl]-6-hydroxyhexanamide
  • [0436]
    Figure US20040214896A1-20041028-C00171
  • TLC: Rf 0.43 (chloroform:methanol:acetic acid=60:10:1), [0437]
  • m.p.: 173-176° C., [0438]
  • [α][0439] D: +31.5 (c 1.02, dimethylformamide),
  • NMR(d[0440] 6-DMSO): δ 10.30 (s, 1H), 8.62 (s, 1H), 7.48 (d, J=8.0 Hz, 2H), 7.47 (d, J=8.4 Hz, 2H), 7.35 (d, J=8.0 Hz, 2H), 7.28 (d, J=8.4 Hz, 2H), 5.22 (d, J=4.4 Hz, 1H), 4.60-4.45 (m, 1H), 2.51 (s, 3H), 1.92 (t, J=7.2 Hz, 2H), 1.70-1.10 (m, 6H).
    • EXAMPLE 7(3) (R)-(+)-N-hydroxy-6-[4-(4-methylthiophenyl)phenyl]-6-hydroxyhexanamide
  • [0441]
    Figure US20040214896A1-20041028-C00172
  • TLC: Rf 0.23 (chloroform:methanol=9:1), [0442]
  • m.p.: 194-197° C., [0443]
  • [α][0444] D: +6.86 (c 0.105, methanol),
  • NMR(d[0445] 6-DMSO): δ 10.29 (s, 1H), 8.62 (s, 1H), 7.61-7.55 (m, 4H), 7.38-7.29 (m, 4H), 5.12 (d, J=4.4 Hz, 1H), 4.58-4.42 (m, 1H), 2.49 (s, 3H), 1.90 (t, J=7.4 Hz, 2H), 1.66-1.02 (m, 6H).
    • EXAMPLE 7(4) (R)-(+)-N-hydroxy-6-[4-(4-(dimethylaminomethyl)phenyl)phenyl]-6-hydroxyhexanamide.hydrochloride
  • [0446]
    Figure US20040214896A1-20041028-C00173
  • TLC: Rf 0.14 (chloroform:methanol=2:1), [0447]
  • m.p.: 214-217° C., [0448]
  • [α][0449] D: +26.54 (c 0.11, methanol),
  • NMR(d[0450] 6-DMSO): δ 10.79 (s, 1H), 10.33 (s, 1H), 8.63 (s, 1H), 7.73 (d, J=8.2 Hz, 2H), 7.64-7.62 (m, 4H), 7.39 (d, J=8.2 Hz, 2H), 5.17 (d, J=3.9 Hz, 1H), 4.58-4.49 (m, 1H), 4.27 (s, 2H), 2.68 (s, 6H), 1.91 (t, J=6.9 Hz, 2H), 1.64-1.18 (m, 2H).
    • EXAMPLE 8(1)˜8(4)
  • By the same procedure as a series of reactions of reference example 1→reference example 2→reference example 3→example 1→example 2 using a corresponding compound instead of 4-chlorobiphenyl, the following compounds of the present invention were obtained. [0451]
    • EXAMPLE 8(1) N-hydroxy-6-(4-(trans-4-butylcyclohexyl)phenyl)-6-hydroxyhexanamide
  • [0452]
    Figure US20040214896A1-20041028-C00174
  • TLC: Rf 018 (ethyl acetate), [0453]
  • NMR(d[0454] 6-DMSO): δ 10.30 (s, 1H), 8.63 (s, 1H), 7.20 (d, J=8.2 Hz, 2H), 7.13 (d, J=8.2 Hz, 2H), 4.99 (d, J=3.9 Hz, 1H), 4.42 (m, 1H), 2.40 (m, 1H), 1.91 (t, J=7.2 Hz, 2H), 1.90-0.90 (m, 21H), 0.85 (t, J=6.9 Hz, 3H).
    • EXAMPLE 8(2) N-hydroxy-6-(4-(trans-4-hydroxycyclohexyl)phenyl)-6-hydroxyhexanamide
  • [0455]
    Figure US20040214896A1-20041028-C00175
  • TLC: Rf 0.12 (chloroform:methanol:triethylamine=8:1:1), [0456]
  • NMR(d[0457] 6-DMSO): δ 10.29 (s, 1H), 8.64 (s, 1H), 7.19 (d, J=8.1 Hz, 2H), 7.13 (d, J=8.1 Hz, 2H), 4.99 (d, J=4.5 Hz, 1H), 4.54 (d, J=4.5 Hz, 1H), 4.42 (q, J=4.5 HZ, 1H), 3.52-3.36 (m, 1H), 2.60-2.30 (m, 1H), 1.95-1.83 (m, 4H), 1.80-1.65 (m, 2H), 1.63-1.10 (m, 10H).
    • EXAMPLE 8(3) N-hydroxy-6-(4-cyclopentylphenyl)-6-hydroxyhexanamide
  • [0458]
    Figure US20040214896A1-20041028-C00176
  • TLC: Rf 0.18 (chloroform:methanol:triethylamine=8:1:1), [0459]
  • NMR(d[0460] 6-DMSO): δ 10.29 (s, 1H), 8.64 (s, 1H), 7.20 (d, J=8.4 Hz, 2H), 7.16 (d, J=8.4 Hz, 2H), 5.00 (d, J=3.9 Hz, 1H), 4.43 (q, J=3.9 Hz, 1H), 3.00-2.85 (m, 1H), 2.06-1.84 (m, 4H), 1.83-1.38 (m, 10H), 1.38-1.10 (m, 2H).
    • EXAMPLE 8(4) N-hydroxy-6-[4-(morpholin-4-yl)phenyl]-6-hydroxyhexanamide
  • [0461]
    Figure US20040214896A1-20041028-C00177
  • TLC: Rf 0.20 (chloroform:methanol=9:1), [0462]
  • NMR(d[0463] 6-DMSO): δ 10.27 (s, 1H), 8.61 (s, 1H), 7.14 (d, J=8.7 Hz, 2H), 6.85 (d, J=8.7 Hz, 2H), 4.80 (d, J=4.2 Hz, 1H), 4.40-4.35 (m, 1H), 3.72-3.69 (m, 4H), 3.05-3.02 (m, 4H), 1.88 (t, J=7.5 Hz, 2H), 1.62-1.07 (m, 6H).
    • EXAMPLE 9 N-hydroxy-6-[3-(4-chlorophenyl)phenyl]-6-hydroxyhexanamide
  • [0464]
    Figure US20040214896A1-20041028-C00178
  • By the same procedure as a series of reactions of example 4→reference example 2→reference example 3→example 1→example 2 using methyl 6-(3-bromophenyl)-6-oxohexanoate instead of the compound prepared in reference example 6, the compound of the present invention having the following physical data was obtained. [0465]
  • TLC: Rf 0.27 (ethyl acetate), [0466]
  • NMR(d[0467] 6-DMSO): δ 10.28 (brs, 1H), 8.62 (brs, 1H), 7.75-7.64 z(m, 3H), 7.57 (s, 1H), 7.52-7.47 (m, 2H), 7.39 (t, J=7.5 Hz, 1H) 7.31 (d, J=6.9 Hz, 1H), 5.16 (d, J=4.5 Hz, 1H), 4.58-4.52 (m, 1H), 1.90 (t, J=7. 2 Hz, 2H), 1.64-1.20 (m, 6H).
    • EXAMPLE 9(1) N-hydroxy-6-[2-(4-chlorophenyl)phenyl]-6-hydroxyhexanamide
  • [0468]
    Figure US20040214896A1-20041028-C00179
  • By the same procedure as a series of reactions of example 9 using methyl 6-(2-bromophenyl)-6-oxohexanoate instead of methyl 6-(3-bromophenyl)-6-oxohexanoate, the compound of the present invention having the following physical data was obtained. [0469]
  • TLC: Rf 0.26 (ethyl acetate), [0470]
  • NMR(d[0471] 6-DMSO): δ 10.24 (s, 1H), 8.61 (s, 1H), 7.56 (d, J=7.5 Hz, 1H), 7.49-7.46 (m, 2H), 7.40-7.24 (m, 4H), 7.11-7.09 (m, 1H), 5.03 (d, J=4.2 Hz, 1H), 4.49-4.44 (m, 1H), 1.80 (t, J=7.5 Hz, 2H), 1.56-1.02 (m, 6H).
    • EXAMPLE 10 N-hydroxy-6-[4-((1E)-2-phenylvinyl)phenyl]-6-hydroxyhexanamide
  • [0472]
    Figure US20040214896A1-20041028-C00180
  • By the same procedure as a series of reactions of reference example 10→example 2 using the compound prepared in reference example 6 and styrene, the compound of the present invention having the following physical data was obtained. [0473]
  • TLC: Rf 0.34 (ethyl acetate), [0474]
  • NMR(d[0475] 6-DMSO): δ 10.28 (s, 1H), 7.59-7.51 (m, 4H), 7.38-7.21 (m, 5H), 7.21 (s, 2H), 4.49-4.45 (m, 1H), 1.89 (t, J=7.5 Hz, 2H), 1.60-1.12 (m, 6H).
    • EXAMPLE 10(1) AND 10(2)
  • By the same procedure as a series of reactions of example 10 using a corresponding compound instead of styrene, the following compounds of the present invention were obtained. [0476]
    • EXAMPLE 10(1) N-hydroxy-6-[4-((1E)-2-(pyridin-4-yl)vinyl)phenyl]-6-hydroxyhexanamide
  • [0477]
    Figure US20040214896A1-20041028-C00181
  • TLC: Rf 0.22 (ethyl acetate:methanol=9:1), [0478]
  • NMR(d[0479] 6-DMSO): δ 10.28 (s, 1H), 8.62 (s, 1H), 8.51 (d, J=5.4 Hz, 2H), 7.58 (d, J=8.1 Hz, 2H), 7.53 (d, J=5.4 Hz, 2H), 7.51 (d, J=16.2 Hz, 1H), 7.33 (d, J=8.1 Hz, 2H), 7.19 (d, J=16.2 Hz, 1H), 5.14 (d, J=4.8 Hz, 1H), 4.52-4.46 (m, 1H), 1.89 (t, J=7.5 Hz, 2H), 1.60-1.10 (m, 6H).
    • EXAMPLE 10(2) N-hydroxy-6-[4-((1E)-2-(pyridin-2-yl)vinyl)phenyl]4-hydroxyhexanamide
  • [0480]
    Figure US20040214896A1-20041028-C00182
  • TLC: Rf 0.22 (ethyl acetate:methanol=9:1), [0481]
  • NMR(d[0482] 6-DMSO): δ 10.29 (s, 1H), 8.63 (s, 1H), 8.56-8.54 (m, 1H), 7.77 (dt, J=7.5 Hz, 1.5 Hz, 1H), 7.64 (d, J=16.2 Hz, 1H), 7.59 (d, J=7.8 Hz, 2H), 7.52 (d, J=8.1 Hz, 1H), 7.32 (d, J=7.8 Hz, 2H), 7.27 (d, J=16.2 Hz, 1H), 7.25-7.21 (m, 1H), 5.13 (d, J=4.5 Hz, 1H), 4.52-4.80 (m, 1H), 1.90 (t, J=7.5 Hz, 2H), 1.63-1.18 (m, 6H).
    • REFERENCE EXAMPLE 13 6-[4-(4-chlorophenyl)phenyl]-6-oxohexanoic acid
  • [0483]
    Figure US20040214896A1-20041028-C00183
  • By the same procedure as a series of reactions of reference example 3 using the compound prepared in reference example 1, the title compound having the following physical data was obtained. [0484]
  • TLC: Rf 0.50 (ethyl acetate), [0485]
  • NMR(d[0486] 6-DMSO): δ 12.00 (s, 1H), 8.05 (d, J=8.4 Hz, 2H), 7.82 (d, J=8.4 Hz, 2H), 7.79 (d, J=8.4 Hz, 2H), 7.56 (d, J=8.4 Hz, 2H), 3.07 (t, J=6.6 Hz, 2H), 2.27 (t, J=7.4 Hz, 2H), 1.80-1.50 (m, 4H).
    • REFERENCE EXAMPLE 14 6-[4-(4-chlorophenyl)phenyl]-6-hydroxy heptanoic acid
  • [0487]
    Figure US20040214896A1-20041028-C00184
  • Under an atmosphere of argon, to a solution of the compound prepared in reference example 13 (560 mg) in tetrahydrofuran (20 mL) was added 0.82 mmol/mL solution of methylmagnesium iodide in diethylether (10.8 mL) at 0° C. The reaction mixture was stirred at room temperature for 1 hour. To the reaction mixture was added 1N hydrochloric acid and the mixture was extracted with ethyl acetate. The extract was washed with water and a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, and concentrated. The obtained residue was purified by column chromatography on silica gel (hexane:ethyl acetate=1:1) to give the title compound (442 mg) having the following physical data. [0488]
  • TLC: Rf 0.30 (hexane:ethyl acetate=1:2), [0489]
  • NMR(CDCl[0490] 3): δ 7.54-7.46 (m, 6H), 7.39 (d, J=8.4 Hz, 2H), 2.30 (t, J=7.2 Hz, 2H), 1.84 (m, 2H), 1.66-1.56 (m, 2H), 1.58 (s, 3H), 1.45-1.32 (m, 1H), 1.30-1.18 (m, 1H).
    • EXAMPLE 11 N-hydroxy-6-[4-(4-chlorophenyl)phenyl]-6-hydroxyheptanamide
  • [0491]
    Figure US20040214896A1-20041028-C00185
  • By the same procedure as a series of reactions of example 1→example 2 using the compound prepared in reference example 14, the compound of present invention having the following physical data was obtained. [0492]
  • TLC: Rf 0.27 (ethyl acetate), [0493]
  • NMR(d[0494] 6-DMSO): δ 10.24 (s, 1H), 8.60 (s, 1H), 7.67 (d, J=8.4 Hz, 2H), 7.58 (d, J=8.4 Hz, 2H), 7.49 (d, J=8.4 Hz, 2H), 7.48 (d, J=8.4 Hz, 2H), 4.87 (s, 1H), 1.85 (t, J=7.2 Hz, 2H), 1.74-1.60 (m, 2H), 1.44-1.34 (m, 2H), 1.30-1.20 (m, 1H), 1.05-0.93 (m, 1H).
    • EXAMPLE 11(1) N-hydroxy-6-[4-(4-chlorophenyl)phenyl]-6-hydroxy-7-octenamide
  • [0495]
    Figure US20040214896A1-20041028-C00186
  • By the same procedure as a series of reactions of reference example 14→example 11 using vinylmagnesium bromide instead of methylmagnesium iodide, the compound of present invention having the following physical data was obtained. [0496]
  • TLC: Rf 0.28 (ethyl acetate), [0497]
  • NMR(d[0498] 6-DMSO): δ 10.26 (s, 1H), 8.62 (s, 1H), 7.67 (d, J=8.5 Hz, 2H), 7.59 (d, J=8.5 Hz, 2H), 7.48 (d, J=8.5 Hz, 4H), 6.12 (dd, J=17.2, 10.6 Hz, 1H), 5.21 (dd, J=17.2, 2.0 Hz, 1H), 5.15 (s, 1H), 5.00 (dd, J=10.6, 2.0 Hz, 1H), 1.84 (m, 2H), 1.83-1.72 (m, 2H), 1.42 (m, 2H), 1.32-1.22 (m, 1H), 1.12-1.00 (m, 1H).
    • EXAMPLE 11(2) N-hydroxy-6-(4-biphenyl)-6-hydroxyheptanamide
  • [0499]
    Figure US20040214896A1-20041028-C00187
  • By the same procedure as a series of reactions of reference example 14→example 11 using 6-(4-biphenyl)-6-oxohexanoic acid instead of the compound prepared in reference example 13, the compound of present invention having the following physical data was obtained. [0500]
  • TLC: Rf 0.26 (ethyl acetate), [0501]
  • NMR(d[0502] 6-DMSO): δ 10.25 (s, 1H), 8.61 (s, 1H), 7.65-7.62 (m, 2H), 7.57 (d, J=8.4 Hz, 2H), 7.46 (d, J=8.4 Hz, 2H), 7.43-7.41 (m, 2H), 7.35-7.29 (m, 1H, 4.86 (s, 1H), 1.85 (t, J=7.2 Hz, 2H), 1.75-1.60 (m, 2H), 1.40 (s, 3H), 1.42-1.18 (m, 3H), 1.04-0.91 (m. 1H).
    • REFERENCE EXAMPLE 15 6-[4-(4-ethylphenyl)phenyl]-6-hydroxyheptanoic acid
  • [0503]
    Figure US20040214896A1-20041028-C00188
  • By the same procedure as a series of reactions of reference example 14 using 6-[4-(4-ethylphenyl)phenyl]-6-oxohexanoic acid instead of the compound prepared in reference example 13, enantiomer mixture of the title compound was obtained. By the following method, (+) isomer and (−) isomer of the title compound, respectively, were obtained from enantiomer mixture. [0504]
  • The enantiomer mixture (6.66 g), (1R,2R)-(+)-1,2-diphenylethylenediamine (4.33 g), ethyl acetate (80 mL) and hexane (20 mL) were mixed. The mixture was refluxed and dissolved completely. The mixture was cooled to room temperature and the crystal precipitated. The precipitated crystal was filtered and washed with a solution of hexane and ethyl acetate (hexane:ethyl acetate=1:1). The filtrate was concentrated. The obtained residue was used in the preparation of (−) isomer. The precipitated crystal was dissolved into ethyl acetate and washed with 1N hydrochloric acid, water and a saturated aqueous solution of sodium chloride and dried over anhydrous magnesium sulfate and concentrated to give (+) isomer of the title compound (2.44 g, 92.4% e.e, HPLC) having the following physical data. [0505]
  • The residue concentrated the filtrate was dissolved into ethyl acetate and washed with 1N hydrochloric acid, water and a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and concentrated. The obtained residue, (1S,2S)-(−)-1,2-diphenylethylenediamine (2.32 g), ethyl acetate (50 mL) and hexane (10 mL) were mixed. The mixture was refluxed and dissolved completely. The mixture was cooled to room temperature and crystal precipitated. The precipitated crystal was filtered and washed with a solution of hexane and ethyl acetate (hexane:ethyl acetate=1:1). The precipitated crystal was dissolved into ethyl acetate and washed with 1N hydrochloric acid, water and a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and concentrated to give (−) isomer of the title compound (2.88 g, 89.9% e.e, HPLC) having the following physical data. [0506]
  • (+) Isomer: [0507]
  • TLC: Rf 0.46 (chloroform:methanol=9:1), Retention time: 6.99 min. Column: DAICEL CHIRAL CELAD-RH, 4.6×150 mm; Eluant: acetonitrile:water=65:35; UV: 256 nm; Flow rate: 1.0 mL/min. [0508]
  • (−) Isomer: [0509]
  • TLC: Rf 0.46 (chloroform:methanol=9:1), Retention time: 14.40 min. Column: DAICEL CHIRAL CELAD-RH, 4.6×150 mm; Eluant: acetonitrile:water=65:35; UV: 256 nm; Flow rate: 1.0 mL/min. [0510]
    • EXAMPLE 12 (+)-N-hydroxy-6-[4-(4-ethylphenyl)phenyl]-6-hydroxyheptanamide
  • [0511]
    Figure US20040214896A1-20041028-C00189
  • By the same procedure as a series of reactions of example 1 example 2 using (+) isomer of the compound prepared in reference example 15, the compound of the present invention having the following physical data was obtained. [0512]
  • [α][0513] D: +14.74 (c 0.555, methanol),
  • TLC: Rf 0.35 (chloroform:methanol=9:1), [0514]
  • NMR(d[0515] 6-DMSO): δ 10.26 (s, 1H), 8.62 (s, 1H), 7.55 (d, J=8.4 Hz, 4H), 7.45 (d, J=8.4 Hz, 2H), 7.27 (d, J=8.4 Hz, 2H), 4.85 (s, 1H), 2.62 (q, J=7.4 Hz, 2H), 1.86 (t, J=7.4 Hz, 2H), 1.78-1.56 (m, 2H), 1.55-1.21 (m, 6H), 1.20 (t, J=7.4 Hz, 3H), 1.12-0.85 (m, 1H).
    • EXAMPLE 12(1) (−)-N-hydroxy-6-[4-(4-ethylphenyl)phenyl]-6-hydroxyheptanamide
  • [0516]
    Figure US20040214896A1-20041028-C00190
  • By the same procedure as a series of reactions of example 12 using (−) isomer of the compound prepared in reference example 15, the compound of the present invention having the following physical data was obtained. [0517]
  • [α][0518] D: −12.18 (c 0.74, methanol),
  • TLC: Rf 0.35 (chloroform:methanol=9:1), [0519]
  • NMR(d[0520] 6-DMSO): δ 10.26 (s, 1H), 8.62 (s, 1H), 7.55 (d, J=8.4 Hz, 4H), 7.45 (d, J=8.4 Hz, 2H), 7.27 (d, J=8.4 Hz, 2H), 4.85 (s, 1H), 2.62 (q, J=7.4 Hz, 2H), 1.86 (t, J=7.4 Hz, 2H), 1.78-1.56 (m, 2H), 1.55-1.21 (m, 6H), 1.20 (t, J=7.4 Hz, 3H), 1.12-0.85 (m, 1H).
    • EXAMPLE 13(1)˜13(44)
  • By the same procedure as a series of reactions of reference example 4→reference example 3→example 1→example 2 using a corresponding ketone derivative instead of the compound prepared in reference example 1, if desired, the conversion into the acid addition salts by conventional means, the following compounds of the present invention were obtained. [0521]
    • EXAMPLE 13(1) (R)-(+)-N-hydroxy-6-(4-biphenyl)-6-hydroxyhexanamide
  • [0522]
    Figure US20040214896A1-20041028-C00191
  • [α][0523] D: +15.1 (c 0.245, methanol),
  • TLC: Rf 0.25 (chloroform:methanol:acetic acid=90:10:1), [0524]
  • NMR(d[0525] 6-DMSO): δ 10.29 (s. 1H), 8.63 (s, 1H), 7.65-7.57 (m, 4H), 7.46-7.30 (m, 5H), 5.13 (d, J=4.5 Hz, 1H), 4.54-4.49 (m, 1H), 1.91 (t, J=7.2 Hz, 2H), 1.64-1.44 (m, 4H), 1.40-1.22 (m, 2H).
    • EXAMPLE 13(2) (R)-(+)-N-hydroxy-6-[4-(4-methylphenyl)phenyl]-6-hydroxyhexanamide
  • [0526]
    Figure US20040214896A1-20041028-C00192
  • [α][0527] D: +11.53 (c 0.215, methanol),
  • TLC: Rf 0.22 (chloroform:methanol:acetic acid=90:10:1), [0528]
  • NMR(d[0529] 6-DMSO): δ 10.29 (s, 1H), 8.62 (s, 1H), 7.56-7.51 (m, 4H), 7.34 (d, J=8.1 Hz, 2H), 7.24 (d, J=8.1 Hz, 2H), 5.11 (d, J=4.5 Hz, 1H), 4.52-4.48 (m, 1H), 2.32 (s, 3H), 1.90 (t, J=7.5 Hz, 2H), 1.62-1.15 (m, 6H).
    • EXAMPLE 13(3) (R)-(+)-N-hydroxy-6-[4-(3-methylphenyl)phenyl]-6-hydroxyhexanamide
  • [0530]
    Figure US20040214896A1-20041028-C00193
  • [α][0531] D: +8.43 (c 0.37, methanol),
  • TLC: Rf 0.22 (chloroform:methanol:acetic acid=90:10:1), [0532]
  • NMR(d[0533] 6-DMSO): δ 10.29 (s, 1H), 8.63 (s, 1H), 7.56 (d, J=8.1 Hz, 2H), 7.44-7.29 (m, 5H), 7.14 (d, J=7.5 Hz, 1H), 5.12 (d, J=4.5 Hz, 1H), 4.59-4.48 (m, 1H), 2.35 (s, 3H), 1.90 (t, J=7.2 Hz, 2H), 1.63-1.12 (m, 6H).
    • EXAMPLE 13(4) (R)-(+)-N-hydroxy-6-[4-(benzoxazol-2-yl)phenyl]-6-hydroxyhexanamide
  • [0534]
    Figure US20040214896A1-20041028-C00194
  • [α][0535] D: +14.5 (c 0.195, methanol),
  • TLC: Rf 0.25 (chloroform:methanol:acetic acid=90:10:1), [0536]
  • NMR(d[0537] 6-DMSO): δ 10.28 (s, 1H), 8.62 (s, 1H), 7.84 (d, J=8.4 Hz, 2H), 7.65-7.58 (m, 2H), 7.42 (d, J=8.4 Hz, 2H), 7.37 (s, 1H), 7.33-7.19 (m, 2H), 5.19 (d, J=4.4 Hz, 1H), 4.59-4.45 (m, 1H), 1.89 (t, J=7.2 Hz, 2H), 1.62-1.05 (m, 6H).
    • EXAMPLE 13(5) (R)-N-hydroxy-6-[4-(2-phenylethynyl)phenyl]-6-hydroxyhexanamide
  • [0538]
    Figure US20040214896A1-20041028-C00195
  • TLC: Rf 0.24 (chloroform:methanol=9:1), [0539]
  • NMR(d[0540] 6-DMSO): δ 10.28 (s, 1H), 8.62 (s, 1H), 7.55-7.32 (m, 9H), 5.20 (d, J=4.4 Hz, 1H), 4.56-4.44 (m, 1H), 1.89 (t, J=7.0 Hz, 2H), 1.60-1.08 (m, 6H).
    • EXAMPLE 13(6) (R)-(+)-N-hydroxy-6-[4-(benzothiophen-2-yl)phenyl]-6-hydroxyhexanamide
  • [0541]
    Figure US20040214896A1-20041028-C00196
  • [α][0542] D: +13.88 (c 0.085, methanol),
  • TLC: Rf 0.25 (chloroform:methanol:acetic acid=90:10:1), [0543]
  • NMR(d[0544] 6-DMSO): δ 10.28 (s, 1H), 8.62 (s, 1H), 7.96-7.92 (m, 1H), 7.84-7.79 (m, 2H), 7.70 (d, J=9.0 Hz, 2H), 7.39 (d, J=9.0 Hz, 2H), 7.36-7.28 (m, 2H), 5.18 (d, J=4.4 Hz, 1H), 4.59-4.48 (m, 1H), 1.89 (t, J=6.8 Hz, 2H), 1.65-1.10 (m, 6H).
    • EXAMPLE 13(7) (R)-N-hydroxy-6-[4-(4-(cyanomethyl)phenyl)phenyl]-6-hydroxyhexanamide
  • [0545]
    Figure US20040214896A1-20041028-C00197
  • TLC: Rf 0.28 (ethyl acetate:methanol=9:1), [0546]
  • NMR(d[0547] 6-DMSO): δ 10.29 (s, 1H), 8.63 (s, 1H), 7.67 (d, J=8.1 Hz, 2H), 7.60 (d, J=8.1 Hz, 2H), 7.41 (d, J=8.1 Hz, 2H), 7.38 (d, J=8.1 Hz, 2H), 5.14 (d, J=4.5 Hz, 1H), 4.52 (m, 1H), 4.06 (s, 2H), 1.91 (t, J=7.2 Hz, 2H), 1.64-1.54 (m, 2H), 1.54-1.44 (m, 2H), 1.39-1.16 (m, 2H).
    • EXAMPLE 13(8) (R)-N-hydroxy-6-[4-(4-ethylphenyl)phenyl]-6-hydroxyhexanamide
  • [0548]
    Figure US20040214896A1-20041028-C00198
  • TLC: Rf 0.29 (chloroform:methanol=9:1), [0549]
  • NMR(d[0550] 6-DMSO): δ 10.42-10.20 (br, 1H), 8.75-8.55 (br, 1H), 7.56 (d, J=8.0 Hz, 2H), 7.55 (d, J=8.0 Hz, 2H), 7.36 (d, J=8.0 Hz, 2H), 7.27 (d, J=8.0 Hz, 2H), 5.12 (d, J=4.4 Hz, 1H), 4.58-4.45 (m, 1H), 2.62 (q, J=7.6 Hz, 2H), 1.91 (t, J=7.4 Hz, 2H), 1.70-1.10 (m, 6H), 1.19 (t, J=7.6 Hz, 3H).
    • EXAMPLE 13(9) (R)-N-hydroxy-4-[4-(4-propylphenyl)phenyl]-6-hydroxyhexanamide
  • [0551]
    Figure US20040214896A1-20041028-C00199
  • TLC: Rf 0.29 (chloroform:methanol=9:1), [0552]
  • NMR(d[0553] 6-DMSO): δ 10.30 (s, 1H), 8.64 (s, 1H), 7.57 (d, J=8.4 Hz, 2H), 7.54 (d, J=8.0 Hz, 2H), 7.36 (d, J=8.0 Hz, 2H), 7.25 (d, J=8.4 Hz, 2H), 5.12 (d, J=4.4 Hz, 1H), 4.58-4.44 (m, 1H), 2.57 (t, J=7.4 Hz, 2H), 1.92 (t, J=7.4 Hz, 2H), 1.72-1.10 (m, 8H), 0.90 (t, J=7.8 Hz, 3H).
    • EXAMPLE 13(10) (R)-N-hydroxy-6-[4-(4-biphenyl)phenyl]-6-hydroxyhexanamide
  • [0554]
    Figure US20040214896A1-20041028-C00200
  • TLC: Rf 0.26 (chloroform:methanol=9:1), [0555]
  • NMR(d[0556] 6-DMSO): δ 10.30 (s, 1H), 8.64 (s, 1H), 7.78-7.60 (m, 8H), 7.54-7.30 (m, 5H), 5.15 (d, J=4.4 Hz, 1H), 4.59-4.46 (m, 1H), 1.91 (t, J=6.8 Hz, 2H), 1.65-1.10 (m, 6H).
    • EXAMPLE 13(11) (R)-N-hydroxy-6-[4-(1-methylpiperidin-4-yl)phenyl]-6-hydroxyhexanamide.hydrochloride
  • [0557]
    Figure US20040214896A1-20041028-C00201
  • TLC: Rf 0.12 (methanol), [0558]
  • NMR(d[0559] 6-DMSO): δ 10.53 (br, 1H), 10.31 (s, 1H), 8.64 (br, 1H), 7.25 (d, J=8.2 Hz, 2H), 7.15 (d, J=8.2 Hz, 2H), 5.06 (br, 1H), 4.44 (t, J=6.0 Hz, 1H), 3.46-3.28 (m, 3H), 3.09-2.96 (m, 2H), 2.73 (d-like, J=4.2 Hz, 3H), 2.00-1.87 (m, 6H), 1.58-1.41 (m, 4H), 1.37-1.15 (m, 2H).
    • EXAMPLE 13(12) (R)-N-hydroxy-6-[4-(indol-2-yl)phenyl]-6-hydroxyhexanamide
  • [0560]
    Figure US20040214896A1-20041028-C00202
  • TLC: Rf 0.33 (chloroform:methanol:acetic acid=60:10:1), [0561]
  • NMR(d[0562] 6-DMSO): δ 11.42 (s, 1H), 10.25 (s, 1H), 8.62 (s, 1H), 7.76 (d, J=8.1 Hz, 2H), 7.47 (d, J=7.5 Hz, 1H) 7.40-7.30 (m, 3H), 7.10-7.00 (m, 1H), 7.00-6.90 (m, 1H), 6.81 (d, J=1.2 Hz, 1H), 5.12 (d, J=4.5 Hz, 1H), 4.55-4.42 (m, 1H), 1.88 (t, J=7.4 Hz, 2H), 1.70-1.40 (m, 4H), 1.40-1.10 (m, 2H).
    • EXAMPLE 13(13) (R)-(+)-N-hydroxy-6-[4-(4-cyanophenyl)phenyl]-6-hydroxyhexanamide
  • [0563]
    Figure US20040214896A1-20041028-C00203
  • [α][0564] D: +4.60 (c 0.265, methanol),
  • TLC: Rf 0.34 (ethyl acetate:methanol=19:1), [0565]
  • NMR(d[0566] 6-DMSO): δ 10.28 (brs, 1H), 8.63 (s, 1H), 7.90 (d, J=9.0 Hz, 2H), 7.85 (d, J=9.0 Hz, 2H), 7.68 (d, J=8.1 Hz, 2H), 7.42 (d, J=8.1 Hz, 2H), 5.19 (d, J=4.8 Hz, 1H), 4.58-4.51 (m, 1H), 1.90 (t, J=7.2 Hz, 2H), 1.59-1.14 (m, 6H).
    • EXAMPLE 13(14) (R)-(+)-N-hydroxy-6-[4-phenyl-2-methylphenyl]-6-hydroxyhexanamide
  • [0567]
    Figure US20040214896A1-20041028-C00204
  • [α][0568] D: +18.31 (c 0.225, methanol),
  • TLC: Rf 0.37 (ethyl acetate:methanol=19:1), [0569]
  • NMR(d[0570] 6-DMSO): δ 10.30 (s, 1H), 8.64 (s, 1H), 7.63-7.60 (m, 2H), 7.46-7.39 (m, 5H), 7.34-7.28 (m, 1H), 5.02 (d, J=4.5 Hz, 1H), 4.72-4.68 (m, 1H), 2.32 (s, 3H), 1.92 (t, J=6.9 Hz, 2H), 1.60-1.22 (m, 6H).
    • EXAMPLE 13(15) (R)-N-hydroxy-6-(4-cycloheptylphenyl)-6-hydroxyhexanamide
  • [0571]
    Figure US20040214896A1-20041028-C00205
  • TLC: Rf 0.43 (ethyl acetate:methanol=9:1), [0572]
  • NMR(d[0573] 6-DMSO): δ 10.28 (s, 1H), 8.63 (s, 1H), 7.17 (d, J=8.3 Hz, 2H), 7.10 (d, J=8.3 Hz, 2H), 4.98 (d, J=4.5 Hz, 1H), 4.41 (m, 1H), 2.61 (m, 1H), 1.89 (t, J=7.2 Hz, 2H), 1.81-1.41 (m, 16H), 1.37-1.10 (m, 2H).
    • EXAMPLE 13(16) (R)-N-hydroxy-6-(9,10-dihydrophenanthren-2-yl)-6-hydroxyhexanamide
  • [0574]
    Figure US20040214896A1-20041028-C00206
  • TLC: Rf 0.37 (ethyl acetate:methanol=9:1), [0575]
  • NMR(d[0576] 6-DMSO): δ 10.30 (s, 1H), 8.63 (s, 1H), 7.77 (d, J=7.2 Hz, 1H), 7.73 (d, J=8.1 Hz, 1H), 7.31-7.17 (m, 5H), 5.10 (d, J=4.5 Hz, 1H), 4.47 (m, 1H), 2.79 (s, 4H), 1.91 (t, J=7.2 Hz, 2H), 1.63-1.44 (m, 4H), 1.41-1.17 (m, 2H).
    • EXAMPLE 13(17) (R)-N-hydroxy-6-[4-(1-ethoxycarbonylpiperidin-4-yl)phenyl]6-hydroxyhexanamide
  • [0577]
    Figure US20040214896A1-20041028-C00207
  • TLC: Rf 0.42 (ethyl acetate:methanol 9:1), [0578]
  • NMR(d[0579] 6-DMSO): δ 10.29 (s, 1H), 8.63 (s, 1H), 7.21 (d, J=8.3 Hz, 2H), 7.15 (d, J=8.3 Hz, 2H), 5.01 (d, J=4.2 Hz, 1H), 4.42 (m, 1H), 4.11-4.01 (m, 2H), 4.01 (q, J=7.0 Hz, 2H), 2.83 (m, 2H), 2.65 (m, 1H), 1.89 (t, J=7.2 Hz, 2H), 1.75-1.71 (m, 2H), 1.55-1.42 (m, 6H), 1.37-1.25 (m, 2H), 1.18 (t, J=7.0 Hz, 3H).
    • EXAMPLE 13(18) (R)-(+)-N-hydroxy-6-[4-(4-(N-methylcarbamoyl)phenyl)phenyl]-6-hydroxyhexanamide
  • [0580]
    Figure US20040214896A1-20041028-C00208
  • [α][0581] D: +12.37 (c 0.08, methanol),
  • TLC: Rf 0.33 (chloroform:methanol=9:1), [0582]
  • NMR(d[0583] 6-DMSO): δ 10.29 (s, 1H), 8.63 (brs, 1H), 8.48-8.43 (m, 1H), 7.89 (d, J=8.4 Hz, 2H), 7.73 (d, J=8.4 Hz, 2H), 7.65 (d, J=8.4 Hz, 2H), 7.39 (d, J=8.4 Hz, 2H), 5.18 (brs, 1H), 4.56-4.50 (m, 1H), 2.78 (d, J=4.8 Hz, 3H), 1.90 (t, J=7.5 Hz, 2H), 1.63-1.11 (m, 6H).
    • EXAMPLE 13(19) (R)-(+)-N-hydroxy-6-(4-cyclohexylphenyl)-6-hydroxyhexanamide
  • [0584]
    Figure US20040214896A1-20041028-C00209
  • [α][0585] D: +12.65 (c 0.16, methanol),
  • TLC: Rf 0.31 (chloroform:methanol=19:1), [0586]
  • NMR(d[0587] 6-DMSO): δ 10.27 (s, 1H), 8.62 (s, 1H), 7.18 (d, J=8.1 Hz, 2H), 7.12 (d, J=8.1 Hz, 2H), 4.98 (d, J=4.2 Hz, 1H), 4.42-4.36 (m, 1H), 2.45-2.39 (m, 1H), 1.89 (t, J=7.2 Hz, 2H), 1.80-1.09 (m, 17H).
    • EXAMPLE 13(20) (R)-N-hydroxy-6-[4-(5-hydroxybenzofuran-2-yl)phenyl]-6-hydroxyhexanamide
  • [0588]
    Figure US20040214896A1-20041028-C00210
  • TLC: Rf 0.27 (chloroform:methanol:acetic acid=60:10:1), [0589]
  • NMR(d[0590] 6-DMSO): δ 10.25 (s, 1H), 9.18 (s, 1H), 8.60 (s, 1H), 7.77 (d, J=8.2 Hz, 2H), 7.38 (d, J=8.2 Hz, 2H), 7.35 (d, J=8.8 Hz, 1H), 7.19 (s, 1H), 6.89 (d, J=2.6 Hz, 1H), 6.69 (dd, J=8.8, 2.6 Hz, 1H), 5.17 (d, J=4.4 Hz, 1H), 4.60-4.40 (m, 1H), 1.88 (t, J=7.1 Hz, 2H), 1.70-1.10 (m, 6H).
    • EXAMPLE 13(21) (R)-N-hydroxy-4-[4-(2-(4-methylphenyl)ethynyl)phenyl]-6-hydroxyhexanamide
  • [0591]
    Figure US20040214896A1-20041028-C00211
  • TLC: Rf 0.41 (chloroform:methanol:acetic acid=60:1 0:1), [0592]
  • NMR(d[0593] 6-DMSO): δ 10.27 (s, 1H), 8.65 (s, 1H), 7.50-7.35 (m, 4H), 7.31 (d, J=8.0 Hz, 2H), 7.20 (d, J=8.0 Hz, 2H), 5.18 (d, J=4.4 Hz, 1H), 4.60-4.40 (m, 1H), 2.30 (s, 3H), 1.87 (t, J=7.1 Hz, 2H), 1.65-1.00 (m, 6H).
    • EXAMPLE 13(22) (R)-N-hydroxy-6-[4-((1E)-2-(4-methylphenyl)vinyl)phenyl]-6-hydroxyhexanamide
  • [0594]
    Figure US20040214896A1-20041028-C00212
  • TLC: Rf 0.43 (chloroform:methanol:acetic acid=60:10:1), [0595]
  • NMR(d[0596] 6-DMSO): δ 10.28 (s, 1H), 7.53-7.38 (m, 4H), 7.26 (d, J=8.0 Hz, 2H), 7.20-7.05 (m, 4H), 4.45 (t, J=6.4 Hz, 1H), 2.25 (s, 3H), 1.87 (t, J=7.0 Hz, 2H), 1.70-1.00 (m, 6H).
    • EXAMPLE 13(23) (R)-N-hydroxy-6-[4-(4-trifluoromethoxyphenyl)phenyl]-6-hydroxyhexanamide
  • [0597]
    Figure US20040214896A1-20041028-C00213
  • TLC: Rf 0.25 (chloroform:methanol 9:1), [0598]
  • NMR(d[0599] 6-DMSO): δ 10.29 (s, 1H), 8.63 (s, 1H), 7.76 (d, J=8.7 Hz, 2H), 7.61 (d, J=8.7 Hz, 2H), 7.43-7.38 (m, 4H), 5.15 (d, J=4.5 HZ, 1H), 4.55-4.95 (m, 1H), 1.90 (t, J=7.5 Hz, 2H), 1.63-1.12 (m, 6H).
    • EXAMPLE 13(24) (R)-N-hydroxy-6-[4-(4-ethylthiophenyl)phenyl]-6-hydroxyhexanamide
  • [0600]
    Figure US20040214896A1-20041028-C00214
  • TLC: Rf 0.40 (ethyl acetate:methanol=4:1), [0601]
  • NMR(d[0602] 6-DMSO): δ 10.29 (s, 1H), 8.63 (s, 1H), 7.59 (d, J=8.4 Hz, 2H), 7.58 (d, J=8.4 Hz, 2H), 7.37 (d, J=8.4 Hz, 4H), 5.13 (br, 1H), 4.51 (t, J=6.0 Hz, 1H), 3.00 (q, J=7.2 Hz, 2H), 1.91 (t, J=7.0 Hz, 2H), 1.58 (m, 2H), 1.48 (m, 2H), 1.39-1.16 (m, 2H), 1.24 (t, J=7.2 Hz, 3H).
    • EXAMPLE 13(25) (R)-N-hydroxy-6-[4-(4-methoxyphenyl)phenyl]-6-hydroxyhexanamide
  • [0603]
    Figure US20040214896A1-20041028-C00215
  • TLC: Rf 0.23 (ethyl acetate:methanol=4:1), [0604]
  • NMR(d[0605] 6-DMSO): δ 10.29 (s, 1H), 8.64 (s, 1H), 7.57 (d, J=8.5 Hz, 2H), 7.53 (d, J=8.5 Hz, 2H), 7.34 (d, J=8.5 Hz, 2H), 6.99 (d, J=8.5 Hz, 2H), 5.11 (d, J=4.2 Hz, 1H), 4.50 (m, 1H), 3.77 (s, 3H), 1.91 (t, J=7.2 Hz, 2H), 1.57 (m, 2H), 1.48 (m, 2H), 1.39-1.16 (m, 2H).
    • EXAMPLE 13(26) (R)-N-hydroxy-6-[4-(4-(1-methylethyl)phenyl)phenyl]-6-hydroxyhexanamide
  • [0606]
    Figure US20040214896A1-20041028-C00216
  • TLC: Rf 0.20 (chloroform:methanol=9:1), [0607]
  • NMR(d[0608] 6-DMSO): δ 10.29 (s, 1H), 8.63 (brs, 1H), 7.55 (d, J=8.4 Hz, 2H), 7.54 (d, J=8.4 Hz, 2H), 7.35 (d, J=8.4 Hz, 2H), 7.30 (d, J=8.4 Hz, 2H), 5.11 (brs, 1H), 4.50 (t, J=6.0 Hz, 1H), 2.98-2.82 (m, 1H), 1.90 (t, J=7.2 Hz, 2H), 1.62-1.20 (m, 6H), 1.21 (d, J=6.9 Hz, 6H).
    • EXAMPLE 13(27) (R)-N-hydroxy-6-[4-(4-(N,N-dimethylcarbamoylmethyl)phenyl)phenyl]-6-hydroxyhexanamide
  • [0609]
    Figure US20040214896A1-20041028-C00217
  • TLC: Rf 0.21 (chloroform:methanol=9:1), [0610]
  • NMR(d[0611] 6-DMSO): δ 10.30 (s, 1H), 8.64 (s, 1H), 7.57 (d, J=8.0 Hz, 4H), 7.37 (d, J=8.0 Hz, 2H), 7.28 (d, J=8.0 Hz, 2H), 5.13 (d, J=4.4 Hz, 1H), 4.59-4.46 (m, 1H), 3.71 (s, 2H), 3.01 (s, 3H), 2.83 (s, 3H), 1.91 (t, J=7.0 Hz, 2H), 1.65-1.10 (m, 6H).
    • EXAMPLE 13(28) (R)-N-hydroxy-6-[4-(benzothiazol-2-yl)phenyl]-6-hydroxyhexanamide
  • [0612]
    Figure US20040214896A1-20041028-C00218
  • TLC: Rf 0.24 (chloroform:methanol=9:1), [0613]
  • NMR(d[0614] 6-DMSO): δ 10.30 (s, 1H), 8.64 (s, 1H), 8.18-8.12 (m, 1H), 8.09-7.98 (m, 3H), 7.60-7.40 (m, 4H), 5.38-5.22 (m, 1H), 4.65-4.55 (m, 1H), 1.92 (t, J=7.4 Hz, 2H), 1.70-1.15 (m, 6H).
    • EXAMPLE 13(29) (R)-N-hydroxy-6-[4-(4-(methoxymethoxymethyl)phenyl)phenyl]-6-hydroxyhexanamide
  • [0615]
    Figure US20040214896A1-20041028-C00219
  • TLC: Rf 0.30 (chloroform:methanol=9:1), [0616]
  • NMR(d[0617] 6-DMSO): δ 10.30 (s, 1H), 8.64 (s, 1H), 7.63 (d, J=8.0 Hz, 2H), 7.59 (d, J=8.0 Hz, 2H), 7.40 (d, J=8.0 Hz, 2H), 7.38 (d, J=8.0 Hz, 2H), 5.14 (d, J=4.4 Hz, 1H, 4.66 (s, 2H), 4.60-4.45 (m, 3H), 3.31 (s, 3H), 1.92 (t, J=7.0 Hz, 2H), 1.70-1.12 (m, 6H).
    • EXAMPLE 13(30) (R)-(+)-N-hydroxy-6-[4-(6-methoxybenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide
  • [0618]
    Figure US20040214896A1-20041028-C00220
  • [α][0619] D: +7.31 (c 0.19, methanol),
  • TLC: Rf 0.15 (chloroform:methanol=9:1), [0620]
  • NMR(d[0621] 6-DMSO): δ 10.29 (s, 1H), 8.63 (brs, 1H), 8.07 (d, J=8.7 Hz, 2H), 7.66 (d, J=8.7 Hz, 1H), 7.52 (d, J=8.7 Hz, 2H), 7.40 (d, J=2.4 Hz, 1H), 6.99 (dd, J=8.7 Hz, 2.4 Hz, 1H), 5.29 (brs, 1H), 4.60-4.56 (m, 1H), 3.83 (s, 3H), 1.90 (t, J=7.5 Hz, 2H), 1.63-1.20 (m, 6H).
    • EXAMPLE 13(31) (R)-N-hydroxy-4-[4-(6-methylbenzoxazol-2-yl)phenyl]4-hydroxyhexanamide
  • [0622]
    Figure US20040214896A1-20041028-C00221
  • TLC: Rf 0.28 (chloroform:methanol=9:1), [0623]
  • NMR(d[0624] 6-DMSO): δ 10.30 (s, 1H), 8.90-8.30 (br, 1H), 8.11 (d, J=8.4 Hz, 2H), 7.65 (d, J=8.2 Hz, 1H), 7.59 (d, J=1.0 Hz, 1H), 7.53 (d, J=8.4 Hz, 2H), 7.21 (dd, J=8.2, 1.0 Hz, 1H), 5.60-4.90 (br, 1H), 4.60 (t, J=6.2 Hz, 1H), 2.46 (s, 3H), 1.91 (t, J=7.4 Hz, 2H), 1.68-1.12 (m, 6H).
    • EXAMPLE 13(32) (R)-N-hydroxy-6-[4-(4-methoxymethylphenyl)phenyl]-6-hydroxyhexanamide
  • [0625]
    Figure US20040214896A1-20041028-C00222
  • TLC: Rf 0.39 (chloroform:methanol=9:1), [0626]
  • NMR(d[0627] 6-DMSO): δ 10.31 (s, 1H), 9.10-8.10 (br, 1H), 7.62 (d, J=8.4 Hz, 2H), 7.59 (d, J=8.4 Hz, 2H), 7.38 (d, J=8.4 Hz, 4H), 5.50-4.70 (br, 1H), 4.52 (t, J=6.2 Hz, 1H), 4.43 (s, 2H), 3.30 (s, 3H), 1.91 (t, J=7.4 Hz, 2H), 1.70-1.10 (m, 6H).
    • EXAMPLE 13(33) (R)-N-hydroxy-4-[4-(5-methoxybenzoxazol-2-yl)phenyl]4-hydroxyhexanamide
  • [0628]
    Figure US20040214896A1-20041028-C00223
  • TLC: Rf 0.13 (chloroform:methanol:acetic acid=90:10:1), [0629]
  • NMR(d[0630] 6-DMSO): δ 10.25 (s, 1H), 8.62 (s, 1H), 8.08 (d, J=8.3 Hz, 2H), 7.63 (d, J=9.0 Hz, 1H), 7.50 (d, J=8.3 Hz, 2H), 7.31 (d, J=2.4 Hz, 1H), 6.96 (dd, J=9.0, 2.4 Hz, 1H), 5.29 (d, J=4.5 Hz, 1H), 4.62-4.52 (m, 1H), 3.79 (s, 3H), 1.88 (t, J=7.2 Hz, 2H), 1.65-1.10 (m, 6H).
    • EXAMPLE 13(34) (R)-N-hydroxy-6-[4-(4-methoxybenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide
  • [0631]
    Figure US20040214896A1-20041028-C00224
  • TLC: Rf 0.28 (chloroform:methanol=9:1), [0632]
  • NMR(d[0633] 6-DMSO): δ 10.32 (s, 1H), 8.64 (s, 1H), 8.12 (d, J=8.4 Hz, 2H), 7.53 (d, J=8.4 Hz, 2H), 7.40-7.28 (m, 2H), 7.02-4.90 (m, 1H), 5.31 (d, J=4.4 Hz, 1H), 4.66-4.54 (m, 1H), 3.99 (s, 3H), 1.92 (t, J=7.4 Hz, 2H), 1.70-1.10 (m, 6H).
    • EXAMPLE 13(35) (R)-(+)-N-hydroxy-4-[4-(4-(piperidin-1-ylmethyl)phenyl)phenyl]-6-hydroxyhexanamide.hydrochloride
  • [0634]
    Figure US20040214896A1-20041028-C00225
  • [α][0635] D: +6.17 (c 0.12, methanol),
  • TLC: Rf 0.21 (chloroform:methanol=4:1), [0636]
  • NMR(d[0637] 6-DMSO): δ 10.41-10.31 (m, 2H), 7.73 (d, J=8.1 Hz, 2H), 7.65-7.61 (m, 4H), 7.39 (d, J=8.1 Hz, 2H), 4.52 (t, J=6.3 Hz, 1H), 4.26 (d, J=5.1 Hz, 2H), 3.32-3.27 (m, 2H), 2.91-2.78 (m, 2H), 1.90 (t, J=7.2 Hz, 2H).
    • EXAMPLE 13(36) (R)-(+)-N-hydroxy-6-[4-(4-hydroxybenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide
  • [0638]
    Figure US20040214896A1-20041028-C00226
  • [α][0639] D: +6.33 (c 0.12, methanol),
  • TLC: Rf 0.42 (chloroform:methanol=17:3), [0640]
  • NMR(d[0641] 6-DMSO): δ 10.35 (s, 1H), 10.30 (s, 1H), 8.63 (s, 1H), 8.10 (d, J=8.1 Hz, 2H), 7.52 (d, J=8.1 Hz, 2H), 7.21-7.14 (m, 2H), 6.78-4.75 (m, 1H), 5.30 (d, J=4.5 Hz, 1H), 4.62-4.54 (m, 1H), 1.91 (t, J=7.2 Hz, 2H), 1.62-1.16 (m, 6H).
    • EXAMPLE 13(37) (R)-N-hydroxy-6-[4-(6-hydroxybenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide
  • [0642]
    Figure US20040214896A1-20041028-C00227
  • TLC: Rf 0.21 (chloroform:methanol:acetic acid=60:10:1), [0643]
  • NMR(d[0644] 6-DMSO): δ 10.25 (s, 1H), 9.80 (s, 1H), 8.60 (s, 1H), 8.03 (d, J=8.2 Hz, 2H), 7.56-7.42 (m, 3H), 7.05 (d, J=2.2 Hz, 1H), 6.81 (dd, J=8.4, 2.2 Hz, 1H), 5.25 (d, J=4.4 Hz, 1H), 4.62-4.50 (m, 1H), 1.88 (t, J=7.4 Hz, 2H), 1.70-1.10 (m, 6H).
    • EXAMPLE 13(38) (R)-N-hydroxy-6-[4-((1E)-2-(4-methylthiophenyl)vinyl)phenyl]-6-hydroxyhexanamide
  • [0645]
    Figure US20040214896A1-20041028-C00228
  • TLC: Rf 0.22 (chloroform:methanol:acetic acid=90:10:1), [0646]
  • NMR(d[0647] 6-DMSO): δ 10.25 (s, 1H), 7.50 (d, J=8.4 Hz, 2H), 7.49 (d, J=9.0 Hz, 2H), 7.30-7.05 (m, 6H), 4.45 (t, J=6.1 Hz, 1H), 2.45 (s, 3H), 1.87 (t, J=7.2 Hz, 2H), 1.65-1.00 (m, 6H).
    • EXAMPLE 13(39) (R)-N-hydroxy-4-[4-(5-methoxybenzofuran-2-yl)phenyl]-6-hydroxyhexanamide
  • [0648]
    Figure US20040214896A1-20041028-C00229
  • TLC: Rf 0.27 (chloroform:methanol=9:1), [0649]
  • NMR(d[0650] 6-DMSO): δ 10.30 (s, 1H), 8.64 (s, 1H), 7.83 (d, J=8.4 Hz, 2H), 7.50 (d, J=8.8 Hz, 1H), 7.42 (d, J=8.4 Hz, 2H), 7.30 (s, 1H), 7.14 (d, J=2.6 Hz, 1H), 6.88 (dd, J=8.8, 2.6 Hz, 1H), 5.21 (d, J=4.4 Hz, 1H), 4.60-4.48 (m, 1H), 3.79 (s, 3H), 1.91 (t, J=7.0 Hz, 2H), 1.68-1.14 (m, 6H).
    • EXAMPLE 13(40) (R)-N-hydroxy-6-[4-(5-methylthiobenzofuran-2-yl)phenyl]-6-hydroxyhexanamide
  • [0651]
    Figure US20040214896A1-20041028-C00230
  • TLC: Rf 0.27 (chloroform:methanol=9:1), [0652]
  • NMR(d[0653] 6-DMSO): δ 10.30 (s, 1H), 8.82-8.42 (br, 1H), 7.84 (d, J=8.4 Hz, 2H), 7.60-7.52 (m, 2H), 7.43 (d, J=8.4 Hz, 2H), 7.31 (s, 1H), 7.23 (dd, J=8.8, 2.0 Hz, 1H), 5.42-4.96 (br, 1H), 4.54 (t, J=6.4 Hz, 1H), 2.51 (s, 3H), 1.92 (t, J=7.0 Hz, 2H), 1.70-1.12 (m, 6H).
    • EXAMPLE 13(41) (R)-(+)-N-hydroxy-6-[4-(4-(2-(dimethylamino)ethyl)phenyl)phenyl]-6-hydroxyhexanamide.hydrochloride
  • [0654]
    Figure US20040214896A1-20041028-C00231
  • [α][0655] D: +22.11 (c 0.635, dimethylformamide),
  • TLC: Rf 0.12 (chloroform:methanol=7:3), [0656]
  • NMR(d[0657] 6-DMSO): δ 10.60 (s, 1H), 10.32 (s, 1H), 8.62 (s, 1H), 7.62 (d, J=8.4 Hz, 2H), 7.57 (d, J=8.4 Hz, 2H), 7.38-7.33 (m, 4H), 5.14 (d, J=4.2 Hz, 1H), 4.54-4.48 (m, 1H), 3.30-3.25 (m, 2H), 3.06-3.00 (m, 2H), 2.78 (s, 6H), 1.91 (t, J=7.2 Hz, 2H), 1.62-1.15 (m, 6H).
    • EXAMPLE 13(42) (R)-(+)-N-hydroxy-6-[4-(4-(2-(dimethylamino)ethoxy)phenyl)phenyl]-6-hydroxyhexanamide.hydrochloride
  • [0658]
    Figure US20040214896A1-20041028-C00232
  • [α][0659] D: +20.47 (c 1.005, dimethylformamide),
  • TLC: Rf 0.32 (chloroform:methanol=4:1), [0660]
  • NMR(d[0661] 6-DMSO): δ 10.56 (br, 1H), 10.32 (s, 1H), 8.63 (s, 1H), 7.61 (d, J=8.5 Hz, 2H), 7.54 (d, J=8.5 Hz, 2H), 7.35 (d, J=8.5 Hz, 2H), 7.07 (d, J=8.5 Hz, 2H), 5.12 (d, J=4.2 Hz, 1H), 4.05 (m, 1H), 4.39 (t, J=5.0 Hz, 2H), 3.50 (t, J=5.0 Hz, 2H), 2.83 (s, 6H), 1.91 (t, J=7.2 Hz, 2H), 1.57 (m, 2H), 1.50 (m, 2H), 1.39-1.17 (m, 2H).
    • EXAMPLE 13(43) (R)-(+)-N-hydroxy-6-[4-(4-(2-(diethylamino)ethyl)phenyl)phenyl]-6-hydroxyhexanamide.hydrochloride
  • [0662]
    Figure US20040214896A1-20041028-C00233
  • [α][0663] D: 18.58 (c 0.93, dimethylformamide),
  • TLC: Rf 0.25 (chloroform:methanol=9:1), [0664]
  • NMR(d[0665] 6-DMSO): δ 10.47 (brs, 1H), 10.32 (s, 1H), 8.62 (brs, 1H), 7.61 (d, J=8.4 Hz, 2H), 7.58 (d, J=8.4 Hz, 2H), 7.37 (d, J=8.4 Hz, 2H), 7.37 (d, J=8.4 Hz, 2H), 5.13 (brs, 1H), 4.53-4.49 (m, 1H), 3.31-3.01 (m, 8H), 1.90 (t, J=6.9 Hz, 2H), 1.62-1.15 (m, 6H), 1.23 (t, J=6.9 Hz, 6H).
    • EXAMPLE 13(44) (R)-N-hydroxy-4-[4-(4-(2-hydroxyethyl)phenyl)phenyl]-6-hydroxyhexanamide
  • [0666]
    Figure US20040214896A1-20041028-C00234
  • TLC: Rf 0.28 (chloroform:methanol=9:1), [0667]
  • NMR(d[0668] 6-DMSO): δ 10.29 (s, 1H), 8.63 (s, 1H), 7.56 (d, J=8.1 Hz, 2H), 7.53 (d, J=8.1 Hz, 2H), 7.36 (d, J=8.1 Hz, 2H), 7.27 (d, J=8.1 Hz, 2H), 5.12 (d, J=4.5 Hz, 1H), 4.64 (t, J=5.3 Hz, 1H), 4.51 (m, 1H), 3.61 (m, 2H), 2.74 (t, J=7.0 Hz, 2H), 1.91 (t, J=7.0 Hz, 2H), 1.63-1.43 (m, 4H), 1.40-1.15 (m, 2H).
    • EXAMPLE 14(1)˜14(5)
  • By the same procedure as a series of reactions of reference example 5→reference example 3→example 1→example 2 using a corresponding ketone derivative instead of the compound prepared in reference example 1, if desired, the conversion into the acid addition salts by conventional means, the following compounds of the present invention were obtained. [0669]
    • EXAMPLE 14(1) (S)-(−)-N-hydroxy-6-[4-(4-methylthiophenyl)phenyl]-6-hydroxyhexanamide
  • [0670]
    Figure US20040214896A1-20041028-C00235
  • [α][0671] D: −26.3 (c 0.99, dimethylformamide),
  • TLC: Rf 0.21 (chloroform:methanol=9:1), [0672]
  • NMR(d[0673] 6-DMSO): δ 10.29 (s, 1H), 8.63 (s, 1H), 7.60 (d, J=8.4 Hz, 2H), 7.58 (d, J=8.4 Hz, 2H), 7.37 (d, J=8.4 Hz, 2H), 7.32 (d, J=8.4 Hz, 2H), 5.12 (d, J=3.9 Hz, 1H), 4.51 (m, 1H), 2.50 (s, 3H), 1.91 (t, J=7.5 Hz, 2H), 1.65-1.15 (m, 6H),
    • EXAMPLE 14(2) (S)-(−)-N-hydroxy-6-[4-(2-(4-methylthiophenyl)ethynyl)phenyl]-6-hydroxyhexanamide
  • [0674]
    Figure US20040214896A1-20041028-C00236
  • [α][0675] D: −33.4 (c 0.99, dimethylformamide),
  • TLC: Rf 0.19 (chloroform:methanol=9:1), [0676]
  • NMR(d[0677] 6-DMSO): δ 10.28 (s, 1H), 8.62 (s, 1H), 7.47 (d, J=8.4 Hz, 2H), 7.45 (d, J=8.4 Hz, 2H), 7.33 (d, J=8.4 Hz, 2H), 7.27 (d, J=8.4 Hz, 2H), 5.20 (d, J=4.8 Hz, 1H), 4.51 (m, 1H), 2.49 (s, 3H), 1.90 (t, J=7.2 Hz, 2H), 1.60-1.40 (m, 4H), 1.35-1.15 (m, 2H).
    • EXAMPLE 14(3) (S)-(−)-N-hydroxy-4-[4-(benzoxazol-2-yl)phenyl]-6-hydroxyhexanamide
  • [0678]
    Figure US20040214896A1-20041028-C00237
  • [α][0679] D: −11.5 (c 0.81, methanol),
  • TLC: Rf 0.21 (chloroform:methanol=9:1), [0680]
  • NMR(d[0681] 6-DMSO): δ 10.30 (s, 1H), 8.64 (s, 1H), 8.15 (d, J=8.4 Hz, 2H), 7.82-7.75 (m, 2H), 7.55 (d, J=8.4 Hz, 2H), 7.45-7.30 (m, 2H), 5.32 (d, J=4.8 Hz 4.65-4.56 (m, 1H), 1.92 (t, J=7.0 Hz, 2H), 1.70-1.20 (m, 6H).
    • EXAMPLE 14(4) (S)-(−)-N-hydroxy-6-[4-(5-methylbenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide
  • [0682]
    Figure US20040214896A1-20041028-C00238
  • [α][0683] D: −33.4 (c 0.99, dimethylformamide),
  • TLC: Rf 0.23 (chloroform:methanol=9:1), [0684]
  • NMR(d[0685] 6-DMSO): δ 10.29 (d, J=1.5 Hz, 1H), 8.63 (d, J=1.5 Hz, 1H), 8.12 (d, J=8.1 Hz, 2H), 7.64 (d, J=8.4 Hz, 1H), 7.58 (d, J=1.2 Hz, 1H), 7.53 (d, J=8.1 Hz, 2H), 7.23 (dd, J=8.4, 1.2 Hz, 1H), 5.32 (d, J=4.2,1H), 4.60 (m, 1H), 2.43 (s, 3H), 1.91 (t, J=6.9 Hz, 2H), 1.70-1.20 (m, 6H).
    • EXAMPLE 14(5) (S)-(−)-N-hydroxy-6-[4-(4-(dimethylaminomethyl)phenyl)phenyl]-6-hydroxyhexanamide.hydrochloride
  • [0686]
    Figure US20040214896A1-20041028-C00239
  • [α][0687] D: −5.39 (c 0.495, water),
  • TLC: Rf 0.25 (chloroform:methanol=2:1), [0688]
  • NMR(d[0689] 6-DMSO): δ 10.31 (m, 2H), 8.64 (s, 1H), 7.76 (d, J=8.0 Hz, 2H), 7.65 (d, J=8.0 Hz, 2H), 7.51 (d, J=8.0 Hz, 2H), 7.41 (d, J=8.0 Hz, 2H), 5.16 (m, 1H), 4.53 (m, 1H), 4.29 (s, 2H), 2.71 (s, 6H), 1.91 (t, J=7.0 Hz, 2H), 1.65-1.15 (m, 6H).
    • EXAMPLE 15 (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-(morpholin-4-ylmethyl)phenyl)phenyl]-6-hydroxyhexanamide
  • [0690]
    Figure US20040214896A1-20041028-C00240
  • By the same procedure as a series of reactions of reference example 4→reference example 3→example 1 using methyl 6-[4-(4-(morpholin-4-ylmethyl)phenyl)phenyl]-6-oxohexanoate instead of the compound prepared in reference example 1, the compound of the present invention having the following physical data was obtained. [0691]
  • TLC: Rf 0.46 (chloroform:methanol=6:1), [0692]
  • NMR(CDCl[0693] 3): δ 7.74 (brs, 1H), 7.54 (d, J=8.1 Hz, 2H), 7.53 (d, J=8.1 Hz, 2H), 7.39 (d, J=8.1 Hz, 2H), 7.38 (d, J=8.1 Hz, 2H), 4.74-4.70 (m, 1H), 3.73-3.70 (m, 4H), 3.30 (s, 3H), 2.48-2.45 (m, 4H), 2.19-2.08 (m, 2H), 1.91-1.34 (m, 6H), 1.41 (s, 6H).
    • EXAMPLE 15(1) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-(dipropylaminomethyl)phenyl)phenyl]-6-hydroxyhexanamide
  • [0694]
    Figure US20040214896A1-20041028-C00241
  • By the same procedure as a series of reactions of example 15 using methyl 6-[4-(4-(dipropylaminomethyl)phenyl)phenyl]-6-oxohexanoate instead of methyl 6-[4-(4-(morpholin-4-ylmethyl)phenyl)phenyl]-6-oxohexanoate, the compound of the present invention having the following physical data was obtained. [0695]
  • TLC: Rf 0.31 (chloroform:methanol=9:1), [0696]
  • NMR(CDCl[0697] 3): δ 7.76 (br, 1H), 7.57 (d, J=8.4 Hz, 2H), 7.52 (d, J=8.4 Hz, 2H), 7.39 (d, J=8.4 Hz, 4H), 4.72 (dd, J=7.0, 5.8 Hz, 1H), 3.59 (s, 2H), 3.30 (s, 3H), 2.40 (t-like, J=7.5 Hz, 4H), 2.34 (m, 2H), 1.84-1.67 (m, 4H), 1.56-1.36 (m, 2H), 1.50 (m, J=7.5 Hz, 4H), 1.41 (s, 6H), 0.87 (t, J=7.5 Hz, 6H).
    • EXAMPLE 16 (R)-(+)-N-hydroxy-6-[4-(4-(morpholin-4-ylmethyl)phenyl)phenyl]-6-hydroxyhexanamide.hydrochloride
  • [0698]
    Figure US20040214896A1-20041028-C00242
  • By the same procedure as a series of reactions of example 2 using the compound prepared in example 15 instead of the compound prepared in example 1 and the conversion into the acid addition salts by conventional means the compound of the present invention having the following physical data was obtained. [0699]
  • [α][0700] D: +6.17 (c 0.12, methanol),
  • TLC: Rf 0.21 (chloroform:methanol=9:1), [0701]
  • NMR(d[0702] 6-DMSO): δ 11.30 (brs, 1H), 10.32 (brs, 1H), 7.73 (d, J=8.7 Hz, 2H), 7.67 (d, J=8.7 Hz, 2H), 7.63 (d, J=8.7 Hz, 2H), 7.39 (d, J=8.7 Hz, 2H), 4.52 (t, J=6.3 Hz, 1H), 4.34 (d, J=5.1 Hz, 2H), 3.94-3.75 (m, 4H), 3.20-2.95 (m, 4H), 1.93 (t, J=7.2 Hz, 2H), 1.65-1.15 (m, 6H).
    • EXAMPLE 16(1) (R)-(+)-N-hydroxy-6-[4-(4-(dipropylaminomethyl)phenyl)phenyl]-6-hydroxyhexanamide
  • [0703]
    Figure US20040214896A1-20041028-C00243
  • By the same procedure as a series of reactions of example 16 using the compound prepared in example 15(1), or the conversion into the acid addition salts by conventional means, the compounds of the present invention having the following physical data were obtained. [0704]
  • Free Form: [0705]
  • [α][0706] D: +20.85 (c 1.01, dimethylformamide),
  • TLC: Rf 0.37 (chloroform methanol=6:1), [0707]
  • NMR(d[0708] 6-DMSO): δ 10.26 (br, 1H), 8.65 (br, 1H), 7.58 (d, J=8.4 Hz, 4H), 7.36 (d, J=8.4 Hz, 2H), 7.35, (d, J=8.4 Hz, 2H), 5.12 (br, 1H), 4.51 (t, J=6.0 Hz, 1H), 3.52 (s, 2H), 2.33 (t, J=7.2 Hz, 4H), 1.91 (t, J=7.2 Hz, 2H), 1.64-1.55 (m, 2H), 1.51-1.37 (m, 6H), 1.36-1.17 (m, 2H), 0.82 (t, J=7.2 Hz, 6H).
  • Hydrochloride: [0709]
  • TLC: Rf 0.37 (chloroform:methanol=6:1), [0710]
  • NMR(d[0711] 6-DMSO): δ 10.58 (br, 1H), 10.32 (s, 1H), 8.62 (br, 1H), 7.74 (d, J=8.4 Hz, 2H), 7.68 (d, J=8.4 Hz, 2H), 7.65 (d, J=8.4 Hz, 2H), 7.40 (d, J=8.4 Hz, 2H), 5.17 (br, 1H), 4.53 (t, J=6.3 Hz, 1H), 4.32 (s, 2H), 2.93 (m, 4H), 1.91 (t, J=7.2 Hz, 2H), 1.82-1.66 (m, 4H), 1.65-1.55 (m, 2H), 1.48 (m, 2H), 1.40-1.20 (m, 2H), 0.86 (t, J=7.2 Hz, 6H).
    • EXAMPLE 17(1) AND 17(2)
  • By the same procedure as a series of reactions of reference example 4→reference example 3→example 1→example 2 using methyl 6-(5-phenylthiophen-2-yl)-6-oxohexanoate or methyl 6-(5-phenylbenzofuran-2-yl)-6-oxohexanoate instead of the compound prepared in reference example 1, the following compounds of the present invention were obtained. [0712]
    • EXAMPLE 17(1) (R)-N-hydroxy-6-(5-phenylthiophen-2-yl)-6-hydroxyhexanamide
  • [0713]
    Figure US20040214896A1-20041028-C00244
  • TLC: Rf 0.19 (chloroform:methanol=9:1), [0714]
  • NMR(d[0715] 6-DMSO): δ 10.42-10.20 (br, 1H), 8.80-8.55 (br, 1H), 7.64-7.56 (m, 2H), 7.43-7.20 (m, 4H), 6.90 (d, J=3.2 Hz, 1H), 5.59 (d, J=4.0 Hz, 1H), 4.80-4.65 (m, 1H), 1.93 (t, J=7.4 Hz, 2H), 1.76-1.15 (m, 6H).
    • EXAMPLE 17(2) (R)-N-hydroxy-6-(5-phenylbenzofuran-2-yl)-6-hydroxyhexanamide
  • [0716]
    Figure US20040214896A1-20041028-C00245
  • TLC: Rf 0.28 (chloroform:methanol=9:1), [0717]
  • NMR(d[0718] 6-DMSO): δ 10.31 (s, 1H), 8.65 (s, 1H), 7.83 (m, 1H), 7.70-7.52 (m, 4H), 7.50-7.28 (m, 3H), 6.75 (s, 1H), 5.53 (d, J=5.4 Hz, 1H), 4.72-4.58 (m, 1H), 1.93 (t, J=7.4 Hz, 2H), 1.84-1.62 (m, 2H), 1.60-1.18 (m, 4H).
    • REFERENCE EXAMPLE 16 (R)-benzyl 6-[4-(4-(methoxycarbonyl)phenyl)phenyl]-6-hydroxyhexanoate
  • [0719]
    Figure US20040214896A1-20041028-C00246
  • By the same procedure as a series of reactions of reference example 4 using benzyl 6-[4-(4-(methoxycarbonyl)phenyl)phenyl]-6-oxohexanoate instead of the compound prepared in reference example 1, the title compound having the following physical data was obtained. [0720]
  • TLC: Rf 0.19 (chloroform:ethyl acetate=19:1). [0721]
    • REFERENCE EXAMPLE 17 (R)-6-[4-(4-(methoxycarbonyl)phenyl)phenyl]-6-hydroxyhexanoic acid
  • [0722]
    Figure US20040214896A1-20041028-C00247
  • To a solution of the compound prepared in reference example 16 (1.36 g) in methanol (20 mL) and tetrahydrofuran (10 mL) was added 10% palladium carbon (136 mg). Under an atmosphere of hydrogen, the reaction mixture was stirred at room temperature for 1.5 hours. The reaction mixture was filtered and concentrated. The obtained residue was washed with ether and dried to give the title compound (951 mg) having the following physical data. [0723]
  • TLC: Rf 0.32 (chloroform:methanol=9:1). [0724]
    • EXAMPLE 18 (R)-N-hydroxy-6-[4-(4-(methoxycarbonyl)phenyl)phenyl]-6-hydroxyhexanamide
  • [0725]
    Figure US20040214896A1-20041028-C00248
  • By the same procedure as a series of reactions of example 1→example 2 using the compound prepared in reference example 17, the compound of present invention having the following physical data was obtained. [0726]
  • TLC: Rf 0.28 (chloroform:methanol=9:1), [0727]
  • NMR(d[0728] 6-DMSO): δ 10.30 (s, 1H), 8.64 (s, 1H), 8.02 (d, J=8.4 Hz, 2H), 7.81 (d, J=8.4 Hz, 2H), 7.68 (d, J=8.4 Hz, 2H), 7.42 (d, J=8.4 Hz, 2H), 5.18 (d, J=4.4 Hz, 2H), 4.61-4.48 (m, 1H), 3.86 (s, 3H), 1.91 (t, J=7.4 Hz, 2H), 1.67-1.10 (m, 6H).
    • EXAMPLE 19 (R)-N-hydroxy-6-[4-(4-carboxyphenyl)phenyl]-6-hydroxyhexanamide
  • [0729]
    Figure US20040214896A1-20041028-C00249
  • By the same procedure as a series of reactions of example 1→reference example 3→example 2 using the compound prepared in reference example 17, the compound of present invention having the following physical data was obtained. [0730]
  • TLC: Rf 0.16 (chloroform:methanol:acetic acid=90:10:1), [0731]
  • NMR(d[0732] 6-DMSO): δ 10.31 (s, 1H), 8.00 (d, J=8.4 Hz, 2H), 7.75 (d, J=8.4 Hz, 2H), 7.66 (d, J=8.4 Hz, 2H), 7.41 (d, J=8.4 Hz, 2H), 5.40-4.90 (br, 1H), 4.61-4.47 (m, 1H), 1.92 (t, J=7.0 Hz, 2H), 1.70-1.10 (m, 6H).
    • REFERENCE EXAMPLE 18 (R)-methyl 6-[4-(4-methylthiophenyl)phenyl]-6-hydroxyhexanoate
  • [0733]
    Figure US20040214896A1-20041028-C00250
  • By the same procedure as a series of reactions of reference example 4 using methyl 6-[4-(4-methylthiophenyl)phenyl]-6-oxohexanoate instead of the compound prepared in reference example 1, the title compound having the following physical data was obtained. [0734]
  • TLC: Rf 0.25 (hexane:ethyl acetate=2:1), [0735]
  • NMR(CDCl[0736] 3): δ 7.57-7.49 (m, 4H), 7.39 (d, J=8.4 Hz, 2H), 7.32 (d, J=8.4 Hz, 2H), 4.72 (t, J=6.2 Hz, 1H), 3.65 (s, 3H), 2.32 (t, J=7.4 Hz, 2H), 1.88-1.25 (m, 6H).
    • REFERENCE EXAMPLE 19 (R)-methyl 6-[4-(4-methylsulfonylphenyl)phenyl]4-hydroxyhexanoate
  • [0737]
    Figure US20040214896A1-20041028-C00251
  • To a solution of the compound prepared in reference example 18 (335 mg) in dichloromethane (10 mL) was added m-chloroperbenzoic acid (504 mg) at 0° C. The reaction mixture was stirred at 0° C. for 1 hour. To the reaction mixture was added an aqueous solution of sodium thiosulfate and the mixture was extracted with ethyl acetate. The extract was washed with water and a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate and concentrated to give the title compound (349 mg) having the following physical data. [0738]
  • TLC: Rf 0.51 (hexane:ethyl acetate=1:4), [0739]
  • NMR(CDCl[0740] 3): δ 8.00 (d, J=8.4 Hz, 2H), 7.76 (d, J=8.4 Hz, 2H), 7.59 (d, J=8.4 Hz, 2H), 7.46 (d, J=8.4 Hz, 2H), 4.80-4.72 (m, 1H), 3.66 (s, 3H), 3.09 (s, 3H), 2.32 (t, J=7.5 Hz, 2H), 1.90-1.30 (m, 6H).
    • EXAMPLE 20 (R)-(+)-N-hydroxy-6-[4-(4-methylsulfonylphenyl)phenyl]-6-hydroxyhexanamide
  • [0741]
    Figure US20040214896A1-20041028-C00252
  • By the same procedure as a series of reactions of reference example 3→example 1→example 2 using the compound prepared in reference example 19 instead of the compound prepared in reference example 2, the compound of the present invention having the following physical data was obtained. [0742]
  • [α][0743] D: +9.84 (c 0.125, methanol),
  • TLC: Rf 0.12 (chloroform:methanol=9:1), [0744]
  • NMR(d[0745] 6-DMSO): δ 10.29 (s, 1H), 8.63 (s, 1H), 7.97 (d, J=8.7 Hz, 2H), 7.91 (d, J=8.7 Hz, 2H), 7.69 (d, J=8.7 Hz, 2H), 7.43 (d, J=8.7 Hz, 2H), 5.19 (d, J=4.5 Hz, 1H), 4.59-4.51 (m, 1H), 3.23 (s, 1H), 1.90 (t, J=7.5 Hz, 2H), 1.62-1.18 (m, 6H).
    • REFERENCE EXAMPLE 20 (R)-methyl 6-[4-(4-hydroxymethylphenyl)phenyl]-6-hydroxyhexanoate
  • [0746]
    Figure US20040214896A1-20041028-C00253
  • By the same procedure as a series of reactions of reference example 4 using methyl 6-[4-(4-formylphenyl)phenyl]-6-oxohexanoate instead of the compound prepared in reference example 1, the title compound having the following physical data was obtained. [0747]
  • TLC: Rf 0.27 (hexane:ethyl acetate=1:1), [0748]
  • NMR(CDCl[0749] 3): δ 7.59 (d, J=8.4 Hz, 2H), 7.57 (d, J=8.4 Hz, 2H), 7.44 (d, J=8.4 Hz, 2H), 7.40 (d, J=8.4 Hz, 2H), 4.78-4.66 (m, 3H), 3.66 (s, 3H), 2.32 (t, J=7.6 Hz, 2H), 2.02-1.20 (m, 6H).
    • EXAMPLE 21 (R)-N-hydroxy-6-[4-(4-hydroxymethylphenyl)phenyl]-6-hydroxyhexanamide
  • [0750]
    Figure US20040214896A1-20041028-C00254
  • By the same procedure as a series of reactions of reference example 3→example 1→example 2 using the compound prepared in reference example 20 instead of the compound prepared in reference example 2, the compound of the present invention having the following physical data was obtained. [0751]
  • TLC: Rf 0.13 (chloroform:methanol=9:1), [0752]
  • NMR(d[0753] 6-DMSO): δ 10.30 (s, 1H), 8.80-8.50 (br. 1H), 7.60 (d, J=8.0 Hz, 2H), 7.58 (d, J=8.0 Hz, 2H), 7.37 (d, J=8.0 Hz, 4H), 5.40-5.00 (br, 2H), 4.60-4.40 (m, 3H), 1.91 (t, J=7.0 Hz, 2H), 1.70-1.10 (m, 6H).
    • EXAMPLE 22 N-methoxy-6-[4-(4-chlorophenyl)phenyl]-6-hydroxyhexanamide
  • [0754]
    Figure US20040214896A1-20041028-C00255
  • By the same procedure as a series of reactions of example 1 using methoxylamine instead of (1-methoxy-1-methylethyl)hydroxyamine, the compound of the present invention having the following physical data was obtained. [0755]
  • TLC: Rf 0.27 (ethyl acetate), [0756]
  • NMR(CDCl[0757] 3): δ 8.21 (br, 1H), 7.52 (d, J=8.0 Hz, 2H), 7.49 (d, J=8.0 Hz, 2H), 7.39 (d, J=8.0 Hz, 4H), 4.74-4.70 (m, 1H), 3.72 (s, 3H), 2.44-2.04 (m, 3H), 1.90-1.62 (m, 4H), 1.58-1.34 (m, 2H).
    • EXAMPLE 23 (R)-(+)-5-(5,5-dimethyl-1,4,2-dioxazolin-3-yl)-1-[4-(5-methylbenzoxazol-2-yl)phenyl]pentan-1-ol
  • [0758]
    Figure US20040214896A1-20041028-C00256
  • A solution of the compound prepared in example 6 (3 g) in toluene (100 mL) was stirred at 100° C. for 3 hours. The reaction mixture was concentrated. The obtained residue was washed with isopropyl ether and dried to give the compound (2.83 g) of the present invention having the following physical data. [0759]
  • [α][0760] D: +24.59 (c 0.81, dimethylformamide),
  • TLC: Rf 0.21 (hexane:ethyl acetate=2:1), [0761]
  • NMR(CDCl[0762] 3): δ 8.21 (d, J=8.4 Hz, 2H), 7.54 (brs, 1H), 7.49 (d, J=8.4 Hz, 2H), 7.45 (d, J=8.4 Hz, 1H), 7.17-7.14 (m, 1H), 4.79-4.75 (m, 1H), 2.48 (s, 3H), 2.30 (t, J=7.2 Hz, 2H), 1.91-1.33 (m, 6H), 1.53 (s, 6H).
    • EXAMPLE 23(1) AND 23(2)
  • Using the compound prepared in example 6(3) or (4) instead of the compound prepared in example 6, if desired, the conversion into the acid addition salts by conventional means, the following compounds of the present invention were obtained. [0763]
    • EXAMPLE 23(1) (R)-5-(5,5-dimethyl-1,4,2-dioxazolin-3-yl)-1-[4-(4-methylthiophenyl)phenyl]pentan-1-ol
  • [0764]
    Figure US20040214896A1-20041028-C00257
  • TLC: Rf 0.57 (hexane:ethyl acetate=1:1), [0765]
  • NMR(CDCl[0766] 3): 67.54 (d, J=8.5 Hz, 2H), 7.51 (d, J=8.5 Hz, 2H), 7.39 (d, J=8.5 Hz, 2H), 7.32 (d, J=8.5 Hz, 2H), 4.71 (m, 1H), 2.52 (s, 3H), 2.30 (t, J=7.5 Hz, 2H), 1.94-1.72 (m, 2H), 1.66 (m, 2H), 1.57-1.35 (m, 2H), 1.53 (s, 3H), 1.52 (s, 3H).
    • EXAMPLE 23(2) (R)-5-(5,5-dimethyl-1,4,2-dioxazolin-3-yl)-1-[4-(4-(dimethylaminomethyl)phenyl)phenyl]pentan-1-ol.1.5 fumaric acid salt
  • [0767]
    Figure US20040214896A1-20041028-C00258
  • [α][0768] D: +15.9 (c 1.16, dimethylformamide),
  • TLC: Rf 0.30 (chloroform:methanol=9:1), [0769]
  • NMR(d[0770] 6-DMSO): δ 7.63 (d, J=8.3 Hz, 2H), 7.60 (d, J=8.3 Hz, 2H), 7.42 (d, J=8.3 Hz, 2H), 7.38 (d, J=8.3 Hz, 2H), 6.57 (s, 3H), 4.54 (t, J=6.0 Hz, 1H), 3.71 (s, 2H), 2.34 (s, 6H), 2.26 (t, J=7.2 Hz, 2H), 1.67-1.23 (m, 6H), 1.43 (s, 6H).
    • EXAMPLE 24 (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-(2-(morpholin-4-yl)ethoxy)phenyl)phenyl]-6-hydroxyhexanamide
  • [0771]
    Figure US20040214896A1-20041028-C00259
  • By the same procedure as a series of reactions of reference example 4→reference example 3→example 1 using methyl 6-[4-(4-(2-(morpholin-4-yl)ethoxy)phenyl)phenyl]-6-oxohexanoate instead of the compound prepared in reference example 1, the compound of the present invention having the following physical data was obtained. [0772]
  • TLC: Rf 0.50 (chloroform:methanol=9:1), [0773]
  • NMR(CD[0774] 3OD): δ 7.52 (d, J=8.7 Hz, 2H), 7.51 (d, J=8.7 Hz, 2H), 7.36 (d, J=8.7 Hz, 2H), 7.00 (d, J=8.7 Hz, 2H), 4.62 (t, J=6.6 Hz, 1H), 4.17 (t, J=5.4 Hz, 2H), 3.72 (t, J=4.7 Hz, 4H), 3.28 (s, 3H), 2.82 (t, J=5.4 Hz, 2H), 2.61 (t, J=4.7 Hz, 4H), 2.13 (t, J=7.2 Hz, 2H), 1.86-1.70 (m, 2H), 1.64 (m, 2H), 1.50-1.23 (m, 2H), 1.33 (s, 6H).
    • EXAMPLE 24(1) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-(2-(morpholin-4-yl)ethyl)phenyl)phenyl]-6-hydroxyhexanamide
  • [0775]
    Figure US20040214896A1-20041028-C00260
  • By the same procedure as a series of reactions of example 24 using methyl 6-[4-(4-(2-(morpholin-4-yl)ethyl)phenyl)phenyl]-6-oxohexanoate instead of methyl 6-[4-(4-(2-(morpholin-4-yl)ethoxy)phenyl)phenyl]-6-oxohexanoate, the compound of the present invention having the following physical data was obtained. [0776]
  • TLC: Rf 0.46 (chloroform:methanol=9:1), [0777]
  • NMR(CDCl[0778] 3): δ 7.70 (brs, 1H), 7.55 (d, J=8.1 Hz, 2H), 7.51 (d, J=8.1 Hz, 2H), 7.39 (d, J=8.1 Hz, 2H), 7.27 (d, J=8.1 Hz, 2H), 4.74-4.69 (m, 1H), 3.77-3.73 (m, 4H), 3.30 (s, 3H), 2.87-2.81 (m, 2H), 2.65-2.60 (m, 2H), 2.55-2.53 (m, 4H), 2.19-1.32 (m, 8H), 1.41 (s, 6H).
    • EXAMPLE 25 (R)-(+)-N-hydroxy-6-[4-(4-(2-(morpholin-4-yl)ethoxy)phenyl)phenyl]-6-hydroxyhexanamide.hydrochloride
  • [0779]
    Figure US20040214896A1-20041028-C00261
  • By the same procedure as a series of reactions of example 2 using the compound prepared in example 24 instead of the compound prepared in example 1 and the conversion into the acid addition salts by conventional means, the compound of the present invention having the following physical data was obtained. [0780]
  • [α][0781] D: +13.52 (c 0.84, dimethylformamide),
  • TLC: Rf 0.31 (chloroform:methanol=9:1), [0782]
  • NMR(d[0783] 6-DMSO): δ 10.92 (brs, 1H), 10.30 (s, 1H), 8.61 (brs, 1H), 7.61 (d, J=8.4 Hz, 2H), 7.54 (d, J=8.4 Hz, 2H), 7.35 (d, J=8.4 Hz, 2H), 7.07 (d, J=8.4 Hz, 2H), 5.12 (brs, 1H), 4.53-4.41 (m, 3H), 4.01-3.93 (m, 2H), 3.84-3.74 (m, 2H), 3.60-3.12 (m, 6H), 1.90 (t, J=7.2 Hz, 2H), 1.62-1.12 (m, 6H).
    • EXAMPLE 25(1) (R)-(+)-N-hydroxy-6-[4-(4-(2-(morpholin-4-yl)ethyl)phenyl)phenyl]-6-hydroxyhexanamide.hydrochloride
  • [0784]
    Figure US20040214896A1-20041028-C00262
  • By the same procedure as a series of reactions of example 25 using the compound prepared in example 24(1) or the conversion into the acid addition salts by conventional means, the compound of the present invention having the following physical data was obtained. [0785]
  • [α][0786] D: +16.80 (c 0.815, dimethylformamide), TLC: Rf 0.41 (chloroform:methanol=17:3),
  • NMR(d[0787] 6-DMSO): δ 10.82 (brs, 1H), 10.30 (s, 1H), 8.62 (brs, 1H), 7.62 (d, J=8.4 Hz, 2H), 7.58 (d, J=8.4 Hz, 2H), 7.37 (d, J=8.4 Hz, 2H), 7.34 (d, J=8.4 Hz, 2H), 5.13 (brs, 1H), 4.53-4.49 (m, 1H), 4.00-3.96 (m, 2H), 3.96-3.72 (m, 2H), 3.51-3.47 (m, 2H), 3.39-3.25 (m, 2H), 3.18-3.02 (m, 4H), 1.90 (t, J=7.2 Hz, 2H), 1.64-1.16 (m, 6H).
  • [Formulation Example][0788]
    • FORMULATION EXAMPLE 1
  • The following components were admixed in a conventional technique, punched out to give 100 tablets each containing 50 mg of active ingredient. [0789]
    (R)-(+)-N-hydroxy-6-(4-(4-chlorophenyl)phenyl)- 5.0 g
    6-hydroxyhexanamide
    calcium carboxymethylcellulose (disintegrant) 0.2 g
    magnesium stearate (lubricant) 0.1 g
    microcrystalline cellulose 4.7 g
    • FORMULATION EXAMPLE 2
  • The following components were admixed in a conventional technique. The solution was sterilized in a conventional technique, filled in ampoules 5 ml each and freeze-dried in a conventional technique to give 100 ampoules each containing 20 mg of active ingredient. [0790]
    (R)-(+)-N-hydroxy-6-(4-(4-chlorophenyl)phenyl)- 2.0 g
    6-hydroxyhexanamide
    mannitol 20 g
    distilled water 500 mL

Claims (13)

1. A method of inhibiting IL-6 production comprising administering to a subject in need of treatment an effective amount of a hydroxamic acid derivative of the formula (I):
Figure US20040214896A1-20041028-C00263
wherein, R1 is
(a) C1-8 alkyl,
(b) C2-8 alkenyl,
(c) C2-8 alkynyl,
(d) halogen,
(e) nitro,
(f) nitrile,
(g) trifluoromethyl,
(h) trifluoromethoxy,
(i) —OR2,
(j) —SR2,
(k) —NR3R4,
(l) —COR5,
(m) keto,
(n) Cyc1,
(o) C1-8 alkyl substituted by —OR2, —SR2, —NR3R4, —COR5 or Cyc1,
(p) —SO2R10,
(q) —O—(C1-8 alkylene)—OR11,
(r) C1-8 alkyl substituted by nitrile, —SO2R10 or —O—(C1-8 alkylene)—OR11,
(s) —O—(C1-8 alkylene)—NR12R13,
(t) —S—(C1-8 alkylene)—NR12R13,
(u) C1-8 alkyl substituted by —O—(C1-8 alkylene)—NR12R13— or —S—(C1-8 alkylene)—NR12R13,
(v) C2-8 alkenyl substituted by —OR2, —SR2, —NR3R4, —COR5, Cyc1, nitrile, —SO2R10, —O—(C1-8 alkylene)—OR11, —O—(C1-8 alkylene)—NR12R13 or —S—(C1-8 alkylene)—NR12R13 or
(w) C2-8 alkynyl substituted by —OR2, —SR2, —NR3R4, —COR5, Cyc1, nitrile, —SO2R10, —O—(C1-8 alkylene)—OR11, —O—(C1-8 alkylene)—NR12R13 or —S—(C1-8 alkylene)—NR12R13;
R2 is hydrogen, C1-8alkyl, C2-9 acyl or Cyc1;
R3 and R4 are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1;
R5 is hydroxy, C1-8 alkyl, C1-8 alkoxy, —NR6R7 or Cyc1;
R6 and R7 are each independently hydrogen, C1-8 alkyl or Cyc1;
R10 is C1-8 alkyl or Cyc1;
Cyc1 is C3-7 mono-carbocyclic ring or 5-7 membered mono-cyclic hetero ring containing 1-4 nitrogen atom(s), one oxygen atom and/or one sulfur atom;
R11 is hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1;
R12 and R13 are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1;
m is 0 or an integer of 1-5;
ring A is C3-15 mono-, bi- or tri-carbocyclic ring or 5-18 membered mono-, bi- or tri-cyclic hetero ring containing 1-4 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s);
ring B is C5-15 mono-, bi- or tri-carbocyclic aryl or 5-18 membered mono-, bi- or tri-cyclic hetero aryl containing 1-4 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s);
E is a bond, —CH═CH— or —C≡C—;
R8 is
(a) C1-8 alkyl,
(b) C1-8 alkoxy,
(c) halogen,
(d) nitro,
(e) nitrile,
(f) trifluoromethyl or
(g) trifluoromethoxy;
with the proviso that when E is a bond, then, optionally, R1 and R8, taken together, may be C1-4 alkylene;
n is 0 or an integer of 1-5;
R9 is hydrogen, C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl;
a nontoxic salt thereof or a prodrug thereof, as an active ingredient.
2. The method described in claim 1, wherein the prodrug of a compound of the formula (I) as an active ingredient is represented by a compound of the formula (IA):
Figure US20040214896A1-20041028-C00264
wherein, R14 is C1-8 alkyl substituted with C1-8 alkyl, C1-8 alkoxy, the other symbols have the same meanings as defined in claim 1.
3. The method described in claim 1, wherein the prodrug of a compound of the formula (I) as an active ingredient is represented by comprising a compound of the formula (IB):
Figure US20040214896A1-20041028-C00265
wherein, the all symbols have the same meanings as defined in claim 1.
4. A hydroxamic acid derivative of the formula (I):
Figure US20040214896A1-20041028-C00266
wherein, R1 is
(a) C1-8 alkyl,
(b) C2-8 alkenyl,
(c) C2-8 alkynyl,
(d) halogen,
(e) nitro,
(f) nitrile,
(g) trifluoromethyl,
(h) trifluoromethoxy,
(i) —OR2,
(t) —SR2,
(k) —NR3R4,
(l) —COR5,
(m) keto,
(n) Cyc1,
(o) C1-8 alkyl substituted by —OR2, —SR2, —NR3R4, —COR5 or Cyc1,
(p) —SO2R10,
(q) —O—(C1-8 alkylene)—OR11,
(r) C1-8 alkyl substituted by nitrile, —SO2R10 or —O—(C1-8 alkylene)—OR11,
(s) —O—(C1-8 alkylene)—NR12R13,
(t) —S—(C1-8 alkylene)—NR12R13,
(u) C1-8 alkyl substituted by —O—(C1-8 alkylene)—NR12R13— or —S—(C1-8 alkylene)—NR12R13,
(v) C2-8 alkenyl substituted by —OR2, —SR2, —NR3R4, —COR5, Cyc1, nitrile, —SO2R10, —O—(C1-8 alkylene)—OR11, —O—(C1-8 alkylene)—NR12R13 or —S—(C1-8 alkylene)—NR12R13 or
(w) C2-8 alkynyl substituted by —OR2, —SR2, —NR3R4, —COR5, Cyc1, nitrile, —SO2R10, —O—(C1-8 alkylene)—OR11, —O—(C1-8 alkylene)—NR12R13 or —S—(C1-8 alkylene)—NR12R13,
R2 is hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1;
R3 and R4 are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1;
R5 is hydroxyl, C1-8 alkyl, C1-8 alkoxy, —NR6R7 or Cyc1;
R6 and R7 are each independently hydrogen, C1-8 alkyl or Cyc1;
R10 is C1-8 alkyl or Cyc1;
Cyc1 is C3-7 mono-carbocyclic ring or 5-7 membered mono-cyclic hetero ring containing 1-4 nitrogen atom(s), one oxygen atom and/or one sulfur atom;
R11 is hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1;
R12 and R13 are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1;
m is 0 or an integer of 1-5;
ring A is C3-15 mono-, bi- or tri-carbocyclic ring or 5-18 membered mono-, bi- or tri-cyclic hetero ring containing 1-4 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s);
ring B is C5-15 mono-, bi- or tri-carbocyclic aryl or 5-18 membered mono-, bi- or tri-cyclic hetero aryl containing 1-4 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s);
E is a bond, —CH═CH— or —C≡C—;
R8 is
(a) C1-8 alkyl,
(b) C1-8 alkoxy,
(c) halogen,
(d) nitro,
(e) nitrile,
(f) trifluoromethyl or
(g) trifluoromethoxy;
with the proviso that when E is a bond then, optionally, R1 and R8, taken together, is C1-4 alkylene optionally;
n is 0 or an integer of 1-5;
R9 is hydrogen, C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl;
with the proviso that when E is —CH═CH— or —C≡C—, ring A is C3-7 mono-carbocyclic ring or 5-7 membered mono-cyclic hetero ring containing 1-4 nitrogen atom(s), one oxygen atom and/or one sulfur atom;
with the proviso that a compound wherein R1 is
(a) C1-8 alkyl,
(b) C2-8 alkenyl,
(c) C2-8 alkynyl,
(o) C1-8 alkyl substituted by —OR2, —SR2, —NR3R4, —COR5 or Cyc1,
(u) C1-8 alkyl substituted by —O—(C1-8 alkylene)—NR12R13— or —S—(C1-8 alkylene)—NR12R13,
(v) C2-8 alkenyl substituted by —OR2, —SR2, —NR3R4, —COR5, Cyc1, nitrile, —SO2R10, —O—(C1-8 alkylene)—OR11, —O—(C1-8 alkylene)—NR12R13 or —S—(C1-8 alkylene)—NR12R13, or
(w) C2-8 alkynyl substituted by —OR2, —SR2, —NR3R4, —COR5, Cyc1, nitrile, —SO2R10, —O—(C1-8 alkylene)—OR11, —O—(C1-8 alkylene)—NR12R13 or —S—(C1-8 alkylene)—NR12R13;
R2 is hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1;
R3 and R4 are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1;
R5 is hydroxyl, C1-8 alkyl, C1-8 alkoxy, —NR6R7 or Cyc1;
R6 and R7 are each independently hydrogen, C1-8 alkyl or Cyc1;
R10 is C1-8 alkyl or Cyc1;
Cyc1 is morpholine, piperidine or piperazine;
R11 is hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1;
R12 and R13 are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1;
m is an integer of 1-5;
ring A is a benzene ring;
ring B is a benzene ring;
E is a bond, —CH═CH— or —C≡C—;
R8 is
(a) C1-8 alkyl,
(b) C1-8 alkoxy,
(c) halogen,
(d) nitro,
(e) nitrile,
(f) trifluoromethyl or
(g) trifluoromethoxy,
with the proviso that when E is a bond then, optionally, R1 and R8, taken together, is C1-4 alkylene;
n is 0 or an integer of 1-5;
R9 is hydrogen, C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl, is excluded;
a nontoxic salt thereof or a prodrug thereof.
5. The prodrug of a compound of the formula (I) described in claim 4, which is represented by the formula (IA):
Figure US20040214896A1-20041028-C00267
wherein, R14 is C1-8 alkyl substituted with C1-8 alkyl, C1-8 alkoxy, the other symbols have the same meaning as defined in claim 4.
6. The prodrug of a compound of the formula (I) described in claim 4, which is represented by the formula (IB):
Figure US20040214896A1-20041028-C00268
wherein, the all symbols have the same meaning as defined in claim 4.
7. The compound described in claim 4, wherein E is a bond and ring A is C3-15 mono-, bi- or tri-carbocyclic ring.
8. The compound described in claim 4, wherein E is a bond and ring A is 5-18 membered mono-, bi-, or tri-cyclic hetero ring containing 1-4 nitrogen atom(s), 1-2 oxygen atom(s) and/or sulfur atom(s).
9. The compound described in claim 4, wherein E is —CH═CH— or —C≡C— and ring A is C3-7 mono-carbocyclic ring.
10. The compound described in claim 4, wherein E is —CH═CH— or —C≡C— and A is 5-7 membered mono-cyclic hetero ring containing 1-4 nitrogen atom(s), one nitrogen atom and/or one sulfur atom.
11. The compound described in claim 4, which is
(1) N-hydroxy-6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanamide,
(2) N-hydroxy-6-(4-biphenyl)-6-hydroxyhexanamide,
(3) N-hydroxy-6-(4-cyclohexylphenyl)-6-hydroxyhexanamide,
(4) N-hydroxy-6-(4-(4-methylphenyl)phenyl)-6-hydroxyhexanamide,
(5) N-hydroxy-6-(4-(4-methoxyphenyl)phenyl)-6-hydroxyhexanamide,
(6) N-hydroxy-6-(4-(trans-4-propylcyclohexyl)phenyl)-6-hydroxyhexanamide,
(7) (R)-N-hydroxy-6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanamide,
(8) (S)-N-hydroxy-6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanamide,
(9) N-hydroxy-6-(4-(benzofuran-2-yl)phenyl)-6-hydroxyhexanamide,
(10) N-hydroxy-6-(4-(pyridin-4-yl)phenyl)-6-hydroxyhexanamide,
(11) N-hydroxy-6-(4-(pyridin-3-yl)phenyl)-6-hydroxyhexanamide,
(12) N-hydroxy-6-(4-(2-chlorophenyl)phenyl)-6-hydroxyhexanamide,
(13) N-hydroxy-6-(4-(3-chlorophenyl)phenyl)-6-hydroxyhexanamide,
(14) N-hydroxy-6-(4-(4-bromophenyl)phenyl)-6-hydroxyhexanamide,
(15) N-hydroxy-6-(4-(thiophen-2-yl)phenyl)-6-hydroxyhexanamide,
(16) N-hydroxy-6-(4-(furan-2-yl)phenyl)-6-hydroxyhexanamide,
(17) N-hydroxy-6-(4-(1,3-dioxy-2,3-dihydroinden-5-yl)phenyl)-6-hydroxyhexanamide,
(18) N-hydroxy-6-(4-(4-methylthiophenyl)phenyl)-6-hydroxyhexanamide,
(19) N-hydroxy-6-(4-(naphthalen-1-yl)phenyl)-6-hydroxyhexanamide,
(20) N-hydroxy-6-(4-(naphthalen-2-yl)phenyl)-6-hydroxyhexanamide,
(21) N-hydroxy-6-(4-(4-acetylphenyl)phenyl)-6-hydroxyhexanamide,
(22) N-hydroxy-6-(4-(4-hydroxyphenyl)phenyl)-6-hydroxyhexanamide,
(23) N-hydroxy-6-(4-(dibenzofuran-4-yl)phenyl)-6-hydroxyhexanamide,
(24) N-hydroxy-6-(4-(2-methoxyphenyl)phenyl)-6-hydroxyhexanamide,
(25) N-hydroxy-6-(4-(3-methoxyphenyl)phenyl)-6-hydroxyhexanamide,
(26) N-hydroxy-6-(4-(4-trifluoromethylphenyl)phenyl)-6-hydroxyhexanamide,
(27) N-hydroxy-6-(4-(4-t-butylphenyl)phenyl)-6-hydroxyhexanamide,
(28) (R)-N-hydroxy-6-[4-(5-methylbenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,
(29) (R)-N-hydroxy-6-[4-(benzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,
(30) (R)-N-hydroxy-6-[4-(2-(4-methylthiophenyl)ethynyl)phenyl]-6-hydroxyhexanamide,
(31) (R)-N-hydroxy-6-[4-(4-methylthiophenyl)phenyl]-6-hydroxyhexanamide,
(32) (R)-N-hydroxy-6-[4-(4-(dimethylaminomethyl)phenyl)phenyl]-6-hydroxyhexanamide,
(33) N-hydroxy-6-(4-(trans-4-butylcyclohexyl)phenyl)-6-hydroxyhexanamide,
(34) N-hydroxy-6-(4-(trans-4-hydroxycyclohexyl)phenyl)-6-hydroxyhexanamide,
(35) N-hydroxy-6-(4-cyclopentylphenyl)-6-hydroxyhexanamide,
(36) N-hydroxy-6-[4-(morpholin-4-yl)phenyl]-6-hydroxyhexanamide,
(37) N-hydroxy-6-[3-(4-chlorophenyl)phenyl]-6-hydroxyhexanamide,
(38) N-hydroxy-6-[2-(4-chlorophenyl)phenyl]-6-hydroxyhexanamide,
(39) N-hydroxy-6-[4-((1E)-2-phenylvinyl)phenyl]-6-hydroxyhexanamide,
(40) N-hydroxy-6-[4-((1E)-2-(pyridin-4-yl)vinyl)phenyl]-6-hydroxyhexanamide,
(41) N-hydroxy-6-[4-((1E)-2-(pyridin-2-yl)vinyl)phenyl]-6-hydroxyhexanamide,
(42) N-hydroxy-6-[4-(4-chlorophenyl)phenyl]-6-hydroxyheptanamide,
(43) N-hydroxy-6-[4-(4-chlorophenyl)phenyl]-6-hydroxy-7-octenamide,
(44) N-hydroxy-6-(4-biphenyl)-6-hydroxyheptanamide,
(45) (+)-N-hydroxy-6-[4-(4-ethylphenyl)phenyl]-6-hydroxyheptanamide,
(46) (−)-N-hydroxy-6-[4-(4-ethylphenyl)phenyl]-6-hydroxyheptanamide,
(47) (R)-N-hydroxy-6-(4-biphenyl)-6-hydroxyhexanamide,
(48) (R)-N-hydroxy-6-[4-(4-methylphenyl)phenyl]-6-hydroxyhexanamide,
(49) (R)-N-hydroxy-6-[4-(3-methylphenyl)phenyl]-6-hydroxyhexanamide,
(50) (R)-N-hydroxy-6-[4-(benzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,
(51) (R)-N-hydroxy-6-[4-(2-phenylethynyl)phenyl]-6-hydroxyhexanamide,
(52) (R)-N-hydroxy-6-[4-(benzothiophen-2-yl)phenyl]-6-hydroxyhexanamide,
(53) (R)-N-hydroxy-6-[4-(4-(cyanomethyl)phenyl)phenyl]-6-hydroxyhexanamide,
(54) (R)-N-hydroxy-6-[4-(4-ethylphenyl)phenyl]-6-hydroxyhexanamide,
(55) (R)-N-hydroxy-6-[4-(4-propylphenyl)phenyl]-6-hydroxyhexanamide,
(56) (R)-N-hydroxy-6-[4-(4-biphenyl)phenyl]-6-hydroxyhexanamide,
(57) (R)-N-hydroxy-6-[4-(1-methylpiperidin-4-yl)phenyl]-6-hydroxyhexanamide,
(58) (R)-N-hydroxy-6-[4-(indol-2-yl)phenyl]-6-hydroxyhexanamide,
(59) (R)-N-hydroxy-6-[4-(4-cyanophenyl)phenyl]-6-hydroxyhexanamide,
(60) (R)-N-hydroxy-6-[4-phenyl-2-methylphenyl]-6-hydroxyhexanamide,
(61) (R)-N-hydroxy-6-(4-cycloheptylphenyl)-6-hydroxyhexanamide,
(62) (R)-N-hydroxy-6-(9,10-dihydrophenanthren-2-yl)-6-hydroxyhexanamide,
(63) (R)-N-hydroxy-6-[4-(1-ethoxycarbonylpiperidin-4-yl)phenyl]-6-hydroxyhexanamide,
(64) (R)-N-hydroxy-6-[4-(4-(N-methylcarbamoyl)phenyl)phenyl]-6-hydroxyhexanamide,
(65) (R)-N-hydroxy-6-(4-cyclohexylphenyl)-6-hydroxyhexanamide,
(66) (R)-N-hydroxy-6-[4-(5-hydroxybenzofuran-2-yl)phenyl]-6-hydroxyhexanamide,
(67) (R)-N-hydroxy-6-[4-(2-(4-methylphenyl)ethynyl)phenyl]-6-hydroxyhexanamide,
(68) (R)-N-hydroxy-6-[4-((1E)-2-(4-methylphenyl)vinyl)phenyl]-6-hydroxyhexanamide,
(69) (R)-N-hydroxy-6-[4-(4-trifluoromethoxyphenyl)phenyl]-6-hydroxyhexanamide,
(70) (R)-N-hydroxy-6-[4-(4-ethylthiophenyl)phenyl]-6-hydroxyhexanamide,
(71) (R)-N-hydroxy-6-[4-(4-methoxyphenyl)phenyl]-6-hydroxyhexanamide,
(72) (R)-N-hydroxy-6-[4-(4-(1-methylethyl)phenyl)phenyl]-6-hydroxyhexanamide,
(73) (R)-N-hydroxy-6-[4-(4-(N,N-dimethylcarbamoylmethyl)phenyl)phenyl]-6-hydroxyhexanamide,
(74) (R)-N-hydroxy-6-[4-(benzothiazol-2-yl)phenyl]-6-hydroxyhexanamide,
(75) (R)-N-hydroxy-6-[4-(4-(methoxymethoxymethyl)phenyl)phenyl]-6-hydroxyhexanamide,
(76) (R)-N-hydroxy-6-[4-(6-methoxybenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,
(77) (R)-N-hydroxy-6-[4-(6-methylbenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,
(78) (R)-N-hydroxy-6-[4-(4-methoxymethylphenyl)phenyl]-6-hydroxyhexanamide,
(79) (R)-N-hydroxy-6-[4-(5-methoxybenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,
(80) (R)-N-hydroxy-6-[4-(4-methoxybenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,
(81) (R)-N-hydroxy-6-[4-(4-hydroxybenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,
(82) (R)-N-hydroxy-6-[4-(6-hydroxybenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,
(83) (R)-N-hydroxy-6-[4-((1E)-2-(4-methylthiophenyl)vinyl)phenyl]-6-hydroxyhexanamide,
(84) (R)-N-hydroxy-6-[4-(5-methoxybenzofuran-2-yl)phenyl]-6-hydroxyhexanamide,
(85) (R)-N-hydroxy-6-[4-(5-methylthiobenzofuran-2-yl)phenyl]-6-hydroxyhexanamide,
(86) (R)-N-hydroxy-6-[4-(4-(2-(dimethylamino)ethyl)phenyl)phenyl]-6-hydroxyhexanamide,
(87) (R)-N-hydroxy-6-[4-(4-(2-(dimethylamino)ethoxy)phenyl)phenyl]-6-hydroxyhexanamide,
(88) (R)-N-hydroxy-6-[4-(4-(2-(diethylamino)ethyl)phenyl)phenyl]-6-hydroxyhexanamide,
(89) (R)-N-hydroxy-6-[4-(4-(2-hydroxyethyl)phenyl)phenyl]-6-hydroxyhexanamide,
(90) (S)-N-hydroxy-6-[4-(4-methylthiophenyl)phenyl]-6-hydroxyhexanamide,
(91) (S)-N-hydroxy-6-[4-(2-(4-methylthiophenyl)ethynyl)phenyl]-6-hydroxyhexanamide,
(92) (S)-N-hydroxy-6-[4-(benzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,
(93) (S)-N-hydroxy-6-[4-(5-methylbenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,
(94) (S)-N-hydroxy-6-[4-(4-(dimethylaminomethyl)phenyl)phenyl]-6-hydroxyhexanamide,
(95) (R)-N-hydroxy-6-[4-(4-(dipropylaminomethyl)phenyl)phenyl]-6-hydroxyhexanamide,
(96) (R)-N-hydroxy-6-(5-phenylthiophen-2-yl)-6-hydroxyhexanamide,
(97) (R)-N-hydroxy-6-(5-phenylbenzofuran-2-yl)-6-hydroxyhexanamide,
(98) (R)-N-hydroxy-6-[4-(4-(methoxycarbonyl)phenyl)phenyl]-6-hydroxyhexanamide,
(99) (R)-N-hydroxy-6-[4-(4-carboxyphenyl)phenyl]-6-hydroxyhexanamide,
(100) (R)-N-hydroxy-6-[4-(4-methylsulfonylphenyl)phenyl]-6-hydroxyhexanamide,
(101) (R)-N-hydroxy-6-[4-(4-hydroxymethylphenyl)phenyl]-6-hydroxyhexanamide,
or a nontoxic salt thereof.
12. The compound described in claim 5, which is:
(1) N-(1-methoxy-1-methyl)ethoxy-6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanamide,
(2) N-(1-methoxy-1-methyl)ethoxy-6-(4-(benzofuran-2-yl)phenyl)-6-hydroxyhexanamide,
(3) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(5-methylbenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,
(4) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(benzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,
(5) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(2-(4-methylthiophenyl)ethynyl)phenyl]-6-hydroxyhexanamide,
(6) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-methylthiophenyl)phenyl]-6-hydroxyhexanamide,
(7) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-(dimethylaminomethyl)phenyl)phenyl]-6-hydroxyhexanamide,
(8) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-(dipropylaminomethyl)phenyl)phenyl]-6-hydroxyhexanamide,
(9) N-methoxy-6-[4-(4-chlorophenyl)phenyl]-6-hydroxyhexanamide,
or a nontoxic salt thereof.
13. The compound described in claim 6, which is
(1) (R)-5-(5,5-dimethyl-1,4,2-dioxazolin-3-yl)-1-[4-(5-methylbenzoxazol-2-yl)phenyl]pentan-1-ol,
(2) (R)-5-(5,5-dimethyl-1,4,2-dioxazolin-3-yl)-1-[4-(4-methylthiophenyl)phenyl]pentan-1-ol,
(3) (R)-5-(5,5-dimethyl-1,4,2-dioxazolin-3-yl)-1-[4-(4-(dimethylaminomethyl)phenyl)phenyl]pentan-1-ol,
or a nontoxic salt thereof.
US10/851,210 1999-09-24 2004-05-24 Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient Abandoned US20040214896A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/851,210 US20040214896A1 (en) 1999-09-24 2004-05-24 Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JPP.HEI.11-270459 1999-09-24
JP27045999 1999-09-24
JP2000206649 2000-07-07
JPP.2000-206649 2000-07-07
US10/088,821 US6770644B1 (en) 1999-09-24 2000-09-22 Hydroxamic acid derivatives, process for the production thereof and drug containing the same as the active ingredient
US10/851,210 US20040214896A1 (en) 1999-09-24 2004-05-24 Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US10/088,821 Division US6770644B1 (en) 1999-09-24 2000-09-22 Hydroxamic acid derivatives, process for the production thereof and drug containing the same as the active ingredient
PCT/JP2000/006506 Division WO2001021583A1 (en) 1999-09-24 2000-09-22 Hydroxamic acid derivatives, process for the production thereof and drugs containing the same as the active ingredient

Publications (1)

Publication Number Publication Date
US20040214896A1 true US20040214896A1 (en) 2004-10-28

Family

ID=26549225

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/088,821 Expired - Fee Related US6770644B1 (en) 1999-09-24 2000-09-22 Hydroxamic acid derivatives, process for the production thereof and drug containing the same as the active ingredient
US10/851,210 Abandoned US20040214896A1 (en) 1999-09-24 2004-05-24 Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/088,821 Expired - Fee Related US6770644B1 (en) 1999-09-24 2000-09-22 Hydroxamic acid derivatives, process for the production thereof and drug containing the same as the active ingredient

Country Status (8)

Country Link
US (2) US6770644B1 (en)
EP (1) EP1215203B1 (en)
KR (1) KR20020032618A (en)
AT (1) ATE289291T1 (en)
AU (1) AU7320100A (en)
DE (1) DE60018194T2 (en)
PT (1) PT1215203E (en)
WO (1) WO2001021583A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007091106A3 (en) * 2006-02-10 2008-03-06 Summit Corp Plc Treatment of duchenne muscular dystrophy
US20090048314A1 (en) * 2007-08-15 2009-02-19 Shabana Ahmed Treatment of duchenne muscular dystrophy
US20110195932A1 (en) * 2007-08-03 2011-08-11 Graham Michael Wynne Drug Combinations for the Treatment of Duchenne Muscular Dystrophy

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709510B2 (en) 2001-02-20 2010-05-04 Chugai Seiyaku Kabushiki Kaisha Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
JP4159361B2 (en) 2001-02-20 2008-10-01 中外製薬株式会社 Treatment of metabolic diseases using malonyl-CoA decarboxylase inhibitors
JP2004359546A (en) * 2001-03-15 2004-12-24 Ono Pharmaceut Co Ltd Prophylactic and/or therapeutic agent for solid cancer comprising hydroxamic acid derivative, its nontoxic salt and prodrug substance thereof as active ingredient
US20050119305A1 (en) * 2001-03-21 2005-06-02 Masao Naka Il-6 production inhibitors
AR035455A1 (en) 2001-04-23 2004-05-26 Hoffmann La Roche TRICYCLE DERIVATIVES OF ALQUILHIDROXAMATO, PROCESSES FOR THEIR DEVELOPMENT, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THE USE OF SUCH COMPOUNDS IN THE PREPARATION OF MEDICINES
ATE380025T1 (en) 2003-05-07 2007-12-15 Univ Aberdeen KETONES AND REDUCED KETONES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE DISEASES
ATE536872T1 (en) 2003-08-01 2011-12-15 Chugai Pharmaceutical Co Ltd CYANOGUANIDINE-BASED AZOLE COMPOUNDS AS MALONYL-COA DECARBOXYLASE INHIBITORS
ATE400272T1 (en) 2003-08-01 2008-07-15 Chugai Pharmaceutical Co Ltd PIPERIDINE COMPOUNDS AS MALONYL-COA DECARBOXYLASE INHIBITORS
WO2005011670A1 (en) 2003-08-01 2005-02-10 Chugai Seiyaku Kabushiki Kaisha Heterocyclic compounds useful as malonyl-coa decarboxylase inhibitors
KR100612485B1 (en) * 2004-01-30 2006-08-17 강용구 Joan Block
WO2007091313A1 (en) * 2006-02-08 2007-08-16 Shizuoka Coffein Co., Ltd Cytokine production inhibitor and heterocyclic phenoxy derivative

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769461A (en) * 1986-09-16 1988-09-06 American Home Products Corporation Quinolinyl benzene hydroxamic acids as anti-inflammatory/antiallergic agents
US4804601A (en) * 1987-06-29 1989-02-14 Xerox Corporation Electrophotographic and electrographic imaging processes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5946244A (en) 1982-09-09 1984-03-15 Nissan Chem Ind Ltd Hydroxamic acid derivative and its preparation
US5804601A (en) 1995-04-10 1998-09-08 Takeda Chemical Industries, Ltd. Aromatic hydroxamic acid compounds, their production and use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769461A (en) * 1986-09-16 1988-09-06 American Home Products Corporation Quinolinyl benzene hydroxamic acids as anti-inflammatory/antiallergic agents
US4804601A (en) * 1987-06-29 1989-02-14 Xerox Corporation Electrophotographic and electrographic imaging processes

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007091106A3 (en) * 2006-02-10 2008-03-06 Summit Corp Plc Treatment of duchenne muscular dystrophy
AU2007213451B2 (en) * 2006-02-10 2013-02-07 Summit (Oxford) Limited Treatment of Duchenne muscular dystrophy
US8518980B2 (en) 2006-02-10 2013-08-27 Summit Corporation Plc Treatment of Duchenne muscular dystrophy
US20110195932A1 (en) * 2007-08-03 2011-08-11 Graham Michael Wynne Drug Combinations for the Treatment of Duchenne Muscular Dystrophy
US8501713B2 (en) 2007-08-03 2013-08-06 Summit Corporation Plc Drug combinations for the treatment of duchenne muscular dystrophy
US20090048314A1 (en) * 2007-08-15 2009-02-19 Shabana Ahmed Treatment of duchenne muscular dystrophy

Also Published As

Publication number Publication date
AU7320100A (en) 2001-04-24
WO2001021583A1 (en) 2001-03-29
EP1215203B1 (en) 2005-02-16
EP1215203A4 (en) 2003-05-02
KR20020032618A (en) 2002-05-03
DE60018194T2 (en) 2006-01-05
DE60018194D1 (en) 2005-03-24
PT1215203E (en) 2005-05-31
ATE289291T1 (en) 2005-03-15
EP1215203A1 (en) 2002-06-19
US6770644B1 (en) 2004-08-03

Similar Documents

Publication Publication Date Title
US7285680B2 (en) β-alanine derivatives and the use thereof
US20050119305A1 (en) Il-6 production inhibitors
US6770644B1 (en) Hydroxamic acid derivatives, process for the production thereof and drug containing the same as the active ingredient
JP4691988B2 (en) LPA receptor antagonist
US20100267778A1 (en) Diphenyl ether compound, process for producing the same, and use
EP1535906A1 (en) Nitrogen-containing compounds
EP1306373A1 (en) 3,4-dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient
WO2006006490A1 (en) Spirocyclic compound
TW200521108A (en) Compounds having lysophosphatidic acid receptor(LPA)-antagonizing effect and their use
WO2004002530A1 (en) Remedy for chronic disease
EP1369419B1 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
EP1604971A1 (en) Cinnamyl alcohol derivative compounds and drugs containing the compounds as the active ingredient
US20040002480A1 (en) Aminobutyric acid derivatives and pharmaceutical composition containing the same as active ingredient
JP2004359546A (en) Prophylactic and/or therapeutic agent for solid cancer comprising hydroxamic acid derivative, its nontoxic salt and prodrug substance thereof as active ingredient
US20070167490A1 (en) Imino ether derivative compounds and drugs containing the compounds as the active ingredient
JP2002348288A (en) Spiroheterocycle derivative and medicine having the same as active ingredient
JP2002080445A (en) Hydroxamic acid derivative compound, method for producing the same and medicament with the same as active ingredient
JPH10251295A (en) Tetrazole derivative
JPWO2001021583A1 (en) Hydroxamic acid derivative compound, its manufacturing method and medicine containing said compound as an active ingredient
US20040063936A1 (en) Pyrimidine derivatives and process for preparing the same
JP2005112802A (en) Ptp1b inhibitor
JP2002193880A (en) Bicyclooctane derivative
JPWO2000059865A1 (en) 4-aminobutanoic acid derivatives and drugs containing the derivatives as active ingredients
JP2006151832A (en) Lactam compound

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION